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Background: Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are common 
and account for approximately 12% of UK hospital admissions. A significant proportion will 
be complicated by respiratory acidaemia which has a high mortality. Non-Invasive ventilation 
(NIV) confers a 2-3 fold reduction in mortality in this setting. Despite this, practice is sub-
optimal; the intervention is underused, infrastructure is lacking, and complex decisions are 
made by a wide range of clinicians. It is feasible that pessimism contributes. 
Aims: To derive and separately validate a simple, bedside, clinical tool to predict in-hospital 
mortality in exacerbations of COPD complicated by respiratory acidaemia requiring assisted 
ventilation. 
Methods: The study was split into two parts with similar methods. The derivation study was 
a single trust (2 sites: one urban and one rural) retrospective study. In patients meeting 
selection criteria, data were collected, and multivariable regression analysis identified 
independent predictors of in-hospital death. A simple predictive model was created. The 
validation study captured a more limited dataset in prospectively recruited patients across 
10 trusts. The predictive model’s performance was assessed. 
Results: 489 patients were identified in the derivation study and 733 in the validation. 
Independent predictors of outcome were confirmed, and a final, simple bedside model 
entitled the NIVO score produced. Using atrial fibrillation, chest X-ray consolidation, eMRCD 
score, Glasgow coma scale, timing of acidaemia relative to admission time and pH in a 
simple scoring system stratified risk was obtained with an area under the receiver operated 
curve of 0.79 in the validation cohort.  
Discussion: Using only simple, readily available indices good prediction of in-hospital 
mortality is feasible. The NIVO score outperformed pre-identified comparator scores in both 
its derivation and validation studies. Potential practical applications include but are not 
limited to guiding level of care, setting treatment limitations and objectifying discussion with 
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Chapter 1. Introduction: COPD 
1.1 What is Chronic Obstructive Pulmonary Disease (COPD)? 
1.1.1  Description and Definition. 
COPD is a complex lung disease characterised by airflow obstruction and often caused by 
smoking. Akin to other chronic diseases, damage is not limited to a single organ and both the 
pulmonary (e.g. airflow obstruction, emphysema, mucus hypersecretion) and systemic (e.g. 
anaemia, osteoporosis, skeletal muscle weakness) effects of COPD contribute to the 
symptoms and disabilities. Manifestations are heterogeneous with some individuals 
developing profound changes in lung architecture as seen in emphysema while others, 
perhaps of a similar age with similar tobacco history exposure, may have far less 
architectural change but instead produce copious secretions and suffer frequent flare ups, 
termed exacerbations. Some patients are too breathless to leave the house or need 
supplementary oxygen while others with similar lung function measurements can walk miles 
with normal oxygen levels. Rate of functional and physiological decline can differ 
dramatically. The psychological effects of chronic breathlessness and disability and their 
interplay with anxiety and depression further broaden disease manifestations. 
The Global Initiative for Chronic Obstructive Lung Disease’s (GOLD) states that  ‘Chronic 
obstructive pulmonary disease is a common, preventable and treatable disease 
that is characterised by persistent respiratory symptoms and airflow limitation 
that is due to airway and/or alveolar abnormalities usually caused by significant 
exposure to noxious particles or gases.’(1)  
This broad definition emphasises that articulating COPD in a single concise definition 
requires simplification but the persistent presence of respiratory symptoms is cardinal. 
COPD is however, a very useful label to communicate that this patient has one of a myriad of 
interlinked phenotypes some of which are well described and long observed but which 
overall, we poorly understand.  Certainly, predicting the future disease state (if any) beyond 
‘COPD’ of a young, heavy smoker is currently difficult. Some treatments such as guiding 
inhaled corticosteroids by peripheral eosinophil count or targeting Roflumilast at those 
producing daily sputum who are frequent exacerbators are clearly in recognition of differing 




Secondly as the definition states there is usually (but not necessarily) chronic exposure to an 
identifiable airborne irritant. In the UK and worldwide the majority of COPD is caused by 
tobacco smoking. In some societies smoke from indoor biomass fires for heating or cooking 
may be a significant contributor.(2) Occupational dusts or chemicals may also be causative.(3)   
Overall, despite heterogeneity COPD does describe a group of patients with more similarities 
than differences and remains a useful diagnostic term. 
1.1.2  Spirometry. 
‘There is no single diagnostic test for COPD. Making a diagnosis relies on clinical 
judgement based on a combination of history, physical examination and 
confirmation of the presence of airflow obstruction using spirometry’.(4) In common 
with other international standards (3,5) the National Institute for Health and Care Excellence 
(NICE) recommends that airflow obstruction as demonstrated by spirometry forms the 
cornerstone of the objective criteria by which COPD is diagnosed.  
Spirometry is performed from maximal inspiration. The amount of air expelled from the lung 
in a single forced expiration in the first second is termed the forced expiratory volume in one 
second (FEV1). The total amount of air expelled from a forced expiration is termed forced 
vital capacity (FVC) or vital capacity (VC) if from a relaxed manoeuvre. In COPD, due to 
dynamic collapse of airways during a forced manoeuvre, the FVC may be significantly lower 
than the VC and consequently underestimate the total air expelled.(6) The largest recorded 
FEV1 divided by the largest FVC or VC forms the FEV1/(F)VC ratio. Current practice is to 
diagnose airflow obstruction when this value is <0.7. Having established airflow obstruction 
further categorisation is possible using the percentage predicted FEV1.(1,4)  
1.1.3  Spirometry Staging. 
Recorded values can be compared to reference values derived from healthy populations. 
These predicted values vary dependent on various factors notably gender, height, age and 
ethnicity.(7-9) A percentage predicted value is the actual recorded value relative to the 
reference value and may be greater than, equal to, or less than 100%. Using a lower limit of 
normal value (i.e. recognising standard deviations) may increase diagnostic accuracy 




A simple way of grading the severity of airflow obstruction in COPD is by spirometry: 
International guideline bodies have adopted the gradation shown in Table 1. In recent years 
there has been recognition that this approach is poorly predictive on an individual patient 
level. 
Table 1 COPD staging by spirometry values. 
 FEV1 (percent predicted) Stage/Grade 
FEV1/(F)VC <0.7 ≥80% Mild 
50-79% Moderate 
30-49% Severe 
<30% Very Severe 
 
These sections represent an acknowledged oversimplification of spirometry and lung 
function testing in COPD. As discussed, COPD is not a single entity and patients with chronic 
bronchitis or emphysema may not have airflow obstruction. Similarly, there is momentum 
toward the use of lower limit of normal in diagnosis and this method may well take over 
from the simple 70% cut off in the future.  
1.2 COPD Epidemiology. 
1.2.1  Genetic Predisposition to Development of Airflow Obstruction. 
Not everyone with chronic inhaled irritant exposure will develop COPD. The Copenhagen 
City Heart Study followed a general population for 25 years and recorded serial investigation 
results including spirometry. After adjusting for tobacco burden, they conclude that 30-40% 
of smokers without initial disease will develop COPD. People who smoked throughout the 
timeframe had a greater risk than intermittent smokers or those that stopped but the 
development of COPD was not universal in smokers. Total tobacco burden was modest 
whether an early quitter or a continuous smoker (mean 14.8-19.1 cigarette pack years).(11) 
Therefore, there are other factors beyond tobacco burden that determine whether a smoker 
will develop COPD or not. Fletcher and Peto proposed a classic representation of lung 
function decline developed from a random population of London men in the 1970s. This 
schematic model reinforces that genetic susceptibility is important with some individuals 
being prone to more rapid lung function decline when exposed to tobacco smoke and others 




particularly the accelerated decline in late disease have been questioned and other schema 
proposed. Figure 1 illustrates this alternate view: the maximum achieved FEV1 in early 
adulthood as determined by genetic and environmental factors in early life is an important 
influence on the likelihood of developing COPD. In this model airflow obstruction can 
develop from normal maximum FEV1 with rapid decline or from a low maximum FEV1 with 
normal rate of decline in FEV1.(13)  
Figure 1 Lung function trajectories leading to chronic obstructive pulmonary disease.(13) 
 
COPD is a global disease found irrespective of race or ethnicity. Small studies inconsistently 
report significantly differing susceptibility between ethnic groups, however, a large meta-
analysis found pacific islanders to be the only outlying group (less COPD than expected).(14) 
Another large study found no relationship between genetic ancestry and COPD rates after 
adjusting for confounders.(15)  
In 1963 the strongest genetic determinant of COPD was identified when the association 
between alpha 1 antitrypsin deficiency and premature emphysema was discovered and 
subsequently linked to a mutation in the SPERINA1 gene.(16) In recent years since the 
development and data-sharing of large genome-wide association studies several loci have 
been shown to be associated with heritability of accelerated lung function decline. A meta-




further gene loci have been identified but reproducibility has bedevilled the field so 
validation in large population datasets is essential.(18) 
1.2.2  COPD Burden. 
COPD is thought to affect 210 million people worldwide but due to variation in diagnosis rate 
the actual number may be much higher.(3) Worldwide COPD is expected to be one of the 
major health burdens in coming decades and prevalence will continue rising.(19) Increasing 
life expectancy is a major contributor; those with the disease live longer and more people 
survive long enough to develop it.(20) 
United Kingdom (UK) smoking rates are now falling, but COPD prevalence is still rising due to 
historical smoking rates, active case finding, improved disease specific survival and, as 
mentioned, an aging population. There is evidence of a plateauing in new diagnosis rates.(21)  
In support of a continued rise in prevalence is a Dutch model of COPD in an aging population 
developed in the early 2000s. This complex, dynamic population model projects the 
incidence and prevalence of COPD based on annualised adjustment of demographics, births, 
deaths, migration and smoking rates. Historical data and spirometry data from nearly 6000 
individuals is incorporated. The model predicted increase across all severity classes in both 
men and women until the end of the modelled period in 2025. Domestic adult smoking rates 
between the UK and the Netherlands at its inception were comparable.(22)  
The burden of COPD in the UK is substantial: there are an estimated 1.2 million people living 
with diagnosed COPD representing 2% of the total population, 4.5% of the population aged 
over 40 and 9% aged over 70. COPD was estimated to be the second commonest reason for 
hospital admission (23) and it accounts for 1.7% of the total National Health Service (NHS) bed 
days.(21) The burden to an individual patient is also substantial with COPD being associated 
with a high symptom burden which will be discussed in more detail. 
1.2.3  Smoking Habits and Health Inequality in the UK. 
Development of COPD is strongly linked to tobacco smoking. In patients with air flow 
obstruction benefit is derived from smoking cessation with the greatest benefit seen in those 




consistently falling for several years across all age groups and those smoking consume fewer 
cigarettes.(25)  
Changes in smoking habits are not however symmetrical across the population, in the UK 
smoking and COPD are contributors to health inequality. Men aged 20-64 employed in 
unskilled occupations are 14 times more likely to die from COPD than those in professional 
roles.(26) Between 2014 and 2016 10.9% of people in managerial and professional 
occupations smoked versus 24.9% of those in routine and manual occupations. Overall 
15.9% of those in employment smoke versus 29.8% of those unemployed. Profound regional 
variations also exist.(25)  Similarly, smoking habits have differed between men and women 
meaning projected COPD rates are not equal for men and women. Globally unemployment is 
a risk factor for COPD.(27) 
Figure 2 Proportion of current smokers, all persons by age group. UK 2010 to 2016. (25) 
 
Impaired lung function in adulthood is associated with childhood poverty. In one study 3641 
British women aged 60-79 were interviewed and had spirometry recorded. After adjustment 
for important confounders such as age, height, adult social class, lifetime smoking status, 
BMI, respiratory medications and physical activity markers of childhood poverty remain 
associated with impaired lung function in late adulthood, particularly paternal manual work 
and no access to a car in childhood. Findings were preserved irrespective of passive smoking 
burden.(28) English data from a national audit shows one third of patients come from the 




A number of factors explain these observations including lower birth weight, childhood 
infections, childhood asthma, exposure to air pollution, maternal smoking in pregnancy, and 
occupational exposure to dusts and fumes. All are associated with deprivation and largely 
independent of individual control.(30-33) One large study found childhood factors to be as 
important as lifetime heavy smoking in the development of adult COPD.(33) While it is 
undeniably extremely important COPD should not just be considered a disease of smoking 
but more a complex combination of social, genetic, developmental and biological factors. 
This is important to prevent COPD being viewed as a self-inflicted illness. 
1.3 COPD Manifestations. 
1.3.1  Pulmonary Manifestations and Symptoms of COPD.  
The direct pulmonary symptoms of COPD are easily described: Dyspnoea, wheeze, chronic 
cough and chronic sputum production are cardinal. Dyspnoea is usually progressive, 
persistent and typically exertional. 
Broadly speaking, airflow obstruction develops as a consequence of loss of elastic recoil due 
to emphysema, increased small airway resistance due to luminal narrowing or both. 
Inflammation caused by cigarette smoke or other irritants leads to over-production of 
elastases as compared to their inhibitors (alpha 1 antitrypsin is an inhibitor whose absence 
leads to emphysema). Elastases, particularly neutrophilic elastase break down tissue and 
lead to airspace enlargement, i.e. emphysema.(34,35) A similar immune response leads to 
airway mucosal infiltration with inflammatory cells, interruption of muco-ciliary clearance 
and connective tissue deposition ultimately leading to a narrowed airway lumen.(36)   
Inflammation is not just found in the small airways, throughout the lungs the airways are 
inflamed, airway defences are impaired and muco-ciliary clearance is impaired. These factors 
lead to the chronic mucus production, pre-disposition towards infection and cough that 
constitute major symptoms. Emphysema reduces the available surface area for gas exchange 
and combined with airflow obstruction leads to dyspnoea and wheeze. High lung volumes 
(hyper-expansion) seen in emphysema particularly lead to inefficient, effortful ventilation; 
exertional dyspnoea is often related to the added effects of dynamic hyperinflation, further 




1.3.2  Extra-pulmonary Manifestations and Comorbidities Associated with COPD. 
COPD is not simply a disease of the lungs, systemic inflammation may play an important role 
in the development of extra pulmonary manifestations of COPD. One theory contends a pro-
inflammatory environment in the lungs ‘spills out’ systemically with downstream effects.(39) 
Compared to controls increased levels of a long list of circulating pro-inflammatory 
mediators have been demonstrated in COPD. C-Reactive protein (CRP), interleukins, 
fibrinogen, leucocytes and tissue necrosis factor alpha (TNFα) are perhaps the most reliably 
described. (39-43) Platelets may also play a role in systemic inflammation and there is 
suggestion that elevated platelet level (thrombocytosis) during exacerbation is associated 
with increased mortality.(44) The proinflammatory environment of COPD has been 
hypothesised as the cause of a host of associated comorbidities. It is difficult to ascribe 
causality to the inflammatory environment over correlation with shared environmental risk 
factors such as smoking, other aspects of COPD such as hypoxaemia or genetic 
predisposition, but it is likely to be at least in part the case. For example elevated 
Interleukin-6 and CRP as may be seen in COPD have both been implicated in accelerated 
ischaemic heart disease (IHD).(45) Irrespective of the precise mechanistic pathway there are 
strong correlations between COPD and other comorbidities that impact significantly upon 
disease progression and mortality.(46-49) The particularly strong association between COPD 
and accelerated ischaemic heart disease is a potential target for mortality reduction. 
Divo et al. recruited 1664 patients across 5 centres, all comorbidities were recorded (79 in 
total). After a median of 51 months follow-up associations with mortality were reported. The 
authors created a ‘comorbidome’ (Figure 3) of those comorbidities present in at least 10% of 
the study population. 12 were significantly associated with increased mortality and are 
depicted inside a dotted line. Increasing circle size represents increasing prevalence, 
proximity to the centre strength of association with increased mortality and colour grouped 
by organ system. These results are not wholly generalisable and an associated comorbidity 
score is not validated. 89% of participants were male which goes some way to explaining the 
strong mortality association of breast cancer and anxiety which were only mortality 
associates in the smaller cohort of females. Nevertheless, it is a powerful reminder that 




Figure 3 COPD comorbidome*.(46) 
 
*Acronyms listed in list of abbreviations 
Skeletal muscle wasting and dysfunction is not a discreet comorbidity as such but is well 
recognised and highly correlated with functional decline and poor outcomes. A combination 
of disuse, catabolism, inflammation and exogenous corticosteroid administration in COPD 
are likely to explain, some or all of the reason why this should be the case.(50,51)  The physical 
training aspects of pulmonary rehabilitation have been developed to counteract the effects 
of myopathy. The recent Cochrane review concluded no further randomised controlled trials 
were required to support the efficacy of pulmonary rehabilitation in COPD.(52) In addition to 
those studied by Divo et.al. a long list of diverse conditions have been associated with COPD 
including (but not limited to)  anaemia,(53) osteoporosis,(54,55) and cataracts.(56)  
1.3.3  Exacerbations of COPD (ECOPD). 
The course of COPD will be punctuated by flare ups where symptoms worsen. These 
episodes are more often than not associated with bacterial or viral infection.(57,58) Three 




one virus (Rhinovirus) are implicated in a majority of infective exacerbations, with a series of 
other bacteria and viruses less commonly involved.(59) In one study, Haemophilus influenzae 
was identified from mucosal biopsy in 87% of patients intubated for ECOPD, 33% with non-
exacerbated COPD and 0% of healthy controls.(60)  
While some debate surrounds the precise definition of an exacerbation of COPD there is 
reasonable consensus. One aspect of the debate perhaps less pertinent to the UK, which has 
universal healthcare, is whether treatment escalation should form part of the criteria as this 
approach inherently incorporates access to healthcare.(61) This aside, the following definition 
is from the 2010 NICE guideline: ‘An exacerbation is a sustained worsening of the 
patient's symptoms from their usual stable state which is beyond normal day-to-
day variations, and is acute in onset. Commonly reported symptoms are worsening 
breathlessness, cough, increased sputum production and change in sputum colour. 
The change in these symptoms often necessitates a change in medication.’  It is 
generally accepted that exacerbations can be categorised into mild (treated using 
bronchodilators only), moderate, using oral glucocorticoids and/or antibiotics) or severe 
(requiring hospital admission). During an exacerbation lung function frequently deteriorates 
and full recovery may not occur.(62) Respiratory failure as a consequence of an exacerbation 
will be discussed later.  





Exacerbations are important to the natural history of COPD. From a large database in 
Quebec, researchers selected patients hospitalised for the first time with ECOPD and 
recorded further hospitalisations for ECOPD or death between 1990 and 2007. 73,106 
patients were included. As can be seen in Figure 4 risk of exacerbation or death remains high 
in the weeks following a severe (hospitalised) exacerbation and an increasing risk was 
observed particularly after the second severe exacerbation.(63)  
1.3.4  Does the Presence of Pneumonia Invalidate a Diagnosis of ECOPD? 
This question can divide opinion and is pertinent to this thesis. It is predominately a question 
of interpretation and opinion rather than of evidence. There are, however, consequences for 
patient selection, treatment algorithms and interpretation of clinical trials. The argument is 
whether pneumonia is an organised, parenchymal process and ECOPD is an isolated airways 
process or whether they can coexist? If clinical presentations conformed to binary 
distinctions then there would be little debate and while there are situations where one 
pathology predominates, it is rarely clear-cut. The alternate position is that the conditions 
frequently occur together, interact along a continuum and separation adds little value. There 
are several cogent points to support this second opinion: 
• This is predominately an academic debate, national audits consistently show a large 
number of patients with ECOPD have complicating pneumonia (29) (18% in UK’s most 
recent audit). This implies that many UK physicians do not separate the two 
diagnoses.   
• Sensitivity and specificity of computerised tomography CT is greater than chest x-ray 
(CXR) to diagnose pneumonia.(64-66) If the distinction were paramount then logically 
one must also insist upon gold standard imaging techniques yet the necessity for CT 
has not been incorporated into national guidance (67) as little extra value is added and 
normal practice is not to CT all. Furthermore, development of radiographic 
consolidation can lag behind symptoms and signs. Imagine a patient presents 
breathless and with clinical signs of consolidation. Imaging on day one is clear but on 
day 2 consolidation is present. Did this patient have pneumonia on day 1, must 





• There is no obvious treatment variation that separation naturally dictates. 
Bronchodilators or corticosteroids should not be withheld to treat bronchospasm if 
present, nor broad spectrum antibiotics, intravenous fluids or inotropes to treat 
sepsis.  
• There are recognised differences between pneumonia in COPD and the simple 
community acquired pneumonia. Notably there is probably a reduced rate of 
empyema in COPD and the lung microbiome and acute microbiology differs, 
specifically, the rate of Pseudomonas Aeruginosa is much higher.(68,69)  
• Following and most importantly: focussing attention upon pneumonia as a separate 
entity may detract from good management of co-existent COPD. For example, the 
use of controlled oxygen or vigilance for and treatment of respiratory failure where 
ambiguity may lead to poor treatment decisions particularly the administration of 
non-invasive ventilation (NIV). 
Fundamentally insisting on separation should ease diagnosis and management not 
complicate it. This is especially true given that these conditions are commonly managed by a 
generalist.(29) For these reasons not drawing an academic distinction and considering these 
conditions to interact is the position of this thesis. The term pneumonic exacerbation of 
COPD (pECOPD) will be used henceforth to describe an exacerbation of COPD with 
coexistent pneumonia. 
1.3.5  Physiology of Respiratory Failure in COPD. 
Under normal circumstances ventilation serves to facilitate gas exchange by moving oxygen 
from the air into the alveoli and removing carbon dioxide which is a by-product of 
metabolism. A potential consequence of COPD is the development of respiratory failure if 
the lungs can no longer provide adequate gas exchange. Respiratory failure can be acute, 
chronic or acute on chronic and is traditionally divided into type 1 and type 2: 
Type 1 respiratory failure: Is where oxygenation can no longer be maintained. This is often 
due to ventilation/perfusion (V/Q) mismatch, i.e. for a given lung unit there is a discrepancy 
between the blood circulating through it and the air reaching the surfaces of gas exchange. 
For illustration, in pulmonary embolism, air will reach diffusion surfaces as normal but the 
blood supply distal to the blockage will be compromised; in the territory of the blocked 




Type 2 respiratory failure: Is where there is failure of both oxygenation and excretion of 
carbon dioxide (CO2) and is due to failure of the respiratory pump and consequently 
impaired alveolar ventilation. As carbon dioxide level rises homeostatic mechanisms can be 
overcome and acidaemia develop.  
Respiratory physiology and homeostasis is a complex relationship between lung mechanics 
and the metabolic environment. Under normal circumstances the amount of CO2 produced 
by the body is equal to the amount excreted by the lungs and there is capacity to increase 
alveolar minute volume and hence pulmonary excretion easily in response to greater 
production (for example during exercise). In COPD, ventilation may not be able to keep up 
with production and type 2 respiratory failure may develop; several important mechanisms 
are described:(38,70-74) 
• Dynamic hyperinflation: rapid breathing and prolonged expiratory time (due to 
airflow obstruction) leads to incremental increase in lung volume as exhalation is not 
completed prior to the beginning of the next breath. In this state, greater effort is 
needed to generate a given tidal volume due to diaphragmatic flattening and 
reduced compliance at higher lung volumes. 
• Loss of elastic recoil in the communicating airways leads to airway collapse in 
expiration and gas trapping.  
• Respiratory muscles tire due to the above processes. Acidaemia and hypoxia have 
supplementary deleterious effects on muscle performance and a vicious cycle 
develops. As CO2 reaches very high levels central ventilatory drive may fall. 
• Low tidal volume breathing develops and has the consequence of alveolar 
hypoventilation. The dead space (i.e. the volume from oro-nasal cavity to the distal 
bronchioles that serves to transmit gas to the alveoli) is more or less fixed and does 
not contribute to gas exchange. For example, if dead space is 200mls and tidal 
volume drops from 800 to 400mls alveolar ventilation drops from 600mls to 200mls. 
• If there is overlap with obesity further constraints can be placed on a failing system, 
abdominal adiposity limiting diaphragmatic movement and chest wall weight may 
prevent adequate ventilation. 
COPD is not a homogenous condition with a single common pathway towards respiratory 




lesser degree. For example, in some cachexia driven respiratory muscle weakness may 
significantly contribute to susceptibility or chronically elevated CO2 may lead to a dulled 
ventilatory response to further rises.  
The next important variable is time, if the above processes occur over days and weeks 
metabolic compensation can occur to buffer the elevated carbon dioxide level and prevent 
acidaemia developing. If, however it occurs more rapidly metabolic compensation cannot 
occur quickly enough and acidaemia eventually develops. A common occurrence is acute on 
chronic respiratory failure. 
An oft preferred term to describe acute, or acute on chronic, respiratory failure is acute 
hypercapnic respiratory failure (AHRF), but this can be misleading as it does not specify the 
presence of acidaemia. Acidaemia due to respiratory failure is particularly important and has 
management implications; the term respiratory acidaemia (RA) will used in this thesis to 
signify type 2 respiratory failure with an arterial pH of <7.35. 
1.4 Mortality and Palliative care in COPD. 
1.4.1  COPD Mortality.  
COPD is currently the fifth commonest cause of death worldwide but is expected to rise to 
fourth by 2030.(75) In the UK, ‘chronic respiratory conditions’ (of which COPD dominates) is 
the 4th commonest cause of death with lung cancer 5th. In the UK, between 1993 and 1999, 
obstructive lung disease was mentioned on 8% of all death certificates, and was the primary 
cause of death in 60% of those.(76) In 2012 5.3% of all deaths in the UK were attributed to 
COPD.(77) 
It should be noted that many of those who die from lung cancer have co-existent COPD. 
Both are overwhelmingly diseases due to smoking, but the presence of airflow obstruction is 
a strong independent risk factor for lung cancer when matched for tobacco burden or age.(78) 
COPD and its consequent disability can limit the investigative and treatment options for lung 
cancer (79) and as such, absolute separation of these mortality statistics is difficult.(47) The 
complex relationship between COPD and comorbidity was examined in large scale in the 
USA, the authors conclude “any mention of COPD in the discharge diagnosis is 
associated with higher hospitalization prevalence and in-hospital mortality from 




associated with COPD is likely underestimated.” (80) In COPD stratified by FEV1 the 
majority of deaths in mild and moderate disease are due to lung cancer and cardiovascular 
events. Only in severe disease does respiratory failure become the predominant cause.(47) 
Mortality during an individual exacerbation can also be considered. The British Thoracic 
Society (BTS) and Royal College of Physicians (RCP) have produced large scale audits of 
clinical practice. In the 2015 audit in-hospital mortality for those admitted with ECOPD was 
4.3%.(29) Mortality was higher in the two preceding reports (7.8% in 2008 and 7.7% in 2003) 
and the authors in 2015 cannot fully explain the magnitude of this change but both selection 
bias and updated oxygen prescribing and delivery methods may play a part.(29,81) A large time 
matched case series reported in-hospital mortality as 7.7%.(82) We can conclude that UK in-
hospital mortality following ECOPD is in the range 4.3-7.8%. Medium to long term mortality 
is high in those who survive hospital admission. Canadian data shown in Figure 5  illustrates 
that following the first hospital admission for ECOPD, 50% of patients will not survive 4 
years.  
Figure 5 Survival curve following first hospitalised ECOPD 
 
Mortality in those who develop respiratory acidaemia is likely to be substantially higher, 
although the mortality consequence simply of developing RA irrespective of persistence is 
difficult to assess. Good outcome data for those that go on to receive treatment for RA in 
the form of assisted ventilation is available and mortality is several times higher than those 




Figure 6 Age Standardised Mortality Rate (ASMR) per 100,00 population aged under 75 by 
cause, England. (83) 
 
As can be seen in Figure 6, in contrast to the other two major sources of premature mortality 
and morbidity cardiovascular disease and cancer where much progress has been made there 
has been relatively less progress in respiratory disease. As diseases so strongly associated 
with deprivation and little chance of a healthy individual being ‘struck down in their prime’ 
there is a danger they are afforded less importance in public policy.  
1.4.2  Palliative Care in COPD. 
Palliative care services have traditionally focussed upon cancer care. In a UK survey of 
palliative care services returned by all primary trusts (NHS administrative bodies now 
superseded by clinical commissioning groups), the overwhelmingly majority (>75%) 
identified ‘patients with diagnoses other than cancer’ as ‘group with most unmet needs in 
terms of end of life care.’(84) Patients with COPD often experience a high symptom burden 
over a prolonged period of time. A landmark study compared patients with advanced COPD 
as defined by FEV1 < 0.75L and one episode of hypercapnic respiratory failure to those with 
unresectable non-small cell lung cancer (NSCLC). The COPD cohort experienced worse 
symptoms across biological, psychological and social domains. Despite this no one in the 




Timely palliative care depends on accurate assessment of prognosis and an understanding of 
the natural history of the disease. The following graphic (Figure 7) developed originally by 
the RAND corporation elegantly illustrates the problem of predicting outcome in diseases of 
organ failure (such as COPD) and hence assigning palliative care.(86,87) Patients with COPD 
may have many exacerbations from which they recover prior to one from which they do not.  
Figure 7 General trajectories of function and well-being over time in eventually fatal 
chronic illnesses. 
 
This unpredictability goes some way to explaining the under-provision of palliative care in 
COPD. Despite several initiatives to promote palliative care, the situation remains sub-
optimal. A recent very large-scale study drawing on coding data from the UK Clinical Practice 
Research Datalink has directly explored receipt of palliative care in patients with COPD in the 
UK.(88) There are several conclusions: 
• The situation is improving (study period 2004-15) but far from ideal. Amongst those 
who died during the study period 16.7% with COPD (without lung cancer) received 
some form of palliative care. Figure 8 shows total numbers accessing palliative care 
by each year in the study. The y axes are scaled differentially by whole population 
and those that died but not separated by presence of lung cancer. The almost 
unfeasibly large rise between 2013 and 2014 is unmentioned by the authors but does 
raise the question of a confounder for example changes to recording.  
• The co-diagnosis of lung cancer was overwhelmingly the factor most associated with 
receipt of palliative care (OR 14.7). Addressing the whole cohort (rather than just 
those that died in the study period) 6% with COPD alone received palliative care 




• Those with COPD alone are more likely to receive a shorter period of palliative care 
with many receiving it in their final month (i.e. terminal care) than those with co-
diagnosed lung cancer. 
Figure 8 Proportion of COPD patients that received palliative care support (PCS) in each 
year during follow up.(88) 
 
The UK national end of life care strategy was rolled out in 2008 with the specific aim of 
reducing non-cancer deaths in hospital.(89) Between 2001 and 2014 there was only a minor 
fall in those with COPD dying in hospital.(90)  Patients with any respiratory disease are far 
more likely to die in hospital. 70% of patients with respiratory conditions will die in hospital 
and few in hospice whereas less than 50% of patients with cancer will die in hospital. 94% of 
hospice deaths in the UK occur in patients with cancer, indeed direct comparison of English 
only data shows 0.9% COPD deaths occur in hospice versus 15.3% of those with lung cancer 
(91,92) This situation is not unique to the UK, a recent population study from Belgium showed 
patients with COPD were far less likely to received palliative care than heart failure, 
dementia or cancer.(93)   
1.5 COPD Chapter Summary. 
COPD is a common, yet complicated and multifaceted condition often related to tobacco 
smoking. It represents a huge burden to healthcare and as people live longer will have an 
increasingly complex interaction with other comorbidities. Despite falling smoking rates 




exacerbations confer an appreciable mortality risk and importantly also influence disease 
trajectory, those resulting in hospitalisation and respiratory failure are particularly pertinent 
to this thesis.  
Little progress has been made by comparison to other major causes of death, the reasons for 
this are unknown but may be in part due to there being less public and political pressure to 
address COPD as compared to cancer of heart disease. COPD should be viewed within its 
societal context; social conditioning to smoke beyond individual control and other biological 
and environmental factors independent of tobacco burden mean this is an illness of social 
deprivation not just one of life choices.  
Provision of palliative care is lacking with unpredictability of illness trajectory likely to be 
playing a role. How to strike the balance between standard versus palliative treatments is 
difficult. Overall, the conclusion of this section is that ‘advanced’ (i.e. complex/nuanced) 
decision making in COPD will become more frequent and more difficult. Good, evidenced 





Chapter 2. Introduction: Non-Invasive Ventilation (NIV). 
2.1 What is Non-Invasive ventilation? 
2.1.1  Description and NIV vs Invasive Mechanical Ventilation (IMV). 
NIV involves a tight-fitting mask connected to a ventilator that delivers breathing support. 
This definition from an early BTS guideline remains true; the “provision of ventilatory 
support through the patient's upper airway using a mask or similar device. This 
technique is distinguished from those which bypass the upper airway with a 
tracheal tube, laryngeal mask, or tracheostomy and are therefore considered 
invasive.”(94).  
The key difference between NIV and IMV is that the interface between patient and 
ventilator is outside the body not positioned within the upper airway. Unless obtunded for 
other reasons, IMV requires sedation to be tolerated. There are numerous practical 
differences between invasive and non-invasive ventilation but perhaps the most important is 
that patients receiving NIV are typically conscious and maintaining their own airway. This is a 
substantial advantage over IMV as: monitoring is less invasive; patients can eat, drink or 
converse with staff and visitors; airway defence mechanisms are to a large part maintained; 
and nosocomial infections are reduced.(95) Patients do not necessarily have to be managed in 
an intensive care setting which may reduce healthcare associated costs, (96) but even when 
managed in an intensive care unit length of stay is reduced.(95)  
2.1.2  History of NIV. 
There are historical references to the application of positive and negative pressure to 
provide ventilatory support dating back centuries. However, the mainstream use of 
mechanised positive (and negative) pressure ventilation is relatively short: Iron lung and 
early ventilators became widespread during the early part of the 20th century with paralysis 
due to poliomyelitis generating much of the early mandate.  What we may recognise as 
modern (positive pressure) NIV is a later development stemming from the 1980s with 
advances in plastics allowing interfaces that create a tight enough seal to form a ventilatory 
circuit with sufficient comfort for viable use. Since the early trials there has been a rapid 
increase in NIV use driven by broadening of indications across condition, physical setting and 




between 1998 and 2004, with further acceleration since then discussed later.(97) This thesis is 
in reference to modern NIV as exemplified in Figure 9. 
Figure 9 Modern non-invasive ventilation set up. 
 
2.2 NIV basic principles. 
2.2.1  Continuous Versus Bi-level Pressure. 
Continuous positive airways pressure (CPAP) is sometimes erroneously described as a form 
of NIV. As the name implies, the delivery of gas is continuous and independent of the 
breathing cycle. This is used notably in the treatment of obstructive sleep apnoea (OSA) and 
pulmonary oedema and unless specified henceforth CPAP is not being discussed.  
Unlike CPAP, NIV provides pressure support during inspiration via episodic delivery of gas 
along a pressure gradient. Pressure is bi-level, an inspiratory positive airway pressure (IPAP) 
and an expiratory positive airway pressure (EPAP). The presence of EPAP means that when 
receiving NIV the lung is never exposed to normal atmospheric pressure. 
2.2.2  How Does NIV Work? 
The mechanisms leading to the development of type 2 respiratory failure in ECOPD were 
described earlier. As it becomes harder to adequately ventilate the alveoli the muscles tire, 
tidal volumes fall and the situation spirals. Incomplete expiration leads to the intrinsic 
pressure in the lungs being higher than atmospheric pressure, this is known as positive end 




will in most cases result in a reduction in work of breathing by offsetting the amount of 
pressure required to initiate inspiratory flow (the inspiratory threshold load). The IPAP 
reduces the work of breathing further and allows respiratory muscles to rest as they no 
longer need to generate the force to produce flow. These changes typically result in an 
improved breathing pattern leading to abatement and reversal in dynamic hyperinflation, 
reduced respiratory rate, increased tidal volume and increased alveolar ventilation. This 
augmented ventilation reverses some of the immediate downward spiral effects of 
respiratory failure and allows time for both recovery of muscle fatigue and medical 
treatments such as bronchodilators, corticosteroids and antibiotics to work.(73,98-100) 
2.2.3  Volume and Pressure Targeted Ventilation. 
There are two basic ways of delivering positive pressure ventilation; volume targeted, or 
pressure targeted although modern ventilators with complex triggering and delivery 
algorithms are blurring such a binary distinction. In volume targeted ventilation the desired 
tidal volume and the time over which it will be delivered is set and the ventilator delivers 
this using the required pressure (which consequently varies). In pressure targeted ventilation 
the operator sets the maximum pressure to be delivered and the ventilator delivers this. 
Pressure pre-set ventilation has the advantage that it accounts for leak which is an 
inevitability to some degree between patient and interface.(101) There is also the advantage 
of negating pressure variation between breaths which may be uncomfortable for the 
patient. Most major trials investigating the use of NIV to treat ECOPD have used pressure 
pre-set ventilation modes. (102,103) 
There are traditional variations in practice between countries; the Eurovent survey,(104) 
although now somewhat out of date and limited to home ventilation, highlights this. As can 




Figure 10 Percentage of pressure and volume pre-set positive pressure ventilators used by 
all home mechanical ventilation users by country. (pressure dark grey) (104) 
 
2.2.4  Spontaneous and Timed Modes. 
Another consideration is when the ventilator delivers a breath. In a fully spontaneous mode 
the ventilator will detect the advent of the patient’s inspiration and deliver its programmed 
cycle. In a fully timed mode the ventilator delivers a set number of breaths per minute 
irrespective of patient efforts. The most common way of delivering NIV is a combination of 
the two; breaths are initiated by patient effort but a timed back up rate (BUR) is present. 
Advances in breath triggering and leak compensation have made modern NIV machines 
more tolerable and more effective than their predecessors.  
2.2.5  Patient/Ventilator Interfaces. 
In addition to the ventilator settings the other major variable is the type of interface. These 
can be mouthpiece, nasal, oro-nasal (also termed full face mask), total face or less 
commonly helmet.  These are depicted in Figure 11. The majority of acute NIV for ECOPD is 




Figure 11 Non-invasive ventilation interfaces. (105) 
 
2.3 When to Use NIV? 
2.3.1  When to Use NIV: Introduction. 
There are many acute situations in which NIV may be considered with variable supportive 
evidence. ECOPD with RA is undoubtedly the most studied with multiple randomised 
controlled trials. Other situations in which NIV can be used with supportive evidence include 
(but not limited to) neuromuscular disease (NMD), obesity hypoventilation syndrome (OHS), 
chest wall deformity (CWD), cardiogenic pulmonary oedema, RA in the context of 
immunosuppression, post-surgery, post-extubation, de-novo respiratory failure and 
palliative care. The evidence to support NIV use in conditions other than COPD is not 
reviewed.  
Home mechanical ventilation (HMV) (2.3.8) is a separate issue with differing indications. A 
clear distinction between an acute episode of deterioration requiring supportive therapy and 
disease progression to the point of necessitating ventilatory support at home should be 
maintained (acknowledging the final insult that pushes a patient over the cusp may be an 




2.3.2  Trial methodology in ECOPD. 
The evidence to support the use of non-invasive ventilation in ECOPD complicated by acute 
RA is compelling. Randomised controlled trials (RCTs) from the 1990s onwards have well 
established its efficacy. Of note there is the lack of blinding in most NIV RCTs due to 
problems creating a non-deleterious sham device although 2 trials have used a sham device 
they claim does not influence usual care.(106,107) Most trials compare usual care to usual care 
+ NIV. Usual care is ill defined but fairly homogenous, it comprises for the most part: 
(controlled) oxygen, antibiotics, corticosteroids and bronchodilators with discretionary use 
of theophyllines. Whether drugs are administered intravenously or orally, the use of 
particular preparations or dosing varies by setting and in line with traditional regional 
practice.  There are 3 main outcomes reported in the literature:  
1) In-hospital mortality. 
2) Need for endotracheal intubation. 
3) Length of (hospital) stay (LOS). 
Other outcomes such as relief of dyspnoea, improvement in pH or reduction in PaCO2, 
physiological improvement, major complication rate or patient experience are variably 
reported. In-hospital mortality is a better outcome measure and a criticism of the literature 
is the absence of internationally defined ‘need for intubation’ criteria. It should be noted 
however that few of these trials are adequately powered to report mortality benefit. As so 
many patients have “do not intubate” orders it is important to note the difference between 
need for intubation by pre-defined criteria and those that were actually intubated. This is an 
important distinction and one that has been intermittently observed in the literature. This 
may be particularly pertinent to the UK where intubation rates are low and is why the Plant 
et al trial design acknowledged this distinction.(103) 
2.3.3  Seminal Trials in ECOPD. 
Early case series suggested efficacy (108-110) as did a further exploratory randomised trial of 
hypercapnic (but not necessarily acidotic) patients conducted in 1993 by Bott et al.(111) In 
1995 Brochard et al.(102) randomised 85 patients admitted to ICU with ECOPD and RA to 
either usual care or usual care + NIV. Fewer patients in the intervention arm required 
intubation under pre-specified criteria (26% vs 74%) and mortality was lower (9% vs 29%). 




heralded the use of NIV outside of the ICU. Participants with mild to moderate acidaemia 
(pH 7.25 – 7.35) and PaCO2 >6kPa were randomised to either usual care or usual care + NIV 
on general respiratory wards. Mortality was halved in the NIV arm (10 vs 20%) with fewer 
patients meeting criteria for intubation (15 vs 27%).  
Table 2 summarises some of the major studies. The majority are RCTs with 2 case control 
series also added. Most compare usual care to usual care + NIV, a minority compare NIV to 
IMV.  NIV investigation has been a global endeavour and several notable studies are not 
available in English. Several studies have included RA in the context of several underlying 
conditions; unless stated as mixed aetiology, studies are limited to COPD. In each study 
either a nasal or oro-nasal mask was used, latterly almost all trials use oro-nasal by default. 
Statistical test results have deliberately not been included in detail as the number of caveats 
required to present this data would render the table unwieldy and the useful oversight 
provided lost.  For the primary outcome whether this is mortality or need for intubation 
significance has been indicated. It should be borne in mind that markedly different 
treatment algorithms e.g. time and intensity of intervention are used across these trials. 
There are few trials to have reported in the last 10-15 years; following its establishment as 
the mainstream treatment for RA in ECOPD it is unlikely ethical approval for a protocol 




Table 2 Major studies of NIV in which some or all patients had ECOPD. 
First/Last Author  
Year 








(In favour of NIV arm unless stated.) 
Comparative data displayed: UC vs UC+NIV 
Comments  
Role of Pneumonia 





60 UC vs UC + NIV 
Multi-centre 
Lower 30-day mortality (30% vs 10%)*  
Median LOS 9D in both arms 
Improved breathlessness and pH. 
Mild or no acidaemia. 
 
Pneumonia unreported  






85 UC vs UC + NIV 
Multi-centre 
 
Lower in-hospital mortality 29% vs 9%* 
Lower need for intubation: 31/42 (74%) vs 11/43 (26%)*  
Median LOS: 35d vs 23d. 
Improved 1 hour encephalopathy score and pH 
‘severe pneumonia excluded’. 
Fewer pneumonic complications 
in NIV group  





31 UC vs UC + NIV 
2 centres 
 
Lower need for intubation: 11/15 (73%) vs 5/16 (31%)*  
Lower need for intubation: 8/12 (67%) vs 1/11 (9%) in 
those with COPD*  
Mixed aetiology (74% COPD) 
Intubation criteria poorly 
defined. 
2 patients each arm with 
pneumonia. 





24 UC vs UC + NIV 
Single-centre 
 
No benefit in any outcome.  Mild acidaemia: pH 7.33 +/-0.01 
Unusual delayed delivery and 
only 2 x 3hr sessions/day 
Pneumonia excluded. 







30 UC vs UC + NIV 
Single-centre 
 
Lower need for intubation: 2/15 (13.2%) vs 1/15 (6.6%) 
4 in UC had rescue NIV (predefined but subjective criteria) 
Median LOS: 14.6d vs 11.7d 
One death only in UC arm. 
One death only in study in UC 
arm. 
Pneumonia present in 5/15 UC 
and 6/15 NIV 





27 UC vs UC + NIV 
Single-centre 
 
Higher in-hospital mortality: 0/11 (0%) vs 4/16 (25%) 
Similar need for intubation: 5/11 (46%) vs 7/16 (44%) 
 
Mixed (unbalanced) aetiology 
(only 22% COPD) 
9/27 (33%) primary diagnosis of 
pneumonia. 7/9 were in NIV 
arm. 






58 UC vs UC + NIV 
Single centre 
 
Lower in-hospital mortality: 31% vs 8%* 
Lower need for intubation: 28% vs 12% 
Lower LOS and breathlessness score 
 
Pneumonia not an exclusion, 





First/Last Author  
Year 








(In favour of NIV arm unless stated.) 
Comparative data displayed: UC vs UC+NIV 
Comments  
Role of Pneumonia 









Lower in-hospital mortality: 1 (6.7%) vs 0 (0%) 
Lower need for intubation rate (2 (13.3) vs 1 (6.7%) 
 
90% male, pH <7.3 excluded. 
Mean pH 7.36 (NIV) vs 7.39 
Pneumonia unreported 





236 UC vs UC + NIV 
Multi-centre 
 
Lower in-hospital mortality: 24/118 (20%) vs 12/118 (10%)* 
Lower need for ventilation: 32/118 (27%) vs 18/188 (15%)* 
Little benefit identified if pH 
<7.3 






49 NIV vs IMV 
Single-centre 
 
Higher in-hospital mortality: 5/26 (19%) vs 6/23 (26%) 
Lower 1-year mortality: 46% vs 26% (expressed as % of 
total not survivors)* 
pH 7.2 both groups 
52% of NIV group received IMV 
Pneumonia not excluded, 
reduced VAP: 13% vs 34% 






34 UC vs UC + NIV 
Single-centre 
 
Lower need for intubation: 7/17 (41%) vs 2/17 (12%)* 
Lower in hospital mortality: 2/17 (12%) vs 1/17(6%) 
Median LOS: 12.3d vs 8.0d 
Not an exclusion 
Further details unknown. 






20 UC + sham NIV 
vs UC + NIV 
Single-centre 
Lower need for ventilation: 10/10 (100%) vs 0/10 (0%)* 
7/10 in sham arm were then successfully treated with NIV. 
2 deaths in NIV arm, 1 in placebo  
Study suspended at planned 
interim analysis due to clear 
benefit of NIV. 
Pneumonia excluded 







41 UC vs UC + NIV 
Single-centre 
 
Lower need for intubation: 14% vs 5% 
Median LOS: 10d vs 7 d. 
Improved 2 hr RR and GCS. 
Pneumonia excluded 
Mortality data unavailable 
 










Lower in-hospital mortality: 11/64 (17%) vs 16/64 (25%) 
Lower duration of ventilation and LOS.  
Fewer serious complications. 
Sick population, mean pH 7.18 
Prospective NIV vs retrospective 
controls. CAP included, 21/64 
(33%) vs 19 (30%) 






52 UC vs UC + NIV 
Single-centre 
 
Need for intubation: 2/27 (7%) vs 2/25 (9%) 
No deaths, reduced 1 hour Borg score  
Median LOS: 7d vs 5d (removal of one outlier). 
Large number excluded due to 
no bed. 
pH <7.30 excluded. (mean 7.4) 
Pneumonia excluded 






64 IMV vs NIV 
Multi-centre 
 
In-hospital mortality: 14/33 (42%) vs 10/31 (32%) 
In hospital mortality COPD: 7/18 (39%) vs 3/20 (15%)  
Mixed aetiology (59% COPD) 
Pneumonia included of whom all 




First/Last Author  
Year 








(In favour of NIV arm unless stated.) 
Comparative data displayed: UC vs UC+NIV 
Comments  
Role of Pneumonia 







36 UC vs UC + NIV 
Single-centre 
 
Lower in-hospital mortality: 16.7% vs 5.6% 
Lower need for intubation: 44.4% vs 11.1% 
Median LOS 8.8d vs 6.1d 
Pneumonia not an exclusion, 
further details unknown 
 
Collaborative 






342 UC vs UC + NIV 
Multi-centre 
 
Lower in-hospital mortality: 12/171(7%) vs 7/171 (4%) 
Lower need for intubation: 26/171 (15%) vs 8/171 (5%)* 
Significant improvement in 24 hour pH PaO2, RR and 
accessory muscle use.  
pH >7.24 including many with 
normal pH 
Pneumonia not an exclusion. 
Low overall mortality. 







60 UC vs UC + NIV 
Single-centre 
 
In-hospital mortality 23% both arms 
Lower need for intubation: 10/30 (33%) vs 3/10 (10%)* 
 
 
Pneumonia not an exclusion,  
 






75 UC + sham NIV 
vs UC + NIV 
Double blinded 
Multi-centre 
“In-hospital mortality was similar in both groups” numbers 
unreported 
Lower need for intubation: 5/37 (13.5%) vs 13/38 (34%)* 
Median LOS 10.5d vs 8.5d 
Significant cross over and off 
protocol ventilation. 
Pneumonia excluded 










Higher in-hospital mortality: 3/20 (15%) vs 2/20 (10%) 
Lower need for intubation: 12/60 (60%) vs 3/20 (15%)* 
Mean LOS 17.8d vs 9.4d 
Data collected 1999-2001 long 
before publication 
Pneumonia present at admission 




2.3.4  Trials Addressing Specific, Clinically Relevant Questions. 
It is not simply the case that NIV is superior to standard medical therapy at reducing IMV. 
Head to head trials have shown at least non-inferiority between NIV and IMV. One difficulty 
of such trials is that rescue therapy when meeting predefined criteria is usually IMV leading 
to significant cross-over. This is a necessary consequence of ethical trial protocols and does 
not imply that had NIV been continued death was certain. Conti et al. randomised 49 
patients with RA to NIV or IMV of which 12 out of 23 initially receiving NIV were intubated. 
In hospital mortality was comparable, but one year outcomes favoured NIV with fewer 
readmitted or requiring long term oxygen therapy (LTOT).(118)  
Early RCTs tended to select less unwell patients but several trials in higher risk patient 
groups have also been positive: 3 important patient groups have been explicitly studied: 
1)  Elderly Patients: Nava et al. compared NIV to standard treatment in patients with 
COPD aged over 75. The primary endpoint was patients meeting intubation criteria; 
those in standard treatment arm meeting this were then offered NIV rescue therapy. 
NIV was successful in 38 out of 41 patients initially randomised to receive it and in 22 
of 26 patients receiving it as rescue therapy. Older patients may not be considered 
eligible for invasive ventilation but NIV offers an alternative, effective therapeutic 
option.(127) Another Italian study compared outcomes in 207 prospectively identified 
people aged either under or over 75 with ECOPD and RA. In-hospital mortality was 
19.8% in the older cohort, which although higher than those younger, is not 
unacceptably high.(128) 
2) Patients with a low Glasgow Coma Scale (GCS): in a prospective study, outcomes in 
958 managed in an ICU setting with or without hypercapnic coma (GCS 8 or lower) 
were compared; the aetiology of RA was heterogeneous.  NIV was considered 
successful when a patient avoided intubation and was discharged to a hospital ward 
fully conscious for at least 24 hours. Of 286 with COPD, 66 had hypercapnic coma. 
NIV success was high in both arms (89% no coma vs 86.3% coma) but in-hospital 
mortality was higher in the coma group (20.4% vs 27.2%). While this study is 
uncontrolled, and potentially not generalisable to those managed outside of ITU, it 
demonstrates that NIV is effective in those with coma with an acceptable mortality 




this is consecutive patients admitted to ICU which imposes considerable selection 
bias.(129) Similar, but perhaps more realistic conclusions were drawn from a case 
control study grouping patients by consciousness score. They found lower GCS to be 
associated with worse outcome but that treatment is not futile.(130)  
3) Patients with community acquired pneumonia (CAP) and respiratory failure: In an 
early, mixed aetiology study patients with CAP and RA were randomised to either UC 
or UC + NIV. NIV reduced need for intubation but not in-hospital mortality. More 
importantly, of patients with COPD treated with NIV (n=12) none met intubation 
criteria vs 54.6% in UC arm (n=11) . In-hospital mortality was similar (8.3% vs 18.2% 
p=0.59) but two month mortality was markedly different in favour of NIV (11.1% vs 
62.5% p=0.05).(131) This study is too small and selected to draw definitive conclusions 
but supports NIV in pECOPD. 
2.3.5  Instances Where NIV Has Not Been Shown to be Beneficial in COPD. 
Not all trials have been positive in support of NIV. NIV doesn’t confer any mortality benefit if 
acidaemia has not developed, i.e. to prevent development of RA rather than treat it once 
established. Much of the evidence for this is extrapolated from trials with a mean pH close 
to the normal range where a substantial number are non-acidaemic rather than from 
specific trials in defined, non-acidotic populations..(117,122,124)    
In probably the only truly negative RCT of NIV vs usual care in ECOPD, Barbe et al. recruited 
24 patients to each arm. Those in the intervention arm received nasal NIV in 3 hours sessions 
once in the morning and once in the afternoon for 3 days. The mean pH was 7.33 in both 
arms and NIV wasn’t commenced until 12-48 hours after admission. No benefit was 
identified in any outcome measure. The very small sample size and unusual manner of 
delivery of the intervention mean few conclusions with reference to modern NIV can be 
drawn.(113) Wood et al also reported no positive findings but their series included mixed 





2.3.6  Cochrane Review and Meta-Analysis. 
A recent Cochrane review and meta-analysis of the use of NIV to treat RA in ECOPD (defined 
as pH <7.35 and PaCO2 >6kPa) included 17 studies comprising 1264 participants drew 
several important conclusions: (132) 
• NIV provides 46% risk reduction of in-hospital death vs usual care without NIV. This 
translates into a number needed to treat (NNT) to save a life of 12. 
• Endotracheal intubation risk is reduced by 65%. Equivalent to a NNT of 5. 
• Length of stay is reduced (mean difference of 3.4 days). 
• The magnitude of benefit in mortality and intubation reduction is maintained 
whether mild or more severe acidaemia using pre-defined pH thresholds (pH <7.3 vs 
those with pH of 7.34-7.30). 
• Similarly, whether NIV is provided in ICU setting or on a ward does not affect 
magnitude of benefit. (This may be true within the clinical trials, but the authors 
caveat careful consideration of local factors such as staffing levels and expertise.) 
• Further RCTs comparing usual care without NIV to NIV are unwarranted and unlikely 
to be granted ethical approval. 
2.3.7  Other Observations from the Literature. 
• The intervention of NIV has been heterogeneously applied both in terms of pressure 
support and duration: in most trials NIV is applied shortly after the identification of 
need and delivered semi-continuously throughout the first 24-48 hours as tolerated. 
NIV use in the first 24 hours varies between publications: Kramer et al report median 
use of 20 hours whereas Plant et. al. report a median of 8 hours. Further variation in 
the published literature surrounds the criteria for NIV removal. Differing weaning 
strategies are employed, convention in the UK is to gradually reduce the time and 
pressure support with guidelines recommending tapering over 2-3 days. In RCTs 
maximum achieved IPAP is also varied usually in the 10-18 range which lies below the 
modern-day UK recommendations of 20-30,(133) there is evidence to suggest higher 
intensity NIV is more effective.(134)  An important future research topic is better 
quantification of NIV delivery and weaning strategies.  
• Mortality in the clinical trials is lower than seen in real world practice. The reasons 




patients excluded from clinical trials. This raises the possibility there may be a cohort 
of patients receiving NIV who derive little benefit. If identification of this group were 
feasible it may lead to better use of palliative care. 
• The role of NIV in pECOPD is poorly understood, as can be seen from the summary 
table the inclusion of patients with pneumonia is variable and reporting is 
inconsistent at best. Limited evidence supports the use of NIV in pECOPD and there 
are certainly no grounds for exclusion of this patient group.  
Overall, there is near universal acceptance that NIV is an excellent, lifesaving treatment for 
patients with ECOPD complicated by RA and offers at least non-inferior alternative to IMV. 
2.3.8  Home Mechanical Ventilation in COPD. 
There have been several trials investigating the use of home ventilation in COPD. Three 
major trials, reported in the recent past are summarised. While not the primary subject of 
this thesis the influence of domiciliary ventilation is likely to significantly alter the landscape 
of in-hospital ventilation over the coming decades. 
Struik et.al: 201 patients with persistent hypercapnia (PaCO2 >6.0 kPa) 48 hours after 
termination of NIV used to treat acute RA were randomised to receive home NIV or usual 
care for 1 year. Pressures were modest, mean IPAP 19.2 (SD 3.4) and EPAP 4.8 (SD 1.0). No 
benefit in the primary endpoint of 1 year admission free survival was shown (65% vs 64%). 
Amongst those that completed the trial there was little difference in PaCO2 (6.4 vs 6.6 kPa) 
suggesting the intervention had little physiological impact.(135)  
Koehnlein et.al: 195 patients with stable disease and a PaCO2 of >7 kPa (i.e. not related to 
exacerbation event) were randomised to NIV or usual care. Patients in the intervention 
group received high intensity NIV (both high pressure and high BUR) targeted to reduce their 
PaCO2 by 20%. Significant 1-year mortality benefit was seen: 12% vs 33%. The major 
criticism of this trial is one of generalisability, 36 centres took 7 years to recruit 195 patients 
suggesting that selection bias may be a lot higher than reported. Generalisability is further 
questioned by a low overall emergency admission rate in both groups and only 3% in the 
control group required acute NIV, substantially less than would be expected in such an 




Murphy et. al: The trial by Struik et. al. was thought to be negative because a substantial 
proportion of hypercapnic patients soon after acute NIV would correct without intervention; 
long term, post discharge outcomes in patients with reversible hypercapnia are comparable 
to those with normocapnia.(137) Murphy et al. randomised 116 persistently hypercapnic 
(PaCO2 >7 kPa) patients 2-4 weeks following acute NIV to either HMV + oxygen or oxygen 
alone. Those receiving HMV had pressure support titrated to achieve CO2 reduction of 0.5-1 
kPa. They found median admission free survival of 4.3 months in the intervention group and 
1.4 months in the control group although no significant difference in mortality alone. COPD 
exacerbation rate was median 3.8 (IQR 1.7-6.0) in the HMV arm and median 5.1 (IQR 1.0-9.2) 
in the oxygen alone arm.(138)  
There is increasing interest in and use of home mechanical ventilation in COPD. Some 
patients cannot be weaned acutely from a ventilator and receive domiciliary ventilation but 
are not included in clinical trials as they cannot be easily randomised. This group will also 
grow, evidence here is derived from clinical experience rather than from RCTs. All these 
patients have advanced COPD and HMV will necessarily interact with any NIV service. Whilst 
use is increasing, results from clinical trials are less impressive than some would hope. Such 
a high intensity intervention comes with increased patient contact and typically direct 
telephone access to a clinician which may well have some treatment or admission avoidance 
effect. Nevertheless, it is intuitive that an intervention able to demonstrate a sustained 
lowering in PaCO2 will in the long run, if patient selection and NIV delivery appropriate, have 
positive outcomes. 
2.4 Current NIV Realities, the Case for Poor Practice and NIV Underuse. 
2.4.1 Information sources. 
There are several excellent sources of information to give a comprehensive oversight of UK 
practice. Crucially these are based on case record review and not from coding databases 
which may give broad oversight but offer few specific insights. NHS procedure coding does 
not currently differentiate between CPAP and NIV providing ventilatory support, (both have 
the same OPCS code E85.2) (139) rendering unverified coding data of limited use. 
The British Thoracic Society produced audit data of NIV practice annually from 2010 to 




sections) with data contributed by almost every NHS trust offer excellent 
generalisability.(29,81) The National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) report was commissioned after concerns over rising mortality and variations in 
practice.(144) 
2.4.2 NIV services: Speed of change. 
NIV services have developed rapidly from a treatment which was the remit of intensive care 
units and a few centres in the early 1990s to a mainstream treatment. 100% of trusts in 
England and Wales responded to the 2015 national COPD audit; in only 0.2% of total cases 
was lack of availability of NIV recorded. For comparison, in 2003 62% of patients with pH 
<7.35 did not receive ventilatory support, of the 36% of cases where the reason for non-
provision is known 10.9% was lack of availability. However, while NIV is available in (nearly) 
every acute trust service, capacity may still not yet meet demand during high requirement 
periods; NCEPOD reports 40% of hospitals had insufficient capacity to meet demand for 
acute NIV.(144) 
Alongside increasing availability there has been increasing use: as a proportion of total cases 
of hospitalised ECOPD, NIV use rose from 8.5% in 2003 to 12% in 2014 without any obvious 
increased need based on ABG criteria.(29,145) This rapid development of services is not limited 
to the UK, in the United States of America (USA) assessing >7 million ECOPD hospitalisations 
between 1998 and 2008 Chandra et al. found an increase in NIV use of 462%.(146) Almost 
identical increases were seen in a study of the Danish national registry between 2004 and 
2011 where NIV use increased 4.6 times.(147) In a large Scandinavian audit of admissions in 
2005 across 3 hospitals 14% of ECOPD admissions received NIV although the authors note 
wide variation between centres.(148)  
2.4.3 Who initiates NIV? 
The NCEPOD report identified 9299 cases in February and March 2015 coded as E85.2 as 
described above. A random selection of up to 5 cases per hospital were selected. 432 cases 
had a clinician completed questionnaire including details of service provision and 353 
underwent external, expert case note review. In 69.1% the indication for NIV was ECOPD and 
overall there is a high proportion of patients with multiple comorbidity, advanced frailty and 




wide range of specialties, the commonest being general medicine. Only a third of cases 
(33.4%) were initiated by respiratory or critical care and the decision to initiate NIV was 
made by a consultant in 28.3% of cases. The specialty of the first consultant to review the 
patient varies and 31.7% were by respiratory or critical care. Therefore, a non-specialist 
junior clinician usually initiates NIV and senior review is by a non-specialist. It should be 
remembered that those initiating NIV are likely to be the same as those deciding not to use 
NIV where potentially indicated. While direct comparison to the UK is problematic, and 
much has changed since 2006, a survey of American practice revealed physician lack of 
knowledge to be the most important reason for under-utilisation of NIV.(149) 
2.4.4 Where is NIV provided and the role of level of care. 
The current and recently updated UK guidelines state: (133)  
• The severity of AHRF, and evidence of other organ dysfunction, 
should influence the choice of care environment. 
• NIV should take place in a clinical environment with enhanced 
nursing and monitoring facilities that are beyond those of a general 
medical ward. 
• Initial care plans should include robust arrangements for escalation, 
anticipating that around 20% of AHRF cases should be managed in 
a level 2 or 3 environment. 
The majority of NIV is delivered on acute medical units or respiratory wards; 8-10% of cases 
are managed in a critical care environment.(29,143,144) It has been recommended that those 
with a pH of <7.26 are managed in a level 2 or 3 environment because of an increased risk of 
treatment failure in these patients.(133,150) What is classed as critical care may provoke 
debate but generally refers to a designated unit with enhanced staffing ratios and 
monitoring facilities. Typically, in the UK it comprises level 2 care which has 1 member of 
staff to 2 patients and level three has 1 to 1 care. The emerging trend toward respiratory 
support units (RSU) raises further nomenclature headaches. In our trust patients managed in 
an RSU are classed and costed as level 2 patients. The following sections seek to highlight 




or high dependency unit (HDU) setting or in a RSU rather than assess the merits of one 
versus another. 
In all episodes of ECOPD in the 2015 National UK COPD audit, 882/13,414 (7%) were 
assessed by critical care, of which 257 (1.9%) were transferred and 0.8% were intubated. 
From the same data set, 1612 (12%) were treated with NIV.(29) In the 2013 BTS NIV audit 91% 
of patients treated with NIV were managed on a ward despite 47% presenting with a pH of 
<7.26.  Moreover, in those needing NIV due to ECOPD (61% of the total population) with a 
pH of <7.26, in-hospital mortality was 28% if NIV commenced in a HDU/ICU vs 40% if outside 
HDU/ICU.(143) Similar findings of underuse of critical care beds especially in high risk patients 
prompted NCEPOD report to conclude: “This raises concerns that it has become 
accepted practice to provide care of NIV patients in non-critical care areas despite 
a high chance of treatment failure.”. The following graphic from NCEPOD (Figure 12) 
shows where NIV was provided. In a number of hospitals no NIV was delivered in critical care 
and in some all of it was, 1-20% was the commonest response.(144)  
Figure 12 Percentage of NIV episodes provided in different clinical areas (NCEPOD report). 
 
As was noted in the COPD and Asthma Outcomes Study (CAOS) there may be a herd effect 
within individual intensive care units leading to marked variation in practice from one 
hospital to another.(151) Point two of the quoted guideline is probably the most important 




whether an NIV service is based around an ICU, a (respiratory) HDU or a respiratory support 
unit (RSU) within a medical ward the importance is recognition that these patients require 
higher staffing ratios than can be offered by a normal ward. The UK has a relative shortage 
of critical care beds. There have been several studies comparing critical care provision 
between countries; it is estimated the UK has between 3.5 and 6.6 ICU beds per 100,000 
population. Compared to Germany (24.6 - 29.2/100,000) France (9.3 - 11.6/100,000) or the 
USA (20.0/100,000) there are significantly fewer ICU beds.(152,153) Italy has developed a 
network of respiratory high dependency care units, a model that some trusts in the UK are 
attempting to mirror.(154) It is possible that as things stand, despite the sensible advice laid 
down in national guidance, for most hospitals in the UK provision of NIV is on a medical 
ward. 
2.4.5 Underuse of NIV. 
Despite the growth in NIV services there remains substantial underuse. In the 2008 national 
audit 26% of patients had respiratory acidaemia but 12% received ventilatory support (NIV 
and/or IPPV). Similar findings were reported in 2015. 10,315 had an admission arterial blood 
gas of which 22% had a pH of <7.35. 4411 went on to have a second blood gas of which 38% 
were acidaemic but only 12% received NIV. The outcomes are displayed in Table 3, data is 
lifted directly from the report where it is presented in such a way that makes drawing out 
the absolute number of patients meeting ABG criteria for ventilation impossible. Who 
developed acidaemia on later ABGs or the time gap between 1st and 2nd samples is not 
reported.  
There is no doubt that a substantial number who could have benefitted from NIV did not 
receive it. It is not feasible to suggest all those in either audit with RA who did not receive 
ventilatory support normalised their pH without NIV. Trials of medical therapy may result in 
correction of respiratory acidaemia in approximately 20% of cases.(155) One may actually 
conclude that potential reversibility is falling as oxygen toxicity from overzealous oxygen use 
is falling following the publication of a definitive RCT proving its harm.(156) Evidence to 
support this assertion can be seen in UK audit data: median pO2 on initial blood gas has fallen 
from 9.2kPa in 2003 to 8.3kPa in 2015 with a similar fall in those with excess pO2 of >13kPa 




Table 3 pH results and % treated with NIV, National COPD audit 2015. 
 ABG result group Treated with NIV 
First/Only ABG 
pH <7.26 507/657  77% 
pH 7.26-7.34 646/1629 40% 
pH ≥7.35 412/8029 5% 
    
Only one ABG 
pH <7.26 15/41 37% 
pH 7.26-7.34 15/323 5% 
pH ≥7.35 59/5612 1% 
    
First and Second ABG 
pH <7.26 & pH <7.26 260/307 85% 
pH <7.26 & pH 7.26-7.34 189/235 80% 
pH <7.26 & pH ≥7.35 144/526 27% 
    
First and Second ABG 
pH 7.26-7.34 & pH <7.26 81/101 80% 
pH 7.26-7.34 & pH 7.26-7.34 406/679 60% 
pH 7.26-7.34 & pH ≥7.35 144/526 27% 
    
First and Second ABG 
pH ≥7.35 & pH <7.26 53/83 64% 
pH ≥7.35 & pH 7.26-7.34 118/275 43% 
pH ≥7.35 & pH ≥7.35 182/2059 9% 
 
In conclusion it has become customary to audit those that receive NIV and evaluate 
processes but there is a missing cohort of patients in whom neither the details of the 
decision not to offer ventilation nor the ultimate outcome is known. One potential cause of 
underuse other than structural inadequacy is pessimism in this patient group. 
2.4.6 Prognostic Pessimism in COPD. 
In COPD, clinicians’ prognostic estimates have been shown to be inaccurate with widespread 
prognostic pessimism. The multicentre CAOS study compared clinicians’ estimated six month 
survival with actual outcomes. 832 patients from 92 ICUs and 3 respiratory HDUs were 
recruited of whom 70.2% survived to discharge and 62% to 180 days. Figure 13 shows 80% 
of clinicians’ 180-day survival predictions were pessimistic, everything above the blue line 




Figure 13 Actual vs predicted 180 day survival.(157) 
 
Consider all patients ranked in order of estimated clinician survival, groups can then be 
compared: In the lowest quintile clinicians estimated survival to be 10% compared to actual 
of 40%. Moreover, in the lowest decile the discrepancy is even greater; estimated survival 
was 3% versus actual survival of 36%.(157) It should be noted that as these patients were 
recruited from inside critical care environments; selection had already been imposed, we 
know nothing about the patients who were declined admission to critical care. However, 
even when asked to estimate outcome of patients who had already been selected for their 
treatment potential, pessimism is rife. The patients who survived to 180 days were surveyed 
with a high (81%) response rate. 73% said their quality was as good as, or better than,  a 
stable period pre-index admission and 96% would choose to receive similar treatment 
again.(151) 
Another important finding reported in a linked paper is the wide variation in practice 
between units. 8717 patients admitted to the participating units between 2000-6 were 
retrospectively assessed. Clinicians may be consistent within their institution but access to 
ICU for patients with COPD is not the same around the country. If everyone in a unit 
practices in a similar manner there is limited opportunity for feedback on judgements.  
Figure 14 shows that some centres have effectively closed their doors to patients with 




disability. CAOS defined severe respiratory disease as: “Permanent shortness of breath 
with light activity due to pulmonary disease. Functionally, this patient is unable 
to work and has shortness of breath performing most normal activities of daily 
living, for example, walking 20 metres on level ground, walking slowly in the 
house, climbing one flight of stairs, dressing or standing.”  
Figure 14 Percentage of patients with COPD and severe respiratory disease in a period of 
stability before admission to the ICUs participating in the CAOS study 2000-2006. n=8717, 
mean and 95% confidence intervals by centre displayed. 
 
A similar pattern of inter-unit variability of is seen in mean age of those admitted. It should 
also be noted that the mean age for most units is close to 65, none is over 70 and there are 
only a handful of units even have an upper confidence interval over 70 years.(151) The mean 
age of a patient admitted to hospital in the UK with ECOPD is 72 and those receiving NIV is 
similar.(29,81,144) Over half of patients admitted to critical care for any reason in the UK are 
over 65 (158) and historical data (2008-9) closer to the study period shows the commonest 
age bracket was 70-74. As shown earlier in the NIV population aged >75 good outcomes can 
be expected and current guidance (published post CAOS) expressly recommends “advanced 
age is not an important determinant of outcome with NIV treatment of AHRF.”(133) 
It would appear that there is considerable variation in practice and at the time of the CAOS 
study at least there was an age bias acting against patients with COPD admitted to critical 




Earlier data from the same group gives a fascinating insight into gatekeeping decisions 
amongst patients with COPD.(159) 98 consultants from one network (34 intensivist, 17 
respiratory, 47 other) were asked to give an opinion on admission to ICU. Three hypothetical 
patients were presented by telephone simulating a registrar/consultant discussion. 
Importantly vignettes were detailed and 70% felt the simulation represented their decision 
very well and a further 24% quite well. Respondents reported a median of 10 gate-keeping 
decisions in the preceding year. Very wide estimated survival probabilities were observed in 
all three simulations with those choosing not to admit the patient to critical care being more 
pessimistic. When the same consultants were asked to identify a predicted in-hospital 
survival below which they would not intubate a hypothetical patient with COPD in their mid-
70s the mean threshold was 22%.  The in-hospital survival for a time matched UK ICU patient 
intubated for ECOPD of 59.4%.(160) One cannot directly compare the two, but a high 
threshold for intubation in ECOPD will lead to a lower overall mortality. It is likely to be that 
well-intentioned clinicians have selected a sensible lower limit for intubation, but their 
estimates of survival are inaccurate and hence too many patients are considered futile cases 
therefore a selection bias towards fitter patients is imposed. 
2.5 NIV Policy and Guidelines. 
2.5.1 British Thoracic Society Guidelines. 
In the absence of clear guidance, it is perhaps more reasonable to excuse poor practice. 
Therefore it is important to note that there has been clear and exhaustive guidance 
surrounding the use of NIV in the UK dating back to 2002.(161) The most up to date guideline 
was released in 2016,(133) guidance is unambiguous and achievable, i.e. it does not set goals 
that only top performing hospitals or trusts could achieve. Some of the key 
recommendations are identified above (2.4.4).   
2.5.2 British Thoracic Society Quality Standards.  
In April 2018 six quality standards were introduced by which acute NIV delivery in the UK can 
be judged. Each statement is accompanied by a clear numerator and denominator to 
standardise audit. These standards and the document as a whole mirror some of the 
systematic problems highlighted. They have been included in full here for reference as they 




Table 4 British Thoracic Society standards for acute non-invasive ventilation in adults. 
1 Acute non-invasive ventilation (NIV) should be offered to all patients who meet evidence-based 
criteria. Hospitals must ensure there is adequate capacity to provide NIV to all eligible patients. 
2 All staff who prescribe, initiate or make changes to acute NIV treatment should have evidence 
of training and maintenance of competencies appropriate for their role. 
3 Acute NIV should only be carried out in specified clinical areas designated for the delivery of 
acute NIV. 
4 Patients who meet evidence-based criteria for acute NIV should start NIV within 60 min of the 
blood gas result associated with the clinical decision to provide NIV and within 120 min of 
hospital arrival for patients who present acutely. 
 
5 All patients should have a documented escalation plan before starting treatment with acute NIV. 
Clinical progress should be reviewed by a healthcare professional with appropriate training and 
competence within 4 hours of starting NIV and by a consultant with training and competence in 
acute NIV within 14 hours of starting acute NIV. 
 
6 All patients treated with acute NIV should have blood gas analysis performed within 2 hours of 
starting acute NIV. Failure of these blood gas measurements to improve should trigger specialist 
healthcare professional review within 30 min. 
 
 
Standards 1,2,3 are particularly relevant to the preceding sections and this thesis. Statement 
1 is in keeping with the observation that there are an unknown cohort who do not receive 
NIV. The numerator/denominator recommends blood gas data is reviewed and all those 
meeting criteria but not receiving NIV be reviewed and discussed.  
2.5.3 Strategy Bodies. 
Increasing NIV usage had been recognised in NHS policy prior to the spotlight of NCEPOD, it 
was identified by both NHS England (“Reducing Premature Mortality”) (163) and the 
Department of Health (“An Outcomes Strategy for COPD and Asthma”) (164) as a key priority. 
This recognition has continued and it features prominently as one of the ‘priorities for 
optimisation’ in the ‘unexpected mortality national challenge’ limb of the COPD RightCare 
pathway. (“RightCare Pathways provide a national case for change and a set of 
resources to support Local Health Economies to concentrate their improvement 
efforts where there is greatest opportunity to address variation and improve 
population health.”) (165) 
Not an official policy institute, but certainly influential, the most recent Cochrane review of 




research would enhance our ability to more accurately select the right patients and 
the right levels of ventilation.”(132)  
2.6 NIV Chapter Summary. 
NIV is one of the success stories of modern respiratory medicine. It has developed rapidly 
and spread from the intensive care unit onto the general medical ward. The strongest 
evidence base is in ECOPD with respiratory acidaemia and a pH in the 7.25-7.34 range. In this 
circumstance under favourable conditions in-hospital mortality is halved. However even 
when specified high risk groups are studied it remains efficacious. 
Non-Invasive ventilation has undergone rapid change, the pace of which may have 
outstripped the expertise and infrastructure required to deliver it. In the UK, the vast 
majority of NIV is delivered on wards rather than in an intensive care or high dependency 
unit. Two thirds of NIV is initiated by non-specialist clinicians and, by extension, most 
decisions not to provide NIV must also be likewise. Only about half of patients with 
respiratory acidaemia during hospitalised ECOPD receive NIV. Some of these patients will 
respond to medical therapy but it is over-optimistic to assume that a (large) proportion of 
the missing would not have benefitted from NIV. The reasons why so many patients are not 
receiving NIV are multifaceted. There is evidence of prognostic pessimism, but other factors 
may include; clinicians feeling out of their depth, lack of knowledge of the treatment 
effectiveness, dismissal of the condition as unimportant and poor infrastructure, though 
these are inferred observations rather than proven facts. Specialists are prognostically 
inaccurate and this is likely to set an example to generalists commonly managing these 
patients and, in part, result in the situation described by NCEPOD where it has become 
normal for patients with high levels of need and high mortality to be managed on medical 
wards. NIV is an extremely effective treatment so in many cases a decision not to ventilate 
on the grounds of assumed poor outcome will be a self-fulfilling prophecy and entrench 






Chapter 3. Introduction: Cognitive Biases and Predictive Modelling. 
3.1.1 Introduction to Cognitive Bias. 
If we accept that there are a cohort of patients missing out on ventilation the next question 
is why? Healthcare institutions, doctors and nurses are not deliberately causing harm. How 
has wholesale bad practice and thinking crept in systematically? It has been alluded to that 
prognostic pessimism and cognitive biases may be contributing. The following sections seek 
to illustrate how this may be so. In a system operating under finite resource, its allocation 
falls to individuals on both macro (e.g. service commissioning) or micro (e.g. individual 
patient entrance to ICU) scales. Some variance can be attributed to differing priorities and 
local pressures, but it seems likely that the inherent biases of human thinking are playing a 
role. “Over the past 40 years, work by cognitive psychologists and others has 
pointed to the human mind’s vulnerability to cognitive biases, logical fallacies, 
false assumptions, and other reasoning failures. It seems that much of our 
everyday thinking is flawed.” (166) Cognitive biases unconsciously influence the analysis of 
information we consume and the decisions and opinions we then make and hold; knowledge 
and vigilance of these psychological pathways could be used by clinicians to adopt more 
rational diagnoses or management plans. More nefarious use is mainstream for example by 
marketers and advertisers to manipulate our purchasing habits.  
Critical appraisal of medical literature is commonplace and is incorporated into many aspects 
of medical education. An appreciation of bias in clinical trials is exactly why double blinded, 
randomised, controlled trials are the gold standard. How bias affects the individual doctor is 
afforded relatively less import by the profession: there is little or no survey data on whether 
clinicians are aware of cognitive bias in their daily practice and there appears to be little 
focus in the UK upon educating doctors as to its effects on medical decision making.(167) A 
search of the Royal College of Physicians website (168) undertaken on 29/01/2018 returned 
24 results comprising courses, workshops and online learning for critical appraisal whereas 
none were returned for bias or cognitive bias. Similarly, the UK specialist training curriculum 
for general internal medicine (GIM) returns 5 hits for critical appraisal and 1 for bias (which 
is subpoint 27/27 under Decision making and clinical reasoning).(169)  
Gallup news has polled Americans routinely for many years on their fear of terrorism (Figure 




and several orders of magnitude less than the more proportional fear of being a victim of 
non-terrorist gun crime. There are many factors at play but there is no doubt the high 
numbers who are either “very worried” or “somewhat worried” are not the product of 
rational thought but of a reflex driven by the inherent biases of the human mind. Availability 
bias which will be explained shortly, explains the upturn in fear that is maintained for years 
after the 2001 terrorist attack. This somewhat sensationalist example is included as a stark 
illustration of the power of cognitive bias and its ability to influence human thinking.   
Figure 15 Gallup Poll: Percentage of Americans fearing terrorism.(170) 
 
3.1.2 What is Cognitive Bias? 
The understanding of decision making has evolved over time. The concept of the dual 
process theory (DPT) has become accepted and applied to the understanding of human 
decisions in many fields. Much of the modern theory and its refinements are attributed to 
the Nobel prize winning psychologist Daniel Kahneman and his co-worker Amos Tversky. It 
contends there are two types of mental process: 
Type 1 or intuitive processes are dominant and account for up to 95% of our decisions. 
These automatic, mental processes are driven by ‘heuristics’ which are mental shortcuts 
derived from emotion, stereotypes and pattern recognition. Most of the time this rapid, type 
1 way of thinking serves us well and prevents dealing with the thousands of decisions we 
make sub or barely consciously everyday. Some examples given by Kahneman include: 
“solve 2+2”, complete the phrase “war and…” or “come up with a good chess move (if 




prone to failure. A systematic heuristic error is a cognitive bias. Heuristics and cognitive 
biases were predominately described in the 1970s by Tversky and Kahneman and have been 
continuously developed, now over 100 different types of cognitive bias have been described. 
One can imagine that there is allegory between the chess master’s autopilot move and the 
doctor’s diagnosis. 
Type 2 process are slow, deliberate and analytical incorporating evidence evaluation. These 
processes are more reliable but are mental resource intensive hence the predisposition 
toward type 1 processing. Some examples include: “dig into your memory to recognise a 
sound”, “determine the validity of complex logical reasoning” or “determine the 
appropriateness of a behaviour in a social setting.” Ideally important decisions 
affecting patients’ lives should be type 2 processes removing as much of the reflex, 
automatic pathway as possible.(171-174)  
Table 5 shows a summary of some important cognitive biases with hypothetical examples of 
how it may impact upon provision of ventilation. 
Table 5, Types of Cognitive Bias. Partially adapted from Croskerry, Acad. Med 2003 (175) 
Type of Bias 
 
Description Ventilation Case example 
Affect Heuristic Risk/benefit perception is linked 
to strength of positive or negative 
effect associated with the 
activity being evaluated 
Having an artificially high mortality 
estimation and consequent high threshold 
for admitting patient to critical care due 
to negative perception of COPD. 
Aggregate Bias Belief that aggregated data used 
to develop guidelines 
disproportionately does not apply 
to one’s own patients who are 
special or more complicated.  
Failure to offer sufficient IPAP due to fear 
of pressure damage and experience of 
historical case of pneumothorax. 
 
Anchoring Giving disproportion value to 
particular feature(s) of a case and 
failing to adjust perceptions with 
time. 
Fixing upon a low FEV1 rather than a good 





Increasing the likelihood of 
frequently occurring or recently 
experienced events as they 
readily come to mind. 
Missing opiate toxicity causing RA in 
patient with mild COPD and attributing 
unexpected respiratory failure to the 
more frequently experienced ECOPD. 
Bandwagon 
effect 
The tendency to do and think as 
others do. Leads to positive 
reinforcement from peers. 
Individual hospitals have markedly 
different thresholds to use of NIV or 
admission to critical care as a result of 
the bandwagon effect. 
Confirmation 
Bias 
To cherry-pick, interpret and 
recall evidence favourable to 
one’s preconceptions rather than 
evidence to refute it.  
Patients with COPD ‘never wean from the 
ventilator’. Citing rates of treatment 
failure without acknowledging other 
variables such as other organ failure or 







Once someone receives a 
diagnostic label it sticks and gains 
traction through repetition in 
case notes. 
Breathless smoker labelled by clinician as 
ECOPD without symptoms or airflow 
obstruction. Ward based NIV may be 
suitable for RA and ECOPD but an 





The way in which information is 
presented influences outcome.  
Junior may present a case with emphasis 
on negatives in terms of chance of death 
rather than the positives and chance to 





To blame patients for their illness 
rather than see it within the 
societal context in which it 
occurred. 
Patients with COPD or obesity may 
consciously or sub-consciously receive 
lower calibre treatment or 
disproportionate rationing due to 
perceived ‘self-inflicted’ illness. 
Gambler’s 
Fallacy 
Belief that independent, 
preceding events may influence 
upcoming ones.  
A sequence of patients failing NIV and 
requiring IPPV may lead to suspicion the 
next case will too and influence decision 
making. 
Hindsight Bias Knowing the outcome of events 
influences the experience and 
perception of those events. 
 
Recall of case in which ventilation was 
not offered and patient died to support 
same action again on grounds of futility. 
Feedback loop with confirmation bias. 
Ignorance trap Making an error may not confer 
immediate detriment to the 
patient and unless fed back 
clinician may be unaware of 
harm. 
Initial failure to act upon RA in a timely 
fashion may not cause immediate death 
but in-hospital mortality rises due to 
complications of prolonged acidaemia. 
Illusory 
correlation 
Perceiving causality whereas 
there is only correlation. Often 
supports a confirmation bias. 
Disliking a particular type of ventilator 
and having consequent reluctance to use 
it following a death. 
Overconfidence 
bias 
The belief we know more than we 
do placing excessive weight upon 
opinion rather than objectivity. 
Stating there is no chance of success in a 
case without reference to objective 
sources of information. 
Playing the 
odds 
Common outcomes are more 
likely than uncommon ones. 
Even high-risk patients can be managed 
on a ward successfully but there is a 
greater chance of treatment failure and 
harm. This risk is however lower than the 




The tendency to over or under 
estimate the probability of the 
whole as compared to its 
component parts.  
Tying in is poor perception of summative 
risk, clinician may cite 2 colinear 
variables as grounds for treatment 
refusal. 
Triage Cueing Patients move through healthcare 
systems along established 
pathways. Treatment is dictated 
to a degree by their physical 
location. 
Patient admitted to level 2 care as there 
are no remaining ward beds. Once into 
critical care is more likely to receive 
level 3 care than a similar patient not 
physically there. 
 
There are many experiments that evidence individual cognitive biases in healthcare from 
psychiatrists over-estimating violent offense risk dependent upon probability framing (176) to 




(177) to a knowledge of outcome inflating ratings of care quality amongst emergency 
department physicians.(178)  
3.1.3 Avoidance of bias: The use of Clinical Scoring Tools. 
Predictive models have been used in many sectors of society to enhance forecasting. In 
healthcare they have been extensively used to both model diagnostic probability for 
example the Wells score to aid diagnosis of venous thromboembolism (179) or to calculate 
risk of death from surgery.(180) Since the advent of statistical modelling it has been compared 
to human judgement. A consistent finding in healthcare settings since the 1950s is statistical 
models and predictive score outperform, or are at least as good as, clinicians.(181-183) Even if 
type 2 pathways are consciously employed and the risk is deeply considered it is very 
difficult to remove the affect heuristic from the perception of factors that confer 
independent risk, estimate their relative weights and then add them together.(184) Added to 
this there are also conscious prejudices acting within both systems and individuals that 
detract from true objectivity. 
3.1.4 Cognitive bias summary 
Cognitive bias is under-recognised in healthcare as a source of systematic error. It is not a 
leap of imagination to conclude that some of the psychological processes described are 
responsible in part for some of the erroneous practices we see in the delivery of NIV in the 
UK. It is possible due to the reliance on timely clinical judgement to initiate treatment and 
the organisational implications of provision (particularly decision devolution cross specialty) 
that NIV is disproportionately affected. Would we be satisfied if half of patients with a 
myocardial infarction, stroke or upper GI bleed did not receive their evidence-based 
treatment? While critical appraisal and self-reflection are accepted components of the 
rounded 21st century medical practitioner, cognitive bias awareness is not; it is difficult to be 
vigilant for and eliminate practices of which one is unaware. A useful addition to complex 
clinical decision making is an unbiased clinical tool which have been shown to offer superior 




3.2 Predicting Outcome in COPD 
3.2.1 Why Predict Outcome? 
The preceding sections have established that COPD is common, and the number and 
complexity of patients is increasing. NIV is an effective treatment for RA in ECOPD and has 
experienced a surge in use over the last 20+ years. In the UK at least, there is evidence of 
underuse with perhaps poor investment/infrastructure, lack of skillset and pessimism 
playing a role. Cognitive biases are interesting and may contribute to the establishment of 
(erroneous) behaviours and are a barrier to objectivity. Guidelines frequently reference high 
risk patients but there is a limited understanding of what a high-risk patient is and how to 
recognise him or her. A robust predictor of in-hospital mortality could help shared decision 
making, improve selection of patients to receive ventilation, guide level of care, improve 
early palliative care, better describe participants in future clinical trials and objectify inter-
hospital variability to name a few. The following sections will give an overview of mortality 
modelling in general COPD patients limited to studies that have developed validated multi-
variable scores and an in-depth review of literature specific to assisted ventilation.  
3.2.2 Predicting Outcome in Stable COPD. 
Many papers have reported both univariate associations with mortality and multiple variable 
models. A long follow up period is required to capture enough events (deaths) to develop a 
tool and then consequently validate it. As such despite much work there is relatively little of 
clinical utility. The BODE index reported in 2004 is the best known and adopted (185) and has 
been subsequently studied to translate its utility into other novel settings such as assessing 
response to pulmonary rehabilitation (186) lung volume reduction surgery (187) or as part of 
the assessment for lung transplantation.(188) BODE comprises: (B) BMI, (O) degree of airflow 
obstruction, (D) Dyspnoea measured on modified medical research council (MMRC) scale 
and (E) exercise capacity measured using six minute walk test (6MWT). Patients can score 0-
10, after separation by quartile there was clear gradation in mortality over 52 months of 
follow-up with those in the highest risk group being 80%.(185) A potential criticism of BODE is 
the inclusion of the 6MWT which may be routinely available in secondary care but is not 
typically so in primary care where the bulk of COPD care is delivered. Other scores have been 




3.2.3 Predicting Outcome in Exacerbations of COPD 
Mortality modelling of outcomes from exacerbations of COPD, which is more pertinent to 
this project, has also borne fruit. Several tools have been derived and validated to predict 
mortality not least by our research group (DECAF programme). 
BAP 65: Retrospective design from a large research database. 88,074 admissions with ECOPD 
were analysed. Half were used to derive and the other half to internally validate the tool.(192) 
Further external validation was reported in separate (existing) dataset.(193) The score 
comprises (B) blood urea nitrogen (BUN) >25mg/dl, (A) altered mental status, (P) Pulse >109 
beats per minute, (65) Age >65. Altered mental status was defined as Glasgow Coma Scale of 
14 or lower or a designation of disoriented, stupor or coma by a physician. The tool 
performed well with an area under the receiver operated curve (AUROC) of 0.77 in its 
external validation. This tool is simple to administer, uses only routinely available indices and 
has the advantage of development in very large cohorts. It is also validated to predict the 
need for mechanical ventilation. However, the potential components were limited to those 
captured by the database, the in-hospital mortality was both low and had unexplained 
significant variation (1.8% derivation/internal validation, 4.1% external validation) and no 
confirmation of COPD diagnosis is available. It has common ground with the CURB 65 tool 
(194) in confusion/altered mental status, urea/BUN, a cardiovascular assessment in blood 
pressure/heart rate and age of 65 but head to head comparisons are not reported in the 
original papers. Unsurprisingly where head to head comparison is available in the DECAF 
validation cohort prediction of in hospital mortality was very similar (CURB 65 AUROC 0.76 vs 
BAP 65 AUROC 0.77).(82) 
DECAF score: Our research group derived and validated the (D) dyspnoea, (E) eosinopenia 
(C) consolidation, (A) acidaemia, (F) fibrillation score which is a robust predictor of in-
hospital mortality in patients admitted to hospital with ECOPD.(82,195) The score was derived 
in 920 consecutive, unique patients and then, in a separate dataset, internally (n=880) and 
externally (n=845) validated. The score is simple to administer and selects a large proportion 
of patients considered low risk. The score employs a novel extension of the traditional 
medical research council dyspnoea (MRCD) scale,(196) termed extended medical research 
council dyspnoea (eMRCD) scale which incorporates a functional assessment of ability to 
wash and dress independently and has clear descriptors of progression between levels 




Table 6: Extended Medical Research Council Dyspnoea Score. 
Extended MRC Dyspnoea (eMRCD) Score  
“In the past 3 months, when you were feeling at your best, which of the following statements best 
describes your level of breathlessness?” 
Only Breathless on strenuous exertion 1 
Breathless hurrying on the level or walking up a slight hill 2 
Walks slower than contemporaries, or stops when walking on the level for 15 min 3 
Stops for breath after walking 100m, or for a few minutes, on the level 4 
Too breathless to leave the house unassisted but independent in washing and/ or dressing 5a 
Too breathless to leave the house unassisted and requires help with both washing and dressing 5b 
 
Using the full 5 variable score the AUROC was 0.86 in the derivation cohort, 0.83 in the 
internal validation and 0.82 in the external validation indicating excellent mortality 
discrimination. The strongest individual predictor of outcome was the eMRCD score. A 
parallel between BODE and DECAF is dyspnoea assessment indicating the importance of 
steady state breathlessness in COPD outcome modelling. Comparison tools such as APACHE 
II,(198) BAP 65, CAPS (199) and CURB 65 none of which capture dyspnoea were significantly 
outperformed by the DECAF tool within both the internal and external cohorts. The DECAF 
score is shown below (Table 7). 
Table 7: The DECAF Score. 
Variable Score 
Dyspnoea:    eMRCD 5a 
                   eMRCD 5b 
1 
2 
Eosinopenia (<0.05 x 109/l) 1 
Consolidation 1 
Acidaemia (pH <7.3) 1 
Atrial Fibrillation 1 




3.3 Predicting Outcome from Assisted Ventilation in COPD. 
3.3.1 Problems Within the Current Literature. 
There are several problems within the current literature which hamper interpretation. Many 
of the methodological decisions described in the next chapter were made to address these 
concerns. Balancing pragmatism and generalisability with scientific rigor is a problem for 
every clinical study but, in the case of predictive modelling, loss of generalisability limits the 
value of the work. 
1) Mixed Aetiology: The indications for NIV are numerous and the disease entities that 
may benefit are distinct. A patient with neuromuscular disease has disease specific 
predictors of adverse outcome not shared by other conditions. The influence of some 
candidate predictors may be mitigated by a heterogenous derivation population and 
some may be disproportionately enhanced by differences in case mixed proportions 
and outcome event frequency between conditions. Fortunately, COPD is the 
commonest condition is most mixed aetiology series, but these effects should be 
remembered. 
2) Misdiagnosis or unconfirmed diagnosis: Anecdotally it is common to find patients 
with a label of COPD with little supporting evidence. This is backed up by some 
evidence.(200) Airflow obstruction, as defined by a fixed FEV1/(F)VC ratio, is ‘less 
abnormal’ in an elderly population leading to over-diagnosis of COPD (201,202) and 
there is frequently error differentiating asthma from COPD.(203) COPD should be 
objectively confirmed as misdiagnosis rates are high and, as alluded to above, 
outcome prediction will be affected by case mix. In one case series 75% of patients 
with obesity hypoventilation syndrome (OHS) admitted to the ICU had been 
misdiagnosed and treated for COPD in the last 2 years.(204) Data extracted from 
coding or unverified databases may include a substantial number of patients without 
COPD. 
3) Selection Bias: In many of the audits and case series from which data is extrapolated 
selection bias has already been applied because, as established, there is a 
discrepancy between those with RA not correcting with medical therapy and those 
that receive NIV. There is a limited amount that can be done to infer the effect of this 




series reported as consecutive may suggest this. ICU case series also necessarily are a 
product of significant selection bias. 
4) Differing outcome measures: Much effort has been put into predicting failure of NIV 
rather than death. There are attractions to this strategy to prevent delay of 
intubation in high risk groups. However, there is no universal standard for diagnosis 
of NIV failure and subjective criteria such as accessory muscle use may be used. 
Moreover, if an elevated RR or low pH are used to prompt consideration of 
intubation and hence to diagnose failing NIV, they will inherently predict that 
outcome.  
5) Management variation: An extrapolation of the above point; rates of intubation and 
the threshold to access critical care beds are very different around the world 
meaning the case mix of those receiving NIV varies greatly which hampers 
generalisability. In the UK where only 1% of ECOPD is intubated outcomes from ICU 
based series with high proportions receiving IMV may be less relevant. Furthermore, 
unlike the chemical structure of a drug, the intervention of NIV has not remained 
constant over time. Many of the studies reviewed are 20-25 years old, over this time 
there have been advances in pressures, interfaces, back up rates and ventilator 
algorithm. Factors identified in early studies may remain equally valid but, without a 
constant baseline interpretation must necessarily be caveated.   
6) Modelling from non-bespoke datasets: A predictive model can only be as good as the 
indices collected. There are examples of modelling from existing clinical and research 
databases using routinely captured data to give a large n. This does not allow for 
inclusion of strong potential predictors of outcome for example patients’ steady state 
breathlessness which may not ordinarily be recorded. Directly related to the point 
above clinical databases are routinely compiled in ICU settings, so ICU derived scores 
are disproportionately reported in the literature compared to the number of patients 
treated there.  
7) Poor methodology: Reporting of univariate associations that may or may not hold up 
under multiple regression analysis as independent predictors of mortality. Validated 
findings in separate (prospective) datasets are rare. Under-powering is also common; 
drawing conclusions from a small number of outcome events. 
8) Complexity: A clinical tool is only useful if it can be simply administered, ideally at the 




software but is not routinely available (in the UK) at the point of NIV delivery to 
augment decision making. There is little chance of such a complex tool being used in 
day to day clinical practice. 
3.3.2 Steady State Variables (Admission Independent). 
3.3.2.1 Age. 
Age has an uncertain effect on outcomes described earlier an RCT of NIV vs standard medical 
therapy in patients aged over 75 with RA predominantly secondary to COPD, rates of 
endotracheal intubation and mortality were lower in the NIV group.(127) Further confirmation 
of good in-hospital outcomes in the over 75 group is reported by Nicolini et al but tempered 
by higher six month mortality.(128) In Confalonieri’s work,(205) age was associated with 
mortality on univariate analysis but not after logistic regression, these findings were 
replicated in a well described, prospective consecutive case series reported by Chakrabarti 
et al.(206)  Age has been identified as an adverse factor in other case series and national 
audits but it is uncertain whether this represents an independent risk or an association with 
other factors such as increasing disability, comorbidities or external factors such as the 
extent and intensity of treatment offered.(207-211)   National guidance states age alone should 
not be used as the basis for treatment denial.(133)  
3.3.2.2 Dyspnoea/Performance Status. 
As described above the use of a dyspnoea score in both stable state COPD and an 
exacerbation of COPD is an important predictor of outcome. It has been infrequently 
collected specifically in the ventilated population. Examining only those with RA from the 
DECAF papers it can be seen there is a strong correlation between eMRCD score and 
inpatient mortality and we already know that eMRCD was the strongest predictor of 
outcome following multiple regression analysis in this population. Figure 16 shows the 
pooled data from the entire derivation and validation cohorts with clear gradation in 
mortality by eMRCD class. It also shows the value of the further division of the traditional 
MRCD class 5 in 5a and 5b. In an abstract addressing only the ventilated patients in the 
derivation cohort, eMRCD remained a strong mortality predictor.(212) Increasing dyspnoea 
score was also associated with higher post discharge mortality during a one year follow up 




Figure 16 Inpatient mortality in ventilated patients stratified by eMRCD score (Pooled data 
from DECAF derivation and validation). 
 
3.3.2.3 Body Mass Index (BMI). 
Low BMI is associated with both inpatient (215) and post-discharge mortality.(213,216) In a large 
cohort including non-ventilated patients, BMI <18.5 and unintentional weight loss were 
associated with in-hospital mortality, but only the former was an independent predictor.(195) 
In a retrospective coding cohort weight loss was associated with in hospital mortality 
amongst patients with COPD requiring LTOT while obesity was a protective factor.(210) 
3.3.2.4 Cough effectiveness. 
Cough effectiveness has shown promise (209,217) but is subjective. Nevertheless, it is intuitive 
that patients who are unable to clear secretions may have worse outcome, as is the case in 
other conditions such as amyotrophic lateral sclerosis (ALS) and bronchiectasis. 
3.3.2.5 FEV1. 
There appears to be no association between FEV1 and inpatient mortality.(206) Indeed, in one 
study the inverse was found.(218) Post discharge there is no association with either 




3.3.2.6 Long Term Oxygen (LTOT) use. 
No difference was found in NIV failure rates at 24 hours in those with preadmission LTOT 
although in-hospital mortality is unreported.(219) A large American coding series suggests 
68.5%  one year mortality (in-hospital + post discharge) from a poorly characterised cohort 
of patients with COPD requiring LTOT however in the absence of a comparison group few 
conclusions can be drawn from this.(210) Long term oxygen use is an independent predictor of 
post discharge mortality in two longitudinal studies.(213,216)  
3.3.2.7 Comorbidities. 
A higher generic comorbidity score such as the Charlson index (220) or one of the 
modifications of it is generally associated with increasing mortality.(221-223) Cardiac co-
morbidities such as heart failure or atrial fibrillation (AF) may be particularly pertinent 
especially in the medium term.(214,224,225) In ICU populations unsurprisingly higher organ 
dysfunction scores are associated with increasing mortality, the observation that multiorgan 
failure adversely effects outcome certainly has face validity but is perhaps not readily 
generalisable to a real world cohort. 
3.3.3  Severity and Timing of Acidaemia. 
3.3.3.1 pH. 
Low pH is the most commonly reported factor associated with outcome. Many studies have 
identified low pH as an adverse marker. Specifically, that a pH <7.25 confers worse 
outcome.(103,143,205,215,226,227) The National Chronic Obstructive Pulmonary Disease Resources 
and Outcomes Project (NCROP) report examined the acidaemic subgroup from the 2008 UK 
national COPD audit in detail, it shows inpatient mortality of pH 7.26-7.34 =  17%; pH ≤7.25 = 
26%.(226) In-hospital mortality was even higher in the 2013 BTS audit report; pH 7.26-7.34 =  
26%; pH ≤7.25 = 36%.(143)   
While there is little doubt that a low pH is a univariate marker of poor outcome, there is a 
danger its importance has been overstated due to a paucity of good multi-variable models. 
Interestingly a higher CO2 level is less commonly reported as an independent associate of 
mortality. An explanation of this is that increased duration of low pH may be the true 
adverse feature and a lower nadir is merely one prolonging factor, others such as concurrent 




examples where pH is significantly associated with mortality or NIV failure on univariate 
analysis but not after multiple regression (211,228) and others where pH is non-
significant.(128,129,229,230) In the case series by Chakrabati et al.(206) the pH was lower in the NIV 
failure group 7.22 vs 7.26, but CO2 was 10.2kPa in both groups. This does suggest that a 
metabolic component is contributing. It should be remembered that, by definition, pH is 
needed to diagnose RA and will almost always be recorded making it an easy candidate to 
study from clinical databases. It is also to be expected that those whose pH does not correct 
after initiation of a treatment designed to correct pH have worse outcomes than those that 
respond to treatment. 
Overall, while questions may be raised pH is an extremely attractive candidate to study and 
probably the best described association with poor outcome. The threshold of 7.25 has been 
so frequently identified as clinically relevant it is very widely known outside of specialist 
circles. 
3.3.3.2 Timing of acidaemia. 
Timing of acidaemia refers to the time between hospital admission and development of RA. 
This may be influenced by access to healthcare and local practices but remains an important 
and overlooked marker of success. Notably this is not the same as late failure of NIV 
whereby a patient may deteriorate post treatment initiation although outcomes may also be 
adverse.  The number of days in hospital prior to admission to ICU is negatively correlated 
with six-month outcomes.(214) It is intuitive to believe that RA treated with ventilation segued 
with acute bronchodilators, corticosteroids, antibiotics etc may have better outcomes than 
those that deteriorate later despite these medical treatments. The strongest evidence to 
support timing as important is from the NCROP report. Progressive mortality is seen when 
stratified thus; a) lowest pH on admission = 12%; b) acidaemia on admission but lower pH 
later recorded = 21%; c) normal pH on admission with subsequent acidaemia = 33%. The 
importance of timing as an independent predictor of in-hospital mortality was reported in a 






Albumin has an uncertain association with mortality, in a large study in which just over one 
third of patients were invasively ventilated, a lower albumin was one of a small number 
factors associated with 6 month mortality,(225) Pacilli et al. found a 5.6 fold increase in NIV 
success for every 1g/dl increase in serum albumin level (223) and it was an independent 
predictor other small studies.(224,231) However, other authors have not identified a significant 
relationship.(208,215) 
3.3.4.2 Glucose. 
The role of hyperglycaemia has been specifically, prospectively examined in one paper.(206) 
Inclusion was limited to COPD and the majority (93%) had spirometry conformation. The 
authors found a random blood glucose of >7 mmol/l in 44/88 (50%) patients of whom only 
16 had a pre-existent diagnosis of diabetes. Hyperglycaemia at this threshold was associated 
with mortality after multiple regression, precise mechanism was not postulated although 
similar findings in heterogeneous critical care admissions are noted. Other studies have not 
replicated this finding. 
3.3.4.3 Inflammatory markers. 
C-reactive protein (CRP) has been reported as a univariate determinant of mortality but not 
after multiple regression. (222,232) Neutrophil count emerged from one regression analysis.(212) 
There are equally examples of non-significance in CRP/white cell count (WCC) and neutrophil 
count.(208) In consecutive patients with COPD requiring intubation the role of procalcitonin 
(PCT) measured at time of ICU admission was investigated. Those with pneumonia were 
excluded but bacterial culture was actively sought via endobronchial aspirate. PCT was an 
independent predictor of outcome (WCC, CRP, temperature, antibiotic use were not) with 
ICU mortality doubled using a 0.24ng/ml dichotomy.(233) In the UK, PCT is not routinely 
analysed limiting use as a candidate predictor. 
3.3.4.4 Troponin I. 
The relationship between chronic cardiovascular comorbidity and COPD has been well 




independent predictor of mortality. 71 individuals with severe COPD were recruited 85% of 
whom were ventilated (majority NIV only), 18% had an elevated  troponin I (>0.5ng/ml) in 
whom in-hospital mortality was 62%.(234) 
3.3.4.5 Urea. 
Higher urea was significantly associated with in-hospital death in an early study although 
much of the focus of this work was upon the use of the now rarely used respiratory 
stimulant Doxapram.(227) It was the only biochemical marker associated with mortality in one 
large, single centre case series.(208) As noted earlier urea features in both the BAP 65 and 
CURB 65 tools. 
3.3.4.6 Pneumonia. 
As discussed (1.3.4), consolidation is thought by some to invalidate a diagnosis of ECOPD. 
However, there is clear evidence from national audits that UK practice does not adhere to 
this. Pneumonia has consistently been shown to be a strong predictor of NIV failure and in-
hospital mortality. (143,209,223,235) In the Pacilli paper the presence of pneumonia decreased 
the success probability by 62%.(223) As shown earlier the original RCTs had a mixed policy 
towards inclusion of patients with pneumonia, where reported outcomes are generally 
worse than in those without consolidation. Interestingly in the large Confalonieri cohort 
where 12.6% had complicating pneumonia it had no impact upon outcome.(205) 
3.3.5 Clinical Observations. 
3.3.5.1 Reduced Consciousness. 
Whether measured using the Glasgow coma scale or otherwise reduced consciousness is, 
where measured, nearly always a univariate associate of mortality and is very commonly an 
independent predictor after regression analysis.(102,211) Several unvalidated regression 
models have included assessment of reduced consciousness.(234,236) In a case control study 
Scala et al. found fairly progressive in-hospital and 90 day mortality from normal conscious 
level through to greatest stupor.(130) One particular study, reviewed earlier is in contrast to 
these findings with no significant difference in NIV success between those with hypercapnic 
coma (GCS <8) and those without in the COPD subgroup.(129) Amongst the literature this Diaz 




hospital mortality was significantly higher than in those with a GCS of <8, particularly if 
unresponsive.  
The association between lower GCS and worse outcome is expected for two reasons, greater 
impairment of consciousness is related to a greater insult such as a higher acute rise in CO2. 
Secondly NIV can be quite an intrusive therapy, confusion or agitation mean chance of 
successful delivery of the intervention is reduced. 
3.3.5.2 Respiratory rate. 
Elevated respiratory rate (RR) potentially relates to greater ventilator asynchrony or a more 
fatigued patient and raises the possibility of greater degree of concurrent metabolic 
acidaemia. Several studies have found association A rate of >30 breaths per minute may be a 
useful cut off.(205,206)  
3.3.5.3 Heart Rate and Blood Pressure. 
One may suspect that those with cardiovascular instability have worse outcomes due to 
sepsis, heart failure or adverse response to the application of positive pressure. Many 
studies incorporate the observations into an acute physiology and chronic health evaluation 
(APACHE) or simplified acute physiology score (SAPS) score so perhaps individual reporting is 
less common. Some studies have found that higher heart rates (HR) or lower blood pressure 
(BP) (particularly unresponsive to fluid resus) are adverse features but this is not a consistent 
finding.(209,237) Interestingly Phua et al in a study comparing outcomes from NIV in COPD to 
other conditions found heart rate one hour after NIV administration to be associated with 
NIV failure on multivariate analysis in the non-COPD group only. A large number of the ‘non-
COPD’ group were in fact pECOPD, it is feasible these data represent the well-established 
poorer outcome in RA and pECOPD in which higher heart rate may be an explainable 
consequence of sepsis.(235) 
3.3.6 Composite tools. 
3.3.6.1 Generic Scores. 
SAPS II (238) and APACHE II are both frequently used in heterogeneous patients admitted to 
critical care and may be routinely captured. Both were derived in large, mixed case ICU 




plotted on a chart. Both are considered together as the data captured and discussion is very 
similar. As might be expected when so much data is incorporated into a prediction matrix 
they have subsequently been validated in many separate disease entities. A huge advantage 
of such scores in addition to individual patient assessment is their international use and 
routine capture by ICU software making them ideal tools for audit and performance 
monitoring. However, because they include such generic variables they are typically 
outperformed by more bespoke, organ or disease specific scores.  
Individually, neither score has been shown to offer particularly strong prediction in a 
ventilated ECOPD population (82,199,239) and, considering the complexity and poor 
generalisability to the non-critical care population, their use to guide care is not 
recommended. Probably due to easy availability they have both been frequently shown in 
ECOPD to be associated with both NIV failure and in-hospital 
mortality.(102,228,230,231,234,236,240,241) Both are returned on lists of multivariate associates of 
mortality but inclusion of a complex, multi-variable score as a single index alongside other 
individual indices is of questionable value. Similarly, incorporation of a whole tool as a single 
index of a new one is fundamentally flawed. 
3.3.6.2 COPD and Asthma Physiology score. 
A comparable but slightly more specific score to predict in-hospital mortality was derived by 
Wildman et al. using data from the UK’s Case Mix Programme Database (a rolling national 
audit). The COPD and Asthma Physiology Score (CAPS) (199)  was derived in 8527 patients 
admitted to one of 168 ICUs, validation was then performed in a separate 7957 patients. As 
implied these patients were a mixture of COPD (>80%) and asthma. The vast majority of 
these patients were invasively ventilated. The score uses 8 variables (heart rate, mean 
arterial pressure, pH, sodium, urea, creatinine, albumin, white blood count) split into 41 
scoring groups with differential weighting applied. As such it is complex to score unless 
automated. The performance was modest (prediction of in-hospital mortality, validated 
AUROC 0.72), but it did outperform the physiological components of comparable ICU utilised 
scores such as APACHE II and SAPS II within this study population. This score has little utility 
outside of the ICU due to its complexity and the population in which it was derived and 
validated. This limits its generalisability and as the authors acknowledge components are 




3.3.6.3 Confalonieri Risk of Failure Chart. 
Published in the European Respiratory Journal in 2005 Confalonieri and colleagues 
prospectively collected data on 1033 consecutive patients in several Italian centres.(205) In 
keeping with the described Italian model (154) the majority were treated in respiratory 
intermediate intensive care units (RIICUs). The patients were admitted between 1998 and 
2000 so it is possible this is a post hoc analysis of an existing, but bespoke, research 
database. There is no detail of how COPD was confirmed, and no spirometry data nor 
smoking history is reported. The study was designed to model risk of NIV failure (need for 
intubation) rather than death. Intubation criteria were pre-defined but include subjective 
criteria such as ‘copious secretions’ and ‘agitation’. Intubation rates varied wildly between 
centres (0%-72.2%). Failure to correct pH, cardiovascular instability and coma development 
were also used to guide intubation but are candidate predictors of said outcome. Two charts 
were generated to predict risk of failure, firstly on admission and secondly after 2 hours 
treatment with NIV. Validation was performed in a separate sample of 145 patients 
admitted to 3 (unspecified) participating units. 
Relatively few population descriptors are reported. Of those available, a high (43.1%) 
proportion received LTOT pre-admission and 12.6% of patients had complicating pneumonia 
(a lower proportion than in UK audits). 236/1033 (22.8%) had NIV failure, of which 185 were 
intubated. There were 142 deaths; 91 (49.2%) of the intubated patients died in hospital and 
an additional 51 patients with a pre-existing do-not-intubate order died without intubation. 
Age, GCS, APACHE II score, respiratory rate, pH, PaCO2, and PaO2/FiO2 were associated with 
NIV failure at admission. The same variables with the exception of respiratory rate and 
PaO2/FiO2 at were associated with NIV failure after 2 hours of treatment. It is unclear 
whether the constituent parts of the APACHE II score were individually modelled. 
The two complied charts are shown in Figure 17. As can be seen they are complex to score. 
The user must calculate the APACHE II score, secondarily score pH, GCS and RR and finally 
plot onto the chart.  Risk stratified into 54 different outcome boxes for 236 outcome events 
(deaths) is of questionable value. It should also be noted that pH, GCS and RR are all 
constituent components of the APACHE II score. The AUROC in the (undescribed) validation 
cohort was 0.71 at admission and 0.83 at 2hrs. It is little surprise there is such discord in this 




Figure 17 Risk of NIV failure chart at admission and after 2 hours of NIV. 
 
3.3.6.4 Scores summary 
The risk of failure chart and CAPS score are the only two published, validated scores 
encompassing multi-variable regression analysis converted into weighted scores designed 
for clinical use. Both are unwieldy and suffer from limitations associated with a narrow pool 
of candidate indices. Neither has been incorporated into routine use in the UK and both 
afford only modest predictive capacity. The published evidence is lacking. No derived score 
has included steady state dyspnoea nor timing of acidaemia as potential indices. There is 
reason to suggest both would be strong predictors. 
3.3.7 Post-Initiation. 
3.3.7.1 Predictors of Poor Outcome. 
As discussed, an assessment of outcome can be made after initiation of treatment. However, 
for reasons already laid out this is not our preferred option (3.3.1). Much of the evidence has 




failure is associated with higher APACHE II scores.(235) Failing to improve (or falling) pH is 
probably the strongest determinant of failure. Varying time cut offs post initiation of 
ventilation at which point reassessment should take place (1-4 hours) have been mooted. 
Similarly, failure to improve physiological indices such as GCS, RR or heart rate may indicate 
worse prognosis. (205,208,242)  
3.3.7.2 Late Failure of NIV. 
Late failure of NIV, following initial correction of respiratory acidaemia, is associated with 
high mortality and is more common in patients who require limited or complete assistance 
with ADLs (frailty). Moretti et al used the definition: “a sudden or progressive worsening 
of arterial blood gas tensions (pH <7.34 with an increase in PaCO2 of >15–20% 
compared with previous arterial blood gas tensions), dyspnoea and/or sensory 
deterioration while still on mechanical ventilation for at least 6 hours/day”. In a 
study comparing continuing NIV to IMV in patients with COPD meeting the above definition 
mortality was high in both arms, but continuing NIV in lieu of invasive ventilation conferred 
an extremely poor prognosis, (mortality: NIV group 92%, Intubated group 53%). Of note 
group selection was based on patient preference, pH at the time of late failure was much 
lower in the NIV group and patient numbers are low.(237) In a similar ICU cohort, late failure 
of NIV was associated with 80% mortality.(236) Cardiac complications and nosocomial 
infection were important contributors to deterioration and death, however the definition of 
late failure included non-objective criteria, limiting wider generalisabilty. Further evidence of 
poor outcomes in an Indian study, despite an ill-defined population, does increase the 
likelihood this is a real finding.(243) In contrast in a small cohort from our institution (n=14) in 
whom late failure was managed with high pressure NIV, we found in-hospital mortality was 
substantially lower (32%).(244) Further study of late failure is warranted to draw definitive 
conclusion. A binary choice between intubation or palliation should late failure develop as 
advocated by some is questionable. Few would argue that failure after initial success places 
a patient in a high mortality bracket, the observed differences are likely to be largely due to 
differing definitions selecting patients with varying salvageability. A universal definition is 




3.3.8 Predicting Outcome in COPD Summary. 
There are numerous univariate and multivariate associates of mortality that have been 
reported across many studies. Few have been specifically designed to address the question 
of risk modelling and those that have usually employed existing and limited databases. Focus 
upon biochemical and physiological continuous indices is a policy that has not yielded 
results.  
Combining evidence and opinion, there are two broad characteristics that appear to increase 
mortality: 1) markers of more advanced (and comorbid) COPD meaning a relatively smaller 
insult may result in higher mortality and; 2) markers of an insult less amenable to rapid 
correction meaning the patient must ‘stand up to’ acidaemia for longer. 
The strongest predictors of outcome have never been all tested together so direct 
comparison is limited but they probably include, steady state dyspnoea, timing of acidaemia 
onset, lower BMI, need for LTOT, lower pH (possibly greater metabolic component), a 
marker of cardiac involvement such as elevated troponin, presence of consolidation, 
reduced consciousness, higher respiratory rate. Others such as age, elevated urea, 
hyperglycaemia are strong candidates for further study.  
3.4 Introduction Summary. 
COPD is an extremely common disease. Due to of historical smoking rates, increased average 
life expectancy and improved disease specific survival prevalence continues to rise. The 
patients we can expect to see in UK hospitals and beyond in the coming years are likely to be 
more complex with greater comorbidity. While some COPD specific improvements have 
been seen they are starkly worse than in other conditions. Exacerbations of COPD are 
important systematically and individually, they lead to significant mortality and can 
detrimentally influence disease trajectory. Exacerbations leading to respiratory acidaemia 
are particularly important but can be successfully treated with non-invasive ventilation. 
COPD in its advanced stages confers a considerable symptom burden and palliative care is 
woefully lacking. 
COPD is associated with deprivation and lower social class; it is incorrect to assume that 
smoking is; 1) the root cause of all COPD and 2) that a decision to smoke is not directly 




addition to other cognitive biases may contribute to under-resourcing. One antidote to 
inequality is objectivity to circumvent the inevitable biases of human nature.  
In NIV we have a treatment for ECOPD complicated by RA that is extremely effective with a 
NNT of 12 to save a life and 5 to avoid an intubation. Further trials to prove its worth are 
unwarranted. The evidence suggests that NIV can be provided on a medical ward, but it is 
crucial that this is an appropriately staffed area overseen by appropriately trained clinicians. 
The UK is particularly poorly placed to deliver higher levels of care with staffing ratios 
appropriate to such a high intensity intervention. While the use of NIV is now routine and 
widespread, the pace of change, financial limitations and established barriers to higher level 
of care mean both the infrastructure and skilled personnel required to manage these 
patients safely and effectively has been outstripped. A significant proportion of patients 
likely to benefit from NIV are not receiving it and their details and outcomes are unknown. 
The NCEPOD report has belatedly drawn attention to these issues. 
The reasons why an effective treatment is being erroneously omitted, and care is delivered 
most commonly by non-specialist staff in often inadequate surroundings, are multifactorial. 
The speed of change is one reason, but another contention is that cognitive bias plays a role 
from national and local governance down to individual patient decision making. Increasing 
awareness of these biases may draw more attention to poor decisions leading to such 
behaviours but without objective data is unlikely to effect change. Predictive modelling is 
more effective than clinician judgement and avoids bias and could provide this objective 
data. The recently published BTS quality standards lay down clear statements against which 
NIV services can be judged. Nevertheless, the evidence to guide prediction is poor with 
numerous factors individually identified but no model to determine risk in clinical use. Key 
indices for study are listed in the preceding section summary. There is enormous potential to 
positively influence practice by risk stratifying patients if a simple, accurate predictive tool 
can be developed. Potential benefits include increasing NIV use by objectively challenging 
prognostic pessimism, guiding level of care, enhancing shared decision-making including 
access to palliative care, improving audit and assisting less experienced clinicians. This study 




Chapter 4. Aims and Governance.  
4.1 Project in Context. 
Professor Bourke’s group has conducted a successful programme of research focussed upon 
statistical modelling of clinical outcomes for patients with exacerbations of COPD. This is the 
fourth project in the programme, the preceding studies have derived, validated and 
implemented the DECAF predictive tool. This study, the NIV Outcomes study has operated 
under the acronym NIVO. DECAF derivation and validation studies have strong 
methodological similarities to NIVO. 
NIVO is a large endeavour spanning 5 years. This thesis reports the derivation project in total 
and the in-hospital validation of the predictive model. Within validation survivors to 
discharge able to give consent were offered inclusion in a consenting follow up study 
assessing longitudinal health related quality of life, anxiety and depression and functional 
status. The sub-group and post discharge outcomes and in-depth longitudinal assessment 
will be the subject of the 5th iteration in the programme and form the basis of a separate 
PhD thesis. The trial manual for the validation study has been included in the appendix (12.3) 
as this includes an oversight of the project in total.  
Aims, Outcomes and statistical methodology within NIVO are very similar for the derivation 
and validation aspects so are discussed here together to avoid undue repetition but results 
are clearly separated.  The development and reporting of both derivation and validation of a 
predictive model is relatively unusual. Derivation alone is more common, indeed one review 
article reports of 86 prognostic models published in leading journals between 2006 and 
2009, 61 included derivation only.(245) 
4.2 Research Aims. 
The overarching aim of this research project is to derive in a single centre and prospectively 
validate in multiple centres simple tools to predict in-hospital mortality for use in a 
population of patients with an exacerbation of COPD complicated by respiratory acidaemia 
that receive assisted ventilation. Tool development was guided by several principles; it 
should be simple to score, use only readily available information, be scored prior to the 




Two tools will be created; 1) using all variables up to the time of ventilation and 2) using only 
information up to the time of senior review. Their future utility is different with the second 
tool aimed at escalation planning, this limits the number of potential variables. 
4.2.1  Principle aims. 
1. Prediction of in-hospital mortality. 
• The derived tool(s) will be validated prospectively, both temporally and 
geographically, in at least 6 diverse sites in the UK, chosen to ensure wide 
variation in socio-economic factors, COPD prevalence, rurality and structures of 
care.  
2. To identify predictors of death within six months. 
• Patients who survive the initial episode requiring NIV continue to have a high 
mortality and readmission risk following discharge. Accurate prediction of short 
and medium-term survival, in those patients surviving the initial admission, may 
further inform decisions about escalation to assisted ventilation acutely and 
during subsequent episodes of acute deterioration and help patients make more 
informed decisions regarding other aspects of care planning. This may improve 
access to palliative care services, currently underutilised in this condition. 
3. To assess 12-month survival and readmissions both in the overall population and in 
patients with, and without, other key characteristics, including: 
• Late failure of NIV (recurrent respiratory acidaemia, despite on-going ventilatory 
support). 
• Long-term oxygen therapy. 
• Home mechanical ventilation on discharge. 
• Eosinopenia at discharge. 




4.3 The Clinical Tools. 
4.3.1  Overview. 
 As described two tools will be generated. These will be termed the “point of deterioration 
tool” and the “admission tool”. 
• The point of deterioration tool is for use in a patient who meets criteria for assisted 
ventilation and incorporates dynamic variables up to the point where the decision to 
ventilate is made. 
• The admission tool is for use in the admission window. It is for use to model risk in 
those that require ventilation in the admission phase but also to plan escalation at 
the point of senior review for those not yet requiring ventilation admitted with 
ECOPD who may yet develop RA.  
4.3.2  Point of Deterioration Tool. 
Ventilation can occur at any point during the admission process although the majority of 
patients (of the order three quarters) develop it in the ‘admission phase’ i.e. within the first 
day when a patient will typically be transitioning through an emergency department to their 
first hospital ward. The aim of this tool is to use multiple variables which may or may not be 
dynamic to give an accurate prediction of the likely outcome. It will be used to assist a 
clinician treating a patient who has developed respiratory acidaemia and ventilation is being 
considered.  
This has several potential benefits such as: giving patients and families realistic outcome 
estimates, refuting prognostic pessimism, preventing unnecessary treatment, guiding level 
of care, facilitating audit and objectifying inter-unit performance. Given the wide range of 
potential uses retaining discrimination across the whole spectrum of cases is important as 
this allows identification of both high and low risk patients. This tool will be used by 
clinicians of all grades. Simplicity is important to allow for routine use i.e. can be added up 
and interpreted mentally and quickly but recall of each individual component is not 
necessary. RA is a medical emergency and it is reasonable to assume that the resultant tool 
if adopted it will be written into local NIV guidelines or proformas for ease of reference. 
It was important that the data collected and incorporated into the model was representative 




presence or absence of consolidation on their admission X-ray may be irrelevant so all 
modelled dynamic data is time linked to the point of the decision. 
4.3.3  Admission Tool. 
The potential utility of this tool is somewhat different. It is only designed to be used in the 
admission phase of a patient’s journey. There are two aspects: 1) the tool should predict 
stratified mortality in those that develop their acidaemia in this admission period in the 
same manner as the point of deterioration tool (of the order of three quarters of patients 
who require assisted ventilation). 2) In those having a senior review (typically consultant 
‘post-take’ ward round) who have been admitted with ECOPD but do not currently require 
ventilation it should predict their future risk of in-hospital death were they to develop RA to 
help guide ventilation planning. The median time to review by a consultant for a patient 
admitted with ECOPD was 10 hours in the latest national audit.(29) 
The candidate predictive variables are consequently different to the point of deterioration 
tool. The use of dynamic information is more limited and must be carefully considered. The 
clear exception being timing of acidaemia as this necessarily interacts with admission 
process and can be very simply incorporated. Only information available in the admission 
window is a candidate for inclusion and its constituents are likely to mainly encompass 
variables independent of admission for example the eMRCD dyspnoea score. 
This tool, if it offers comparable prediction, confers potential advantage over the point of 
deterioration tool due to wide utility, however there is a significant chance that due to the 
reduction in candidate indices accurate predictive modelling is reduced to a point whereby 
the advantage is lost.  
4.4 Governance. 
4.4.1 Funding. 
Two separate, open, competitive grants totalling £130,000 were obtained. In neither case 
did the funder have any involvement in trial design, data collection, analysis, discussion or 
dissemination. Further financial support was secured for the validation aspect from the 




4.4.2 Patient and Public Involvement. 
Patient and public opinion was sought throughout development and influenced aspects, 
including the aims, design, and planned implementation and dissemination. The feedback on 
the study was overwhelmingly positive. The local research design service patient user group 
representing a broad spectrum of disease including COPD was consulted. Additionally, we 
established a local COPD focus group including patients and carers with experience of NIV 
who offer a disease specific viewpoint. Lay person, general medical and disease-specific 
opinions were obtained and informed our decisions.  
The project aims were universally supported giving the proposals a strong mandate. There 
was concern regarding the underutilisation of NIV nationally and enthusiasm from patients 
for increasing NIV uptake. Carers stated that improved prognostication would reduce anxiety 
generated by recurrent admissions each with uncertain outcome. 
The feedback cemented our pre-existent priority that the project’s main focus is to optimise 
NIV uptake and challenge prognostic pessimism. However, in addition, the focus groups, 
including patients with personal experience of NIV, confirmed that NIV can be intrusive and 
they would only agree to treatment if it were likely to confer benefit. This supports the need 
for simple, robust prognostic tools to identify those patients unlikely to survive, as well as 
those likely to benefit. 
Finally, there was endorsement of collecting data without individual patient consent and 
understanding of the importance of this specific point. 
4.4.3  Ethical Considerations. 
Of importance to the project are ethical constraints surrounding consent. To accurately 
model outcome and produce a generalisable tool it is vital that all potential patients are 
included. Patients unable to consent would not be random; those confused, most unwell or 
who rapidly deteriorated would be unable to give timely informed consent. These patient 
groups however are amongst those at highest risk and hence exclusion would have a 
devasting effect on both predictive capability and generalisability. For this reason, ethical 
approval to gather data without individual patient consent akin to an audit was sought. This 
does limit some of the indices available for collection and means that the intervention and 




Following discussion with patient groups and presentation to local ethics committee both 
derivation and validation were granted ethical approval to collect data without individual 
patient consent. 
4.4.4  Regulatory approval. 
Both aspects of the trial have local Caldicott approval and Trust registration.  
• Derivation project approval granted 29/4/15 by NRES Committee North West - 
Liverpool Central, REC reference: 15/NW/0389. IRAS project ID 174869. 
• Validation project ethics approval granted 11/7/16 by HRA North East - Tyne & Wear 
South Research Ethics Committee REC reference: 16/NE/0213 IRAS project ID 
206694. 
• Validation project Health Research Authority (HRA) approval granted 27/7/16. 
4.4.5 Protocol registration. 
Both aspects were separately registered with the ISRCTN registry. 
• Derivation: ISRCTN16977236 
• Validation: ISRCTN22921168 
4.4.6 Participating sites. 
4.4.6.1 Derivation. 
The derivation of the clinical tool was exclusively from a single trust, Northumbria 
Healthcare NHS Foundation Trust. Two sites contributed patients, North Tyneside General 
Hospital and Wansbeck general hospital. The former drains a largely urban population with 
areas of high deprivation and the latter a mixed urban/rural population encompassing most 
of the sparsely populated English county of Northumberland. 
4.4.6.2 Validation. 
Northumbria undertook internal validation, nine external sites contributed patients to the 
external validation (Table 8). Of note internal validation has been reported in many studies 
from a random selection of the derivation cohort. The internal validation in NIVO is a 




Northumbria trust underwent reorganisation that resulted in all NIV being delivered in a 
third, newly opened hospital. We self-imposed a limit of 200 patients to prevent the 
validation total being dominated by the sponsor organisation. 
Table 8 Participating Sites. 
 Town/City Hospital(s) 
1 Gateshead Queen Elizabeth Hospital 
2 Leeds St James’ Hospital 
3 Llanelli Prince Philip Hospital 
4 London St Thomas’ Hospital 
5 Northumbria 
North Tyneside General Hospital 
Wansbeck General Hospital 
Northumbria Specialist Emergency Care Hospital 
6 Nottingham 
Queens Medical Centre 
City Hospital 
7 Oxford 
John Radcliffe Hospital 
Churchill Hospital 
8 Plymouth Derriford Hospital 
9 South Shields South Tyneside General Hospital 
10 Taunton Musgrove Park Hospital 
 
An element of site selection was employed in an attempt to minimise the effect of excessive 
patient selection on clinical grounds. Prior to accepting a site details of their ventilation 
practice including number, patients’ functional status and mortality were studied. Other 
factors such as number of ventilators and service design were considered. This process was 
designed to avoid inclusion of sites selecting out the most unwell patients as this potentially 
prevents identification of the most adverse factors. No absolute criteria were imposed and 
there is inherent subjectivity in this approach, but it was felt to be a better method than no 
selectivity at all. Essentially if we were convinced NIV was used liberally to appropriate 
patients the site was accepted. Sites were further selected to widely encompass a cross 
section of rurality, ethnicity and deprivation. We also deliberately included small district 
general hospitals, larger general hospitals and large tertiary hospitals. In the results section 
external sites are anonymised. 
During data collection external sites were not informed of the final predictive model as there 
was fear this may influence usual care. For example, knowledge of a particularly poor 




ventilation and hence reducing the chance of that validating that very finding by non-
inclusion. Similarly, the details of the strongest predictors of outcome were withheld from 
public presentation until the very end of the recruitment window. 
Each site had a physical site initiation visit by the study team with ongoing support available 
7 days a week by dedicated telephone or email. 
4.4.7 Data Management. 
For the validation aspect of the study a bespoke, online data submission and management 
system was commissioned. Real time data monitoring by the study team was performed 
throughout. This system conformed to all encryption standards and is password protected. 
Sites could only access their own data and patient identifying details are held by the local 
site only. 
4.4.8 Trial Steering Committee. 
Regular meeting with teleconferencing were held 3 monthly during the recruitment period. 
These teleconferences were opportunities to discuss any issues arising ‘day to day’ and 
proactively identify problems. Independent chair and lay representative were present and 





Chapter 5. Methods. 
5.1 Patient Identification. 
5.1.1  Derivation. 
The DECAF derivation and validation projects aided patient identification. These cohorts 
were robustly identified by prospective daily screening to ensure consecutive patients 
admitted with ECOPD running 12/2008-06/2010 and 01/2012-05/2013. These two cohorts 
were the starting point from which to identify every ventilated patient. Patients could only 
be included in these studies once, so anyone ventilated during subsequent admissions would 
not be captured and there is a lengthy interim period. A number of steps were taken to 
ensure complete capture of consecutive ventilated patients: 
1. Any patient recorded in derivation project as ventilated was included. 
2. Any patient in derivation not initially ventilated had subsequent admissions checked 
and if ventilated included. 
3. Any patient ventilated in the validation project were included unless after checking 
preceding admissions an earlier episode of ventilation from the interim period 
between the cohorts was identified. If an earlier episode were identified it was 
selected. 
4. Non-ventilated patients in the validation cohort had preceding admission from the 
interim period checked and subsequent admissions in the validation window 
checked. 
5. Coding searches were performed over the entire period particularly to pick up 
patients ventilated during the interim period. 
6. NIV service database and ICU database was interrogated to identify ventilated 
patients. 
7. Following steps 1-6 any potential ventilation event was further filtered as feasible by 
electronic record review (particularly to remove CPAP) and any duplicates removed. 





 In order to achieve the best possible coding search different coding searches were tested 
against the known cohorts to ensure they picked up the patients we definitively knew were 
ventilated at that time. 
Final search criteria of: Age >34 + Any ICD10 J96 (Respiratory failure) or E85 procedure code 
filtered by: a primary diagnosis of influenza or pneumonia (ICD-10: J10 - J18) and a 
secondary diagnosis of COPD (J41 - J44) or a primary diagnosis of COPD (J41 - J44). As 
already noted, CPAP shares the E85 procedure code with NIV so many were ineligible (2.4.1).  
5.1.2  Validation. 
Validation recruitment was prospective: At all sites screening of physical locations delivering 
ventilation was undertaken in real time. Local arrangements were implemented dependent 
on service design to ensure consecutive patients were captured. Cross reference with service 
records and coding was recommended. The ideal situation is that the (key predictive) data is 
collected prior to outcome i.e. whether survived to discharge or not is known. This is 
impractical to achieve in all cases (for example if a patient is admitted, ventilated and dies 
within one night the researcher is likely to know the outcome prior to data collection). 
However, as described the external sites were unaware of which indices were the key 
predictors and internally the model of care and resources available made collection without 
knowledge of outcome easily achievable. 
5.2 Selection Criteria. 
5.2.1  General Observations. 
It is important that a predictive model is readily generalisable to the target population. 
Models are often applied more broadly than the populations in which they were derived; 
this can lead to clinicians acting upon false information. An example can be seen in the case 
of CURB 65, patients from nursing care were excluded but the score is frequently applied to 
such populations.(194) With this is mind, the selection criteria were kept as unrestrictive as 
feasible. For example, no upper limit was placed upon BMI, patients with high BMIs could 
still be included provided the site lead felt the predominant process leading to respiratory 
failure was ECOPD. Similarly, patients with pECOPD were included in keeping with our 
position that it is arbitrary to differentiate between a predominate airways versus 




spirometry demonstrating airflow obstruction prior to the index admission in addition to a 
history of smoking. This was to minimise the effect of misattributed diagnosis. 
5.2.2 Inclusion criteria. 
• Age 35 years or older. 
o No upper age limit was imposed, it is likely that someone under the age of 35 
has a primary process other than COPD, for example asthma. 
• Smoking history greater than or equal to 10 pack years. 
o In keeping with the above point there may be instances where COPD is 
exclusively due to non-smoking exposures, however these patients are 
comparatively rare in the UK and imposing a relatively modest minimum 
tobacco burden is likely increase overall diagnostic accuracy. 
• Obstructive spirometry (FEV1/FVC < 0.7). 
o Spirometry must precede admission. Allowing spirometry during the index 
admission would impose a significant survival bias as only those reaching a 
stable state would typically be able to perform the test. Any spirometry 
irrespective of how old was counted with the most recent obstructive 
spirometry recorded. Where available primary care records were sought. 
• ECOPD primary diagnosis. 
o Specifically, those admitted for a reason clearly unrelated to ECOPD were 
ineligible even if they subsequently met all other criteria. For example, a trip 
and fracture with post-operative RA would be excluded whereas someone 
who fell as a consequence of drowsiness and hypercapnia due to evolving RA 
in ECOPD would be eligible. 
• Respiratory acidaemia treated with NIV or IPPV (arterial blood gas pH <7.35, pCO2 
> 6.5). 
o Of note between completion of the derivation aspect and commencing the 
validation the BTS guidelines changed the PaCO2 threshold from 6.0 to 
6.5.(133,150) Criteria mirrored this change to reflect current practice therefore 
the derivation study has a lower threshold of 6.0 in keeping with the guidance 




5.2.3  Exclusion Criteria. 
• Previous inclusion in the study. 
o There are pros and cons to allowing an individual patient to be included 
multiple times or only count a single episode. Using only single episodes 
increases the proportion of outcome events and mitigates the effect of a 
single patient with multiple admissions.  
o In one specific instance a patient could be ‘included’ twice: If a patient had 
the reduced (‘clinical diagnosis’) dataset collected but was then readmitted 
having had spirometry in the intervening period and met all criteria then this 
second case would now be eligible for full inclusion. This patient would 
therefore only be analysed once for the primary outcome. 
• Other illness likely to limit survival to less than 1 year. 
o This principally refers to metastatic cancer and sites were instructed to 
consider someone as eligible as their default position. Treatment in someone 
expected to die may be substantially different to treatment in others. 
Expected mortality due to COPD did not count towards this exclusion. 
N.B. In the validation aspect patients in whom no pre-admission spirometry was available 
but in whom the lead clinician made a clinical diagnosis of ECOPD had a reduced dataset 
collected. If adopted into clinical practice the resultant tool is likely to be applied to such 
patients. This approach allows us to ensure it works in such a population and further 
enhances generalisability. These patients however did not count towards the minimum 
number of patients to achieve power. 
5.3 Data Collection. 
5.3.1  Collection Methods and Notes. 
For both aspects of the study all volumes of notes and electronic data such as laboratory 
results, radiology or digital records were viewed. Data was entered onto a case report form 
(CRF) and then transcribed onto an electronic database.  
One of the problems with predictive modelling from existing databases is a narrow pool of 
candidate indices. Data collected was extensive, indices were selected following discussion 




utility, some potentially interesting variables could not be collected within the observational 
design, so we could not for example, mandate that PCT be recorded for study purposes. Not 
all information is intended for entry into a regression model, much is to accurately describe 
the population under study. For practical reasons the information in the validation aspect 
was reduced to areas of particular interest, population descriptors and indices associated 
with mortality.  
The following sections will expand on several, key areas and indices, discussion of all indices 
collected would be exhaustive, some further details of data collection are recorded in the 
trial manual listed in the appendix (12.3). Many of the indices were recorded at admission 
and if different the point of ventilation. This is to allow differential modelling. This does add 
some complexity to data recording.  
5.3.2 Timing of Data Collection. 
Conceptualising the timings of these tools can be challenging and were a primary focus of 
site initiation visits and ongoing external site support. Figure 18 shows the time frames data 
would be collected for 3 hypothetical patients who develop their acidaemia at different 
points into admission. 
In the admission tool we collected data from the admission window (4 hours), curtailed by 
the point the index acidaemia developed if this occurred within the admission window. This 
is designed to replicate data that could be expected to be available to a consultant or senior 
initially reviewing the patient or on a post take ward round. Practically this consists of data 
from the initial radiology and blood sciences. The worst (i.e. most abnormal) bedside 
observations and the presence of AF were recorded from a period up to a maximum or four 
hours prior to development of RA. Considering the hypothetical patients in Figure 18, Patient 
A develops acidaemia early so the data collection window closes prior to the 4-hour window 
i.e. from admission to 2.5 hours. Patients B and C both develop their acidaemia after 4 
hours, so the maximum ‘admission’ window is open for data collection. 
The point of deterioration tool is very different, this is all available data in the 24 hours prior 
to deterioration, data prior to admission or post deterioration is not however collected 
irrespective of timings. Therefore, patient A has data collected from admission to 2.5 hours. 




admission to deterioration covering 16 hours. Patient C deteriorates later into admission 
after 72 hours. Data here is collected from 24 hours prior to point of deterioration ie from 
48-72 hours; (If this patient deteriorated after 26 hours data would be collected from hours 
2-26).  
Figure 18 Time windows for data collection for three hypothetical patients. 
 
n.b. boxes represent development of acidaemia, arrows represent data collection windows. 
5.3.3  Demographics and Descriptors. 
Full patient identifying information was not submitted centrally. Date of birth could, 
following ethics committee approval, be submitted to calculate age on admission. Date of 
birth, gender and ethnicity are important not only as population descriptors but also for 
calculation of predicted spirometry values. Time of admission was taken from patient 
administration system (PAS) unless an earlier time could be objectively verified e.g. From an 
ABG result or notes entry. This situation is common amongst critically unwell patients in 
whom clinical actions may slightly precede entry onto electronic systems. The timing of 
other key points in a patient admission were recorded such as admission to inpatient ward 
or senior review. Post ED senior review was defined any consultant other than A+E 
consultant. 
Northumbria healthcare operates a system of cottage hospitals to accommodate such a 
large geographical region. Many patients are discharged to these hospitals to convalesce 
prior to returning home or are admitted to ‘step-up beds’ from the community. They are 




round a week. As such length of stay is often quite prolonged and patients only go to these 
hospitals when ‘medically fit’. For the purposes of the study a discharge to a cottage hospital 
it counted as the end of their period of acute care and the day of transfer recorded as the 
discharge date. In line with this position if they were admitted from one it was counted as an 
admission from the community and the date and time of admission to the general hospital 
used. 
5.3.4  COPD Details. 
Date and details of prior spirometry were recorded. In rare cases, inclusion was allowed 
without the precise spirometry values available. This was in cases where there was definitive 
evidence of spirometry having been performed and airflow obstruction being proven. For 
example, if a specialist makes a specific reference to airflow obstruction in their letter but 
the values are not included and missing this patient could be included. It is important to note 
a simple mention of COPD did not count in this regard. Requirement of supplementary 
oxygen was LTOT only as defined by conventional criteria, not short burst or palliative 
oxygen. 
5.3.5  The Extended Medical Research Council Dyspnoea Scale (eMRCD). 
The traditional MRCD (196) grades patients from 1 to 5 and has been used in research and 
clinical practice for many years. While the original scale is excellent a novel extension (197) 
developed by this research group (3.2.3) is a potential improvement in two principle areas:  
Firstly, it clearly lays out the rules on how to score between levels which have been 
somewhat ambiguously applied historically and the measurement window is defined “in the 
last 3 months when feeling at your best.” Grade 4 in either score reads “stops after 
walking 100 m, or for a few minutes, on the level.” If the patient can walk 20 yards 
only how would the dyspnoea be graded? eMRCD specifies that the dyspnoea must achieve 
all specified aspects of the higher (worse) dyspnoea grade before being scored as such. 
Another area of grading contention lies in the role of assistance: Exemplifying this, consider 
a patient who is helped out of their house to the supermarket by a family member, perhaps 
pushed in a wheelchair. Is this patient housebound or not? eMRCD specifes that the patient 
must be able to do the activity unassisted (and under their own steam i.e. an electric scooter 




specifications include that even if other disability (not dyspnoea) is the predominant reason 
why a higher grade is scored the higher score stands. 
Secondly, the traditional highest dyspnoea level 5 (“too breathless to leave the house”) is 
split into 5a (“Too breathless to leave the house unassisted but independent in 
washing and/ or dressing”) and 5b (“Too breathless to leave the house unassisted 
and requires help with both washing and dressing”). This distinction recognises the 
difference between those that can complete activities of daily living autonomously and 
those that cannot.  
Collection of eMRCD can be simple or comparatively difficult depending on the quality of 
note-keeping. Fortunately, a good assessment of functional status is usually included in 
cases where ventilation is required. Using a combination of inpatient and outpatient medical 
notes, occupational therapist, nursing, and physiotherapy notes a good assessment can 
usually be made. Prospectively if there was uncertainty the patient could be approached to 
verify. 
5.3.6  Comorbidities and Medications. 
All components of the Charlson index and APACHE II score were collected according to their 
specified definitions for the derivation study, to ease data collection the Charlson index was 
dropped from the validation study. Atrial fibrillation (AF) was of particular interest following 
the DECAF projects. AF was defined as present whether chronic, paroxysmal or de novo. A 
single transient episode of AF in the context of historical acute illness did not count as 
paroxysmal atrial fibrillation (PAF) but 2 or more did. Certain medications associated with 
COPD outcomes were recorded at admission and discharge for accurate population 
description. 
5.3.7  Observations, Physical Measurements, Blood Tests. 
Readily available observations and constituents of comparison tools were recorded as 
continuous variables. The worst value (greatest deviation from accepted normal) was 
recorded within the given timeframe, readings did not need to come from the same set of 
observations. Most recent height and weight was recorded preferentially. Weight was 
ideally from the same admission but prior readings accepted provided no history of weight 





ABGs including date, time, FiO2 and sampling method were recorded at admission, first 
recorded RA, NIV initiation, 24 hours post and after cessation prior to discharge if 
application. The time pH corrected was separately recorded. If CO2 was reported as ‘high’ 
this was imputed as the maximum integer that analyser could return. In the case of the 
derivation project this was 20. 
5.3.9  Radiology. 
Presence or absence of consolidation at admission and at ventilation recorded in following 
hierarchy: attending physician interpretation (to mimic reality), radiologist report, 
researcher interpretation. Diaphragm height was recorded in attempt to model hyper-
expansion. The maximum elevation from a straight line drawn between lateral and medial 
hemi-diaphragm insertion points was taken (Figure 19). This data is being captured in an 
exploratory capacity and there will be inter-user variability around marking diaphragm 
insertion points particularly the medial insertion point but this has not been evaluated and 
no kappa value is available. The right hemithorax was used preferentially.  
Figure 19 Diaphragm height measurement. 
 
5.3.10 Timing of acidaemia. 
The time of acidaemia onset was expected to be an important predictor of outcome. 




time points in the decision-making process to instigate ventilation that could be used. 
Hospital arrival is always the starting point. From here time to a) index episode of acidaemia 
(i.e. ignoring episodes of acidaemia that occur earlier but correct with treatments other than 
ventilation); b) the ABG that prompted NIV or c) the point that ventilation is initiated are all 
valid indices. There are advantages and disadvantages to each method and moreover, after 
binary categorisation there will always be little difference in the populations, but it is 
important to understand what is being referred to.  
No single time-point is perfect however, the problem with a) is differences in medical 
treatments between units may make this a less standardisable unit and c) is that a short-
term issue with bed or ventilator availability may be being measured.  The preference in the 
NIVO population is to take the time of the ABG that prompted NIV as this is highly 
reproducible and less exposed to variation not captured in the recorded data. 
5.3.11  Ventilation. 
Previous acute ventilation and HMV details were recorded for context. Date and time of 
initiation, ventilator settings after 1 hour and maximally and discontinuation time and 
reason describe the onset, duration and intensity of the intervention. Far greater detail 
would have added little, NIVO did not control the intervention and the focus is upon 
modelling prior to initiation. 
5.3.12  Late failure. 
Varying definitions of late failure have been used (3.3.7.2), while simple conceptually i.e. 
those that deteriorate after a period of correction the definition becomes quite complex. 
Our definition was designed to avoid capturing those who have early oscillations and may 
dip transiently back into the acidaemic range. Those that have a clear, late deterioration 
were the desired target. Our definition reads: “Late failure is recurrence of respiratory 
acidaemia prior to discontinuation of ventilation. pH should drop to below 7.35 
with a rise in CO2 of at least 1kPa and to >6.5kPa from the lowest recorded post 





A subsequent episode of ventilation within the same admission was termed relapse provided 
24 hours were elapsed after cessation of index event. If less than 24 hours had elapsed this 
was considered failure of weaning and therefore a continuation of the index event.   
5.3.14  Outcomes. 
In-hospital mortality was extended out to one week if a patient was discharged with 
expressed palliative intent on a care of the dying pathway. Advanced care planning such as 
not for readmission to hospital or addition to a primary care palliative care register would 
not fulfil these criteria. Outcomes such as readmission, HMV usage, death to one year were 
recorded. Post discharge outcomes in the validation arm are not reported in this thesis. 
5.4 Statistical Plan. 
5.4.1 General plan and approach. 
5.4.1.1 Power. 
In order to estimate the sensitivity of the tool (and assuming a standard error of 5%) 85 
deaths should be studied in each cohort (assuming an expected sensitivity of 70%). With an 
estimated in-hospital mortality rate of 20% at least 425 patients are required in both the 
derivation and validation cohorts. 
5.4.1.2 Missing Data. 
For both derivation and validation cohorts, missing variables were imputed by expectation 
maximisation algorithm, to minimise bias. All subsequent analysis were performed on 
complete dataset. Comparison to original dataset will be made to ensure no statistically 
significant discrepancy.  
5.4.1.3 Population Description. 
Parametric variables were identified by visual inspection of the histogram. To characterise 
the patient sample, proportions will be used for categorical variables, means with standard 
deviations (SD) for parametric variables, or medians with inter-quartile ranges (IQR) for non-




5.4.1.4 Univariate Analysis. 
To compare characteristics and outcomes between population groups, Chi-Squared test was 
used to compare categorical variables, Student’s T-test to compare parametric data, and 
Mann-Whitney U to compare non-parametric variables. To examine for trends across 
multiple sites, ANOVA were used for parametric data and Kruskal-Wallis for non-parametric 
variables.  
Two-sided p values are reported unless specified. When the independent samples T test was 
used. Variance was assessed using Levene’s test. This test would be statistically significant if 
there was unexpected variance between the samples. Assuming Levene’s is non-significant 
the significance level the ‘assumption of equal variance two sided significance level’ will be 
reported. 
5.4.2 Multivariate analysis. 
5.4.2.1 Multivariable Analysis Background. 
A number of methodological steps are required to advance from a pool of candidate indices 
to a model that has utility. The following sections will explain the steps taken. There remains 
within the statistical literature significant debate as the best way to achieve this end. There 
is a balance to be struck between ‘pure’ statistical methodology which usually entails a 
parsimonious approach of minimal assumption and the alternative approach of greater 
simplification for example by categorising a continuous variable which may lead to less exact 
prediction but potentially creation of a model that is wieldy enough to translate to clinical 
practice. It is important to remember that handling one or more variables as continuous 
within a model requires computation. 
The greatest criticism of prognostic modelling is the reporting of outcomes from (small), 
selective, retrospective datasets without validation in separate cohorts. In an excellent 
summary paper on the topic Steyerberg et al (245) suggest: reliable models for clinical practice 
are more likely to be obtained when they are: 
• Developed using a large, high quality dataset. 
• Based on a study protocol with a sound statistical analysis plan. 




The presence of a defined, published protocol is particularly important to avoid the 
otherwise subversive effect of publication bias as coherently argued by Hemingway and 
colleagues.(246) 
5.4.2.2 Principles of Regression Analysis. 
All forms of regression analysis attempt to draw unknown (predictive) information from 
available data. The outcome or dependent variable is predicted by the predictor or 
independent variable(s). In linear regression using continuous variables a model is an 
equation to represent the line of best fit through the data. Knowledge of this equation 
allows prediction of outcome from new data. Simple regression refers to a single predictor 
variable and multiple regression to more than one predictor variable.  
Consider a scatter plot where the y axis outcomes are either 0 or 1, it appears as two parallel 
lines. There is no possibility of drawing a line of best fit through this data as there is no linear 
relationship (which is a basic assumption of linear regression). To predict outcome from 
independent variables in this instance, where the outcome variable belongs to one of two 
mutually independent states, logistic regression is employed. The logit conversion 
overcomes this violation of linearity and the outcome value will be between 0 and 1. So if an 
outcome value is closer to 1 is probable from the model the outcome will belong to the 
group assigned to 1. 
In the case of NIVO it was necessary to model a binary outcome (alive or deceased) from 
several variables therefore multiple logistic regression is employed. Other considerations 
that will be further discussed include variable selection, collinearity, method of entry into a 
model, assessment of how well the model fits the data.(247,248) 
5.4.2.3 Variable Selection. 
Many variables collected are to explore and report interesting associations or accurately 
describe the population under review and were never considered as candidate predictors. It 
is important to both include feasible variables and remove extraneous ones. One cannot 
simply enter every variable into a multiple regression analysis as this would result in over-
fitting. Overfitting occurs when the model is too tightly tied to the source data and will not 




15 cases or 10 outcome events for each predictor candidate predictor.(247-249) Therefore, 
which variables are to be entered into a regression analysis must be carefully selected. 
Following extensive literature review as described a pool of potential candidates was 
generated which was initially narrowed by limiting to univariate associations with outcome. 
Again, using Chi-squared test to compare categorical variables, Student’s T-test to compare 
parametric data, and Mann-Whitney U to compare non-parametric data. Those with 
significance of <0.1 were eligible for further screening prior to entry into multiple regression. 
Only variables with potential for utility could be taken forward: for example, the gradation 
by ejection fraction on echocardiogram may be an accurate predictor but this data is not 
readily available in an emergency department outside of normal working hours when the 
tool must be able to be applied. Similarly, the presence or absence of a medication may be 
strongly associated with outcome but there is such strong bias attached to this it is a poor 
candidate predictor. 
5.4.2.4 Screening of Variables with Univariate Significance (<0.1). 
To progress further to inclusion in the regression analysis predictors underwent several 
further screening steps: 
• Assessment of face validity, there must be a plausible association between the 
outcome and the predictor otherwise excluded. 
• Asymmetrical split, categorical variables with only a small proportion of the 
population in one category (<10%) were excluded. 
• Collinear variables, if two (or more variables) have substantial overlap only one was 
carried forward to the final model (see next section) 
5.4.2.5 Assessment of Collinearity. 
Collinearity exists where variables are measuring (in part) the same thing. For example, 
white cell count and neutrophil count are highly likely (and in our case were found to be) 
collinear. Not all associations will be as conceptually obvious as this and statistical 
assessment will reveal more occult associations. If variables were found to be highly 
collinear only one was taken forward to regression analysis. The most clinically relevant 




Three assessments were used: (247,250)  
1. Pairwise correlation co-efficient >0.7 using Pearson’s correlation for parametric or 
Spearman’s for non-parametric. 
2. Variance inflation factor of >3. 
3. High conceptual correlation, for example WCC and neutrophil count. These variables 
would very likely be identified by the above assessments but if not only one would be 
considered for entry into final regression equation as they clearly measure a similar 
concept. 
5.4.2.6 Entry into Regression Model. 
After selecting candidate variables there are several methods of entry. Stepwise methods 
are commonly employed in predictive model building. Forward stepwise entry method 
sequentially adds the variable most strongly associated with outcome until all variables that 
achieve a prespecified significance level are entered. Backward stepwise methods 
sequentially remove the least significant associate until only those achieving a prespecified 
level of significance remain.  
A backward stepwise method was chosen for NIVO with a significance level of p < 0.05.(251) 
5.4.3 Assessment of Model. 
5.4.3.1 Model Fit. 
Considered selection of candidate variables and the significance level within the regression 
equation are the most important determinants of a well-fitted model. The predictive model 
will produce an outcome probability for each case. A residual is the difference between 
observed outcome and predicted outcome. To render these values interpretable and apply 
standard cut-offs they are converted into standardised or studentised residuals, studentised 
being considered most accurate. Greater than 5% of cases having a studentised residual of 
+/-1.96 is indicative of a poorly fitting model. Cook’s distance is a further method of 
examining outliers with values >1 a cause for concern.(247) Further examination of outliers 





Calibration refers to how well the predicted outcomes relate to the observed outcomes. To 
assess this, cases are grouped (usually 10 groups in large sample sizes) and the number of 
predicted outcomes to the number of observed outcomes in each group compared. The line 
of best fit of this plotted graphically is informative. Perfect calibration has a gradient of 1.(247) 
A further method of comparison is using the Hosmer-Lemeshow goodness of fit test 
(HLGFT), non-significance is indicative of good calibration.(252)  
R2 is a further assessment of a model. It describes how much of the variability in outcome 
can be explained by the model itself. A value of 1 indicates all variation in outcome is 
accounted for by the model. Ultimately the optimum assessment of calibration is successful 
validation in a separate dataset. 
5.4.3.3 Discrimination. 
Discrimination is how well the model can distinguish between a high risk and a low risk 
patient. In logistic regression this is commonly assessed by the area under the receiver 
operated curve (AUROC). This is a measurement of sensitivity and specificity. A straight, 45-
degree line would give an AUROC of 0.5 akin to pure chance. Perfect discrimination would be 
1.(247)  
5.4.4 Tool Building. 
5.4.4.1 Background and Guiding Principles. 
The final tool must adhere to several principles: 
• Offer good prediction. 
• Be simple to administer. 
• Have face validity. 
Selection of which variables to include, the number of variables, and assignation of 




5.4.4.2 Handling of Continuous Variables. 
For maximum utility all variables in the tool(s) will be split into two or three categories. 
Ideally a dichotomy unless significant reward in terms of model accuracy is offered. To select 
the appropriate cut off the following hierarchy was used: 1) ROC curve analysis, 2) results 
from previous research, 3) a clinically meaningful value, 4) a median split. 
To ascertain a split point from ROC curve analysis an individual continuous variable is plotted 
against outcome and the curve inspected. The presence of a clear ‘shoulder’ closest to the 
top left hand corner (assuming a positive relationship) corresponds to be optimum cut off in 
terms of sensitivity and specificity.  
5.4.4.3 Selection and Weighting. 
Following the steps outlined a small list of categorised variables was developed. This was 
then converted into a clinical tool by ascribing numerical weighting to presence of adverse 
features to allow each case to be given a score. 
No absolute rules can be imposed upon variable selection, the appearance of the resultant 
tool and the weighting applied to the composite indices. The ideal situation is that a small 
number of predictors offer excellent performance, can be added together in a simple 
manner and weighting requires only one or two integers.   
To assess variable weighting a proportional beta coefficient was created by dividing each 
beta coefficient by the smallest beta coefficient of all included variables. By definition this 
will result in the least influential variable being divided by itself and returning a value of 1. 
The Wald test is another commonly reported assessment of the relationship between 
variables in a model and will be used as a secondary guide and handle in a similar manner. 
Clinical judgement must also be used in tool building, the reasons why particular decisions 
are made is outlined.(253)  
Mortality at each step of any developed score was inspected to ensure progressive mortality 





Addendum following Viva examination suggesting extra clarity: “Add a description of the 
work undertaken in this thesis within the methods sections. It was clear at oral exam that Dr 
Hartley undertook a huge amount of work to complete this impressive work” 
The entire derivation database was generated ‘bespoke’ by myself with reference to source 
data. All analysis is my own and exclusive to this work. This was not interrogation of an 
existing database. For both studies; all CRFs, manuals, IRAS forms and ethics was myself. 
Development of online data management system was myself working directly with a IT 
company. Shortly after recruitment began to the validation study day to day workload was 






Chapter 6. Results: Derivation study Part 1, Population 
Characterisation.  
6.1 Data Handing. 
6.1.1  General. 
The derivation project is reported in this thesis in full, but validation study results are limited 
to a description of the population and the validation of the predictive tool. A more fulsome 
exploration of the validation results will be presented in the next thesis from Professor 
Bourke’s group.  
Data was exported from database into Microsoft Excel and then into IBM SPSS v22. Some 
variables were computed immediately for example the time timing of acidaemia was 
calculated from the between first attendance and the relevant ABG time. 
6.1.2  Data screening. 
Where able, data was ranked by value and outliers examined. Data entry errors were 
identified and rectified. Spot checking of random CRFs did not reveal additional significant 
data entry error. 
6.1.3  Missing Data. 
Rates of missing data were low in indices collected for the primary aims of clinical tool 
creation. Most indices with higher rates were blood tests that are not requested routinely. 
Indices with >1% missing values up to the point of deterioration are reported.  Phosphate 
87.9% and troponin 87.0% were by far the most commonly missing and were not considered 
further. Glucose (serum or BM) 25.8%, bilirubin 23.1%, total protein 20.2%, albumin 19.0%, 
potassium 6.7%, CRP 4.7%, previous pulmonary rehabilitation 4.7%, oxygen saturation 4.5%, 
haemoglobin 4.5%, Eosinophils 4.1%, WCC 3.9%, platelets 3.9%, haematocrit 3.9%, 
neutrophils 3.9%, sodium 3.3%, urea 3.3%, base excess 3.1%, diastolic blood pressure 1.6%, 
systolic blood pressure 1.4%, heart rate 1.4%. 
Missing values were imputed where appropriate by expectation-maximisation algorithm. 




significance. Indices with >10% missing data were not considered for further analysis 
irrespective of imputation results. 
Due to the uncontrolled study design, the rates of missing data post NIV initiation and at 
hospital discharge are variable and are reported in the relevant sections. These aspects are 
clearly separate from the primary aims and should not be confused. An illustration of this is 
arterial blood gases; we could rely on this data being available for collection in the initiation 
phase of NIV, but collection of blood gases at 24, 48 and 72 hours is variable and often 
missing. 
6.2 Population Description. 
6.2.1  Headline summary. 
489 unique cases were identified admitted to hospital between 30/11/2008 and 19/5/2013 
of whom, 365 survived to discharge and 124 (25.4%) died in-hospital. 
6.2.2  Demographics. 
The population of North Tyneside and Northumberland is homogenous, with over 95% of 
the population in both areas reported as white British and born in the UK in the 2011 
census.(254,255) Every patient in this cohort was coded as white British. 
Table 9 Whole population demographics. 
Variable Value 
Female 62.6% 
Age*  72.8 (10.0) 
Admitted to North Tyneside General Hospital,  52.2% 
Cigarette Pack Years* 49.5 (26.0) 
Current smoker  48.7% 
1(+) respiratory admission in last 12 months 38.7% 
1(+) non-respiratory admission in the last 12 months 17.8% 
Charlson Index 2 (1-3) 
*Mean (SD) †Median (IQR) 
The high proportion of females is notable as compared to the national COPD audits where 
there is a rising proportion of females but still significantly lower than our sample. 




(51%).(29,81,145) Unfortunately, the gender of those receiving ventilation is not reported in 
these audits. It is noteworthy that the NCEPOD report has a higher proportion of females at 
56.9% (144) than the best estimate of time matched background prevalence (51% 2015 
report). The local background (admitted) COPD population is well characterised by the 
DECAF derivation and validation which span the same time period in which 56.4% were 
female.(82,195) In this context 62.6% female represents the same proportional increase from 
our background population as that seen in the national figures.  
The reason(s) why females appear to be over-represented in UK NIV populations is unclear. 
Survival long enough to develop severe disease without succumbing to other conditions 
commoner in males particularly cardiovascular disease may be one explanation. 
6.2.3  Home Circumstances. 
Most patients are admitted from their own home with 10% admitted from institutional care 
(a combination of residential care, nursing care or a community hospital). 
Table 10 Pre-admission home care circumstances. 
Admitted From Percentage of Total 
Home 70.1 
Home + formal carers 12.1 
Sheltered accommodation 5.1 
Sheltered accommodation + formal carers 2.7 
Residential care 4.3 
Nursing care 3.7 
Community hospital 2.0 
 
Anecdotally, a large number of patients received informal care from family or friends. This is 
not definitively captured by the data. There is, however some supportive objective data: as 
shown in Table 12 over half of the population are housebound due to breathlessness 
(eMRCD 5a and 5b) but only 25% have formal support at home. 
6.2.4  COPD details. 
Selecting patients with ECOPD resulting in RA has resulted in a population with severe COPD 




median eMRCD grade of 5a indicates marked functional limitation. This is a cohort of with a 
high level of morbidity. 
Table 11 Key descriptors of COPD. 
Variable Value 
FEV1 (L)* 0.81 (0.36) 
FEV1 (%)* 38.0 (16.4) 
FEV1/FVC* 0.44 (0.12) 
Exacerbations reported in the last year* 2 (1-4) 
Previous pulmonary rehabilitation  14.6% 
eMRCD† 5a (4-5a) 
LTOT on admission 29.2% 
 * Mean (SD) †Median (IQR) 
 
Exacerbation history is difficult to ascertain from retrospective records and this was only 
recorded if positively identified. These exacerbations are not verified against standardised 
criteria but are as accurate a possible estimation from inpatient notes, clinic letters, GP 
correspondence and GP prescription records where available. No data either positive or 
negative could be reported in 113 (23.1%).  
6.2.5  eMRCD. 
The eMRCD score was expected to be an important predictor of in-hospital mortality and we 
are fortunate to have robust comparison data from previous research. Table 12 shows most 
NIVO patients fall into the three highest dyspnoea categories with over 50% housebound 
due to dyspnoea. In both cohorts there is a clear and progressive increase in in-hospital 
mortality the higher the dyspnoea category. There is an upshift in eMRCD score by 
comparison to the DECAF derivation cohort (patients admitted with ECOPD but not 
necessarily requiring ventilation) collected in the same trust. This upshift, and that mortality 
is higher in each dyspnoea category, is unsurprising given our cohort is selected from those 





Table 12 eMRCD comparision between NIVO and DECAF derivation cohorts. 
 NIVO DECAF 
eMRCD  
N (% of total 
population) 
Mortality (% within 
dyspnoea grade) 
N (% of total 
population) 
Mortality (% within 
dyspnoea grade) 
1 0 (0%) 0 (0%) 6 (0.7%) 0 (0%) 
2 9 (1.8%) 1 (11.1%) 46 (5.0%) 0 (0%) 
3 45 (9.2%) 3 (6.7%) 171 (18.6%) 4 (2.3%) 
4 171 (35.0%) 19 (11.1%) 382 (41.2%) 15 (3.9%) 
5a 164 (33.5%) 48 (29.3%) 173 (18.8%) 30 (17.3%) 
5b 100 (20.4%) 53 (53%) 142 (15.4%) 47 (33.1%) 
Total 489 124 (25.4%) 920 96 (10.4%) 
 
Figure 20 is a graphical representation of the distribution of patients from the NIVO cohort 
by eMRCD score and the associated number of in hospital deaths in each division. 
Figure 20 Number of Patients admitted in each eMRCD category and corresponding in-
hospital mortality count (NIVO data). 
 
6.2.6  Admission Medications 
Selected medications are displayed. These are presented to accurately characterise the 
population but are not candidates for inclusion in a predictive model. While there are 
prescription guidelines and therefore theoretically some degree of standardisation, in 
practice the reasons why a particular patient is or is not taking a medication may be 
eMRCD




















numerous and have no valid association with mortality risk. The exception to this is the use 
of long term oxygen which is a drug, but its prescription is based upon objective 
physiological criteria and hence it has been handled separately. Exemplifying that 
medications are unsuitable candidate predictors of in-hospital mortality, the only medication 
here significantly associated with mortality is Carbocisteine where there is a weakly 
significant result (2 tailed p=0.046) favouring increased mortality when taking the drug.  
Table 13 Selected pre-admission medications. 
Medication Percentage taking on admission 
Long term steroid 11.0 
Diuretic 44.4 
ACE inhibitor 29.7 




Long Acting Beta Agonist (LABA) 82.0 
Long Acting Muscarinic Agonist (LAMA) 76.6 





The prescription of diuretic is high as many patients were prescribed diuretics particularly 
Bendroflumethiazide for hypertension. With changes to hypertension guidelines this is likely 
to fall in the validation cohort.  
The number of patients receiving LAMA may seem lower than expected, however a number 
of patients were prescribed regular nebulised ipratropium bromide (a short acting 
muscarinic agonist) and hence were not concurrently prescribed a long acting muscarinic 
agonist. The precise numbers are unavailable. 
6.2.7  Chest X-ray Findings and Pneumonia. 
Each chest x-ray was examined by the same researcher to determine presence or absence of 




consolidation was collected differently, this was determined from the clinical notes 
irrespective of the researcher’s interpretation of the x-ray.  
Table 14 Chest X-ray findings. 
Variable Value 
Chest X-Ray consolidation (admission) 43.6% 
Chest X-Ray consolidation (at ventilation) 47.2% 
Any pleural effusion (admission) 18.8% 
Number of posterior Ribs† 9 (8-9)  
Diaphragm Height (cm)* 2.1 (0.93) 
* Mean (SD) †Median (IQR) 
The rate of consolidation is high, this may reflect the severity of exacerbation or may be 
artificially so due to poor x-ray interpretation by attending clinicians, this point is however 
moot if the results are generalisable within the validation cohort, and it is important that the 
data is reflective of real life so as not to include data in a clinical tool which is not readily 
generalisable.  
6.3 Timing of Acidaemia. 
6.3.1  Timing data handling. 
In most cases the date and time of the first development of acidaemia is recorded. If the 
initial episode of acidaemia resolved this was recorded and the time of acidaemia associated 
with the first episode of ventilation was taken. In 7 cases the initial episode of acidaemia was 
either not recognised or did correct but the objective verification of such is missing. In these 
7 cases there is mild acidaemia (mean pH 7.32) and a prolonged time gap between the initial 
acidaemic blood gas and the blood gas that prompted ventilation (median 1914 minutes IQR 
1836m-2613m). As such in these 7 cases the initial acidaemia is considered to have resolved 
and the time of blood gas prompting ventilation is used. The derivation data was collected 
prior to electronic storage of ABG results so loose print outs were frequently missing.  
6.3.2  Notes on timing of acidaemia. 
The interaction between timing of acidaemia and outcome must be carefully considered in 
the context of the clinical situation and the realities of provision of care. The majority of 




index episode of acidaemia occurs in the first 12 hours. The hypothesis is that those that 
deteriorate later into admission have done so despite the provision of active medical 
treatment for their ECOPD and that this represents an independent mortality risk. Pre-
hospital variables and fluctuations in staffing ratio, time of day, day of week or how busy an 
emergency department is may well interact in the short term with identification of 
acidaemia and/or instigation of medical treatment. Therefore, ascribing a cut-off too close to 
the admission time may well capture confounders devoid of reproducible meaning. 12 hours 
was selected for its clinical significance in the admission sequence and ease of recall. The 
NHS standard is for patients to be seen by a consultant within 14 hours of admission to 
hospital (256) and as already stated the mean time to consultant review of a patient with 
ECOPD is 10 hours. Having a cut off within this key decision-making window is sensible to 
maximise the real-world applicability of the results.  
As stated in 5.3.10 the time of greatest interest in the NIVO cohort is the time from first 
admission to hospital to the time of the ABG that prompted ventilation. 
6.3.3  When does acidaemia develop? 
Figure 21 Time from admission to episode of acidaemia prompting ventilation. 
 
It should be noted that in Figure 21 the X axis scale is non-linear.  
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6.3.4  Relationship between time and in-hospital mortality. 
Twelve hours is a compelling cut-off due to the described associations with existing models 
of UK care. Other potentially useful thresholds are 24 hours and 48 hours which are shown 
in Table 15.  
Table 15 In-Hospital mortality graded by acidaemia development after 12, 24 and 48 
hours. 
 Under threshold Over threshold 
Threshold Number Mortality Number Mortality 
12 hours 361 (73.8%) 65 (18%) 128 (26.2%) 59 (46.1%) 
24 hours 395 (80.8%) 74 (18.7%) 94 (19.2%) 50 (53.2%) 
48 Hours 430 (87.9%) 87 (20.2%) 59 (12.1%) 37 (62.7%) 
 
As expected, there is a progressive mortality the later into admission the index acidaemia 
occurs but with fewer patients captured the later the threshold is placed. The particularly 
high in-hospital mortality after 48 hours may be a useful threshold where identification of 
patients at high risk of death has greater priority over stratification across the risk spectrum. 
6.3.5  Clinical differences between early and late deterioration. 
The data presented in Table 15 illustrates the starkly increased mortality between those that 
present with RA and those that develop it further into admission, in whom, depending on 
the time threshold used mortality is 2.5 to 3 x higher. It appears that the later into admission 
this occurs the worse the outcomes are. It may be that time is merely a surrogate marker of 
other adverse markers or it may be as hypothesised that those patients that deteriorate 
despite medical treatment are inherently less salvageable. 
Table 16 explores whether there are significant differences between the groups. Groups 
have comparable FEV1, requirement of LTOT and need for institutional care, there is no 
evidence of increased renal failure, metabolic component of acidaemia, inflammatory 
response or physiological derangement at the time of ventilation as measured by the CAPS 
score. Those deteriorating later have significantly higher pH which does not account for 
excess mortality. These patients are however, older, more frequently have chest X-ray 
consolidation and have a higher eMRCD score with a greater proportion of those with 




Table 16 Clinical differences between patients developing their acidaemia <12 hours 
versus>12 hours. 
Variable <12 Hours >12 Hours P value 
eMRCD† 5 (4-5a) 5 (4-5b) 0.034 
eMRCD 5b 64 (17.7%) 36 (28.1%) 0.015 
LTOT 110 (30.5%) 33 (25.8%) 0.366 
Institutional Care 36 (10.0%) 13 (10.2%) 1.000 
FEV1%* 37.6 (16.2) 39.3 (17.0) 0.310 
Age* 71.8 (9.93) 75.5 (9.83) <0.001 
Urea† 7.0 (5.2-11.1) 7.65 (5.33-10.4) 0.925 
CRP† 50 (15-123) 56 (15-113) 0.811 
WCC* 13.4 (5.5) 13.0 (8.9) 0.124 
pH† 7.26 (7.19-7.30) 7.28 (7.23-7.31) <0.001 
Base Excess* 3.9 (6.5) 3.5 (6.5) 0.589 
Confusion at ventilation 69 (19.3%) 33 (25.8%) 0.130 
Consolidation 43.5% 57.8% 0.006 
* Mean (SD) †Median (IQR)  (dynamic clinical data e.g. ABG data is worst in 24 hours pre NIV) 
6.4 Ventilation.  
6.4.1  Ventilation Description. 
The focus of the study is NIV but those receiving IMV are also included to make the 
population as generalisable as possible. A large majority of this population received 
exclusively NIV. This is in keeping with UK practice.  
Table 17 Descriptors of ventilation. 
Variable Value 
Formal Oxygen trial  38.4% 
Exclusively NIV  94.5% 
Duration ventilated whole days completed† 3 (1-5) 
Duration ventilated hours† 84 (37-128) 
Previous NIV ever  21.9% 
NIV in last 12 months  10.0% 
HMV admission  2% 
Worst pH pre-ventilation† 7.26 (7.20-7.30) 
Worst PaO2 pre-ventilation
† 8.3 (6.9-9.9) 
Worst PaCO2 pre-ventilation
† 9.9 (8.5-11.7) 




Duration ventilated in hours is taken from the initiation to discontinuation time. It does not 
imply continuous use. 
Formal oxygen trials are recorded if the acting clinician(s) identified RA and prior to the 
delivery of ventilation administered a trial of treatment for one hour that included active 
control of the delivered FiO2. From retrospective notes, no assessment of how well this trial 
was delivered is feasible.  
There was no statistically significant association between ever receiving NIV or receiving NIV 
in the last 12 months and in-hospital mortality.  
6.4.2  Intubated Patients. 
27/489 patients were intubated of whom 13 had received NIV prior to intubation. Intubated 
patients were significantly younger, had both lower pH and base excess at outset and were 
less likely to be in receipt of long term oxygen. Percent predicted FEV1, consolidation on X-
ray and CO2 level were not significantly different.   
There was no significant association between intubation and in-hospital mortality (one tailed 
p= 0.372) nor whether NIV was initiated prior to intubation or not so the population will be 
handled as a whole. This is representative of the real world and avoids unnecessary 
subgrouping of the population.  
6.4.3  Ventilator Settings. 
Table 18 Ventilator settings for those receiving NIV at initiation, 1 hour and maximum 
achieved. 
Variable Initiation 1 hour Maximum 
IPAP† 16 (16-18) 18 (16-20) 20 (18-20) 
EPAP† 4 (4-5) 4 (4-5) 4 (4-5) 
Back up rate† 12 (12-12) 12 (12-12) 12 (12-12) 
* Mean (SD) †Median (IQR) 
During the period of study, the default back up rate of the ventilator applied as per the local 
guideline was 12 breaths per minute. Latterly there has been a tendency towards higher 
back up rates (and higher target pressures) which may well be shown in the data from the 




hour to maximum and is perhaps an indication of good care with active titration over the 
acute period. 
6.4.4  Ventilation summary. 
Previous work by the study group has focussed upon the outcomes of patients admitted 
with ECOPD modelling based upon their admission indices alone. Across all the group’s 
modelling studies the intervention is uncontrolled. Treatment for uncomplicated ECOPD 
however is comparatively simple and standardised and so there is less chance that poorly 
delivered treatment influences outcome significantly.  
This population are in receipt of a potentially heterogeneously applied intervention which 
confers a large mortality benefit therefore there is greater potential for intervention 
variation to cause outcome variation. Comparing mean pressures or duration of treatment 
between those who died or survived would reveal little of value in an uncontrolled setting. 
That, as a population these patients had well established RA, received several days of NIV 
with adequate pressure support is important. It establishes that the population being 
treated are readily generalisable and the ventilation being provided was of a high average 
standard. Some comparative national data would support this. In 2011 the mean IPAP at one 
hour was 15 and in 2012 the mean maximum in the first 24 hours was 16.5 (141,142) both of 
which are exceeded here. 
6.5 Arterial Blood Gases. 
6.5.1 Arterial Blood Gases Pre, During and Post Ventilation 
A wealth of ABG data was collected. It is all presented but it transpires that the regularity of 
ABGs drops off markedly after ventilation is established.  The rate of missing data is variable 
due to frequent non-sampling at the designated timepoints on clinical grounds. As the rates 
of missing data are variable and high, the data is simply presented in its rawest form without 
imputation.  
Rates of missing data are not always the same within a time category. For example, 
occasionally only the pH and CO2 may be written into the medical notes and others omitted. 
It may seem erroneous that there be missing data at the point of NIV but this is not so. All 




is missing and only prose remains such as ‘still acidaemic, for NIV’ or equivalent. For the 
regression analysis the worst pH in the 24 hour period prior to ventilation was used rather 
than the NIV ABG as displayed here to reduce the effect of confounders. 
Table 19 Arterial blood gas data at various time points. 
Time Missing pH† pCO2* pO2* BE* Bicarbonate* 
Admission 9 7.30 (7.23-7.36) 9.34 (2.94) 7.29 (8.19) 4.8 (6.0) 32.9 (6.9) 
At NIV 13 7.27 (7.21-7.31) 9.34 (2.94) 7.29 (8.12) 4.8 (6.0) 33.24 (6.9) 
1 Hour 26 7.31 (7.26-7.35) 9.09 (2.49) 9.64 (4.13) 4.5 (6.2) 32.9 (7.1) 
4 hours 61 7.34 (7.28-7.38) 8.42 (2.27) 9.82 (3.75) 5.2 (6.5) 32.8 (7.3) 
24 hours 264 7.36 (7.32-7.41) 7.95 (2.01) 9.59 (3.47) 6.2 (5.7) 33.2 (7.9) 
48 hours 364 7.37 (7.32-7.43) 7.94 (1.77) 9.87 (4.19) 7.3 (6.9) 34.4 (7.4) 
72 Hours 394 7.39 (7.34-7.44) 8.05 (1.86) 9.04 (2.54) 8.9 (8.2) 35.8 (8.7) 
Steady 360 7.42 (7.39-7.45) 7.56 (1.40) 8.48 (1.85) 10.0 (5.6) 34.7 (6.4) 
* Mean (SD) †Median (IQR) 
Despite the very high rates of missing data which is unlikely to be missing at random the 
results here are broadly in line with expectations. Acidaemia is steadily eroded as CO2 falls 
but few other conclusions should be drawn.  
6.5.2  pH correction 
Blood gases are conventionally sampled at 1-2 hours, 4-6 hours and then thereafter daily 
until clinically unnecessary or as prompted by clinical status. There are many influences upon 
when and why these blood gases are actually sampled, if at all. Therefore, in an uncontrolled 
study such as this there is ‘noise’ in the data surrounding pH correction. The time of first 
blood gas showing a corrected pH (≥7.35) after ventilation was instigated was recorded. 
Patient refusal to have further blood gases may result in that patient being recorded as ‘did 
not correct’. Assumption of correction on clinical grounds by the attending team may also 
result in several blood gases being ‘skipped’ and therefore an artificially prolonged time to 
correction being recorded. However, even with these caveats in place the trends in the 
following data are interesting. 
In order to capture the above clinically relevant time points while acknowledging the real-
world sampling variation the data was split into those that correct 0-2 hours, 2-8 hours, 8-36 




those that did correct) was 499 minutes (8 hours, 19 minutes) with an interquartile range of 
121-1498 minutes. 
Table 20 Time to pH correction after instigation of ventilation. 
Time to Correction Total In-hospital Mortality 
0-2 hours 103 (21.1%) 17 (16.5%) 
2-8 hours 97 (19.8%) 19 (19.6%) 
8-36 hours 143 (29.2%) 21 (14.7%) 
>36 hours 70 (14.3%) 11 (15.7%) 
Did not correct 76 (15.5%) 56 (73.7%) 
 
As expected from a population in whom a large majority survive most patients (84.5%) 
correct their pH at some point after instigation of ventilation, moreover, and most of these 
patients survive to discharge (83.5%). It is also unsurprising that failure to correct pH confers 
a very poor outcome. 20 patients in this group did survive to discharge so presumably did 
correct their pH at some point but it was not shown on a blood gas. These patients could be 
assumed to belong to the >36 hour group in which case an alternative way of presenting this 
is to combine the ‘>36 hours’ and the’ did not correct’ data.  146 patients had not objectively 
corrected by 36 hours and the in-hospital mortality was 66 (45.2%). 
6.5.3 Time to pH correction in those with late deterioration. 
Another possible reason why mortality differs between those who deteriorate early and late 
may be delayed correction of pH, i.e. failure to correct quickly and hence the more 
prolonged exposure to the physiological stress of low pH. Table 21 shows there aren’t 
marked differences in time to pH correction whether deterioration occurs early or late, 
proportions in each time category are similar. Indeed, a greater proportion of late 
deteriorators correct rapidly. Given that mortality is much higher in the later deteriorating 
group a greater shift toward later or no correction may have been expected. The mortality 
data reveals that by far the greatest proportion of deaths come from those that do not 
correct pH in early deteriorators, amongst late deteriorators this is the largest group, but 
deaths are more spread across the time categories with a majority of deaths coming in 
patients that did correct their respiratory acidaemia at some point after ventilation was 




Table 21 Comparison of time to correction and in-hospital mortality stratified by early or 
late deterioration. 
 Early deterioration <12 hours Late deterioration >12 hours 






0-2 hours 67 (18.6%) 4 (6.2%) 36 (28.1%) 13 (22.0%) 
2-8 hours 73 (20.2%) 8 (12.3%) 24 (18.8%) 11 (18.6%) 
8-36 hours 115 (31.9%) 11 (16.9%) 28 (21.9%) 10 (16.9%) 
>36 hours 56 (15.5%) 7 (10.8%) 14 (10.9%) 4 (6.8%) 
Did not correct 50 (13.9%) 35 (53.8%) 26 (20.3%) 21 (35.6%) 
* Percentage of column total.  
† Percentage of total <12 hour in-hospital deaths.  
# percentage of total >12 hour in hospital deaths. 
6.6 Time to discharge or death 
As stated in (6.2.1) 124/489 (25.4%) patients died in hospital. Comparison to national data is 
tricky as it assumes similar levels of patient selectivity. Despite these misgivings this 
mortality rate is in the region expected. The decision to collect unique patients is also likely 
to have an effect: previous NIV is a recognised factor associated with better outcome. 
Therefore, one could expect the earlier component of the cohort to have lower mortality as 
it captures the ‘frequent flyers’. Later the proportion requiring NIV for the first time will be 
greater. This effect is indeed seen: 1st 100 patients have in-hospital mortality of 17.5% and 
the remainder have in-hospital mortality of 27.1%. 
Table 22 Time to discharge or death 
Variable Duration (days) 
Length of stay (survivors to discharge n=365) † 10 (7-17) 
Days to inpatient death (n=124) † 7 (2-14) 
 * Mean (SD) †Median (IQR) 
Further details of the outcomes following discharge are reported in Chapter 8. Length of stay 
is quite prolonged as one may expect following a life-threatening event and in the context of 
high levels of pre-admission morbidity. The days from admission to inpatient death show a 






Chapter 7. Derivation Results Part 2: Creating Clinical Tools 
7.1 Univariate Associations with Mortality 
7.1.1 General 
In order to develop two tools, data must be analysed differentially. Largely speaking only 
indices that are independent of the admission can be considered for the admission tool 
otherwise too many caveats would be introduced into an escalation plan. 
Some data, for example the presence of a particular comorbidity, is independent of the 
timeframe but others WCC, for example, fluctuates. It does not stand up to face validity to 
include the admission WCC to predict the outcome of an event that may occur 2 weeks later. 
In specific circumstances where we hypothesised a dynamic variable may be associated with 
outcome using the admission data the relationship with outcome in those deteriorating after 
12 hours was examined to test the hypothesis. In this manner we ascertained that the 
presence of admission consolidation still predicted outcome later but admission eosinophil 
count was rejected as it did not. 
For the point of deterioration tool if the decision occurred 2 hours into an admission, then 
only data from the first two hours would be available for analysis. If the decision occurred 4 
days into an admission, then the information analysed in this case would be that in the 24 
hours prior to the decision. Secondly, as previously outlined (5.4.2.3) many of the population 
descriptors are not suitable for inclusion as candidate predictors.  
7.1.2  Factors Independent of Admission 










Gender (Female %) 62.6% 61.9% 64.5% 0.605 
Age*  72.8 (10.0) 71.0 (10.0) 77.9 (8.1) <0.001 
Admitted from institutional 
care 
10% 7.9% 16.1% 0.09 
BMI* 24.6 (7.3) 24.3 (7.3) 22.4 (6.8) <0.001 





Defining comorbidities can be problematic, the definitions used in the project are included in 
NIVO manual (12.3). Few show a clinical or statistical relationship with mortality but are 
important to describe the population under study.  










Asthma 9.8 9.0 12.1 0.323 
Bronchiectasis 7.6 7.4 8.1 0.808 
Obesity Hypoventilation 
Syndrome 
1.0 1.1 0.8 0.782 
Obstructive Sleep Apnoea 4.3 4.9 2.4 0.233 
Cor Pulmonale 18.6 18.4 19.4 0.815 
     
Chronic Atrial Fibrillation 10.9 8.8 16.9 0.012 
Paroxysmal Atrial Fibrillation 6.8 5.2 11.3 0.020 
Atrial Fibrillation at time of 
Acidaemia 
15.5 11.9 26.0 <0.001 
Congestive Cardiac Failure 13.5 11.0 21.0 0.005 
Ischaemic Heart Disease 28.6 26.8 33.9 0.135 
Left Ventricular Systolic 
Dysfunction (LVSD) 
14.1 12.1 20.2 0.025 
Myocardial Infarction 14.9 13.7 18.5 0.190 
Peripheral Vascular Disease 6.1 6.0 6.5 0.865 
     
Anxiety 20.4 21.9 16.1 0.167 
Cerebrovascular Disease 11.5 10.1 15.3 0.117 
Cognitive Impairment 8.6 7.7 11.3 0.214 
Depression 29.2 31.2 23.4 0.097 
Dementia 3.9 3.3 5.6 0.241 
Hemiplegia 1.2 1.4 0.8 0.622 
     
Connective Tissue Disease 2.5 2.2 3.2 0.520 
Diabetes 13.3 13.7 12.1 0.650 
 
Cardiac comorbidities are of particular interest and both AF and LVSD are significantly 




acidaemia which includes chronic AF, PAF and acute (i.e. between admission and acidaemia). 
Another observation is that both depression and anxiety are protective.  Interpretation 
should be with caution as they were not formally assessed using a validated tool but 
recorded from clinical notes. Therefore diagnostic inaccuracy and recording bias are likely to 
be contributary. 
7.1.2.2 COPD Factors 
Table 25 Association with in-hospital mortality - COPD factors 
Variable Total Population Survived to discharge Died in hospital P value 
Cigarette pack years* 49.5 (26) 50.3 (1.3) 47.3 (2.6) 0.278 
Current smoker % 48.7% 55.6% 28.2% <0.001 
FEV1 (L)* 0.81 (0.36) 0.82 (0.36) 0.77 (0.35) 0.109 
FEV1%* 38 (16.4) 37.6 39.2 0.372 
FVC* 0.44 (0.12) 1.88 (0.69) 1.81 (0.76) 0.356 
FEV1/FVC Ratio
† 0.44 (0.35-0.53) 0.44 (0.36-0.53)  0.44 (0.33-0.52) 0.334 
eMRCD† 5 (4-5a) 4 (4-5a) 5 (5a-5b) <0.001 
LTOT 29.2% 26.3% 37.9% 0.014 
Previous NIV 21.9% 22.5% 20.2% 0.592 
* Mean (SD) †Median (IQR) 
The apparent survival benefit of being a current smoker is due to confounders. There are 
numerous significant differences between the populations. Ex-smokers are older; mean 
(76.2 vs 69.2 years), with higher eMRCD dyspnoea score median 5a vs 4. FEV1 was not 
significantly different but slightly lower in ex-smokers despite a significantly lower average 
tobacco burden. LTOT was far commoner amongst ex-smokers (40.2% vs 17.6%) but this is 
likely to be due in part to safety concern leading to reduced prescription of oxygen to active 
smokers even if they have physiological need.  
Other important observations are: The hypothesised strong association between steady 
state dyspnoea and mortality is observed and a similar but less significant association is seen 
with LTOT prescription. In keeping with previous studies FEV1 is not associated with 
mortality in this cohort as either an absolute value or as a percentage of predicted. 
Interestingly previous NIV is also not associated with mortality. One may have expected it to 
be protective; i.e. to have survived treatment with NIV once or more makes one more likely 




unique episodes will have undoubtedly diluted this effect. Nevertheless, one may have 
expected a stronger protective signal. 
7.1.3 Dynamic factors.  
7.1.3.1 Clinical Findings Including Radiology. 
Chest X-rays were reviewed by the same researcher to verify presence of effusion, number 
of ribs and presence to measure diaphragm height. Consolidation was recorded in the 
hierarchy of clinical team interpretation (to mirror reality), radiologist report or researcher 
interpretation.  












47.2% 40.5% 66.9% <0.001 
Consolidation at admission 43.6% 38.4% 58.9% <0.001 
Confusion at ventilation 20.9% 16.4% 33.9% <0.001 
Pleural Effusion admission 18.8% 13.8% 33.6% <0.001 
Diaphragm Height (cm)* 2.1 (0.93) 2.13 (0.95) 1.95 (0.85) 0.063 
Number of posterior Ribs† 9 (8-9) 9 (8-9) 9 (8-9) 0.937 
Accessory Muscle Use 37.7% 38.8% 34.4% 0.384 
Ineffective Cough 86.0% 90.0% 74.2% <0.001 
Purulent sputum 43.6% 43.6% 43.5% 0.998 
Pedal Oedema on 
admission 
36.5% 35.5% 39.7% 0.405 
* Mean (SD) †Median (IQR) 
Several indices here are subjective and potentially unsuitable for inclusion in subsequent 
predictive models. For example, we were interested in whether presence of effusion or 
surrogate markers of hyper-inflation were associated with mortality. These are exploratory, 
in this cohort we see effusion is associated with mortality, but markers of hyper-expansion 
are not (although diaphragm height could be retained for consideration by our criteria). As 
such both of these are interesting for future verification but not for inclusion in final model. 
As expected, consolidation is significantly associated with in-hospital mortality. Similarly, 
ineffective cough is strongly associated with mortality, there is an inherent bias in collecting 




intuitive that those with most impaired cough have higher mortality. This another variable 
that requires further exploration in the future. 
7.1.3.2 Physiological Observations (in the period prior to ventilation). 










Systolic Blood pressure* 123.0 (32.4) 124.9 (32.5) 117.4 (31.8) 0.026 
Diastolic Blood Pressure* 69.7 (19.2) 70.3 (19.4) 67.8 (18.5) 0.223 
Mean Arterial Pressure* 87.4 (21.9) 88.5 (22.1) 84.4 (21.0) 0.071 
Heart Rate* 112.4 (22.1) 111.3 (22.6) 115.7 (20.4) 0.057 
Respiratory Rate* 28.6 (8.1) 28.1 (8.3) 29.8 (7.3) 0.041 
Temperature* 35.8 (5.8) 35.8 (6.1) 35.9 (4.8) 0.832 
Lowest oxygen 
Saturations* 
83.4 (10.7) 84.3 (10.5) 82.5 (11.3) 0.115 
GCS† 15 (14-15) 15 (14-15) 14 (12-15) <0.001 
* Mean (SD) †Median (IQR) 
Several routinely observations, many of which are constituents of the APACHE II and CAPS 
tools are associated with in-hospital mortality. The worst (greatest deviation from normal) 
was recorded. Very few patients oscillate either side of normal ranges within a given window 
so collection of this data is straightforward and determining which was ‘worst’ is largely 
unambiguous. 
7.1.3.3 Blood Tests (in the period prior to ventilation). 
A number of other blood tests were also recorded but the rate of missing data was 
unacceptably high and hence they are not reported. These include phosphate (88%) 
troponin (87%), total protein (23%) and bilirubin (20%). 
19% of Albumin and 25.7% of Glucose values were also missing, these are reported due to 
the strong association with mortality in previous work, but they are not included in model 
development (3.3.4).  





Table 28 Association with in-hospital mortality - Blood Tests. 
Variable Total Population 
Survived to 
discharge 
Died in hospital 
P 
value 
Haemoglobin (g/dL)* 13.6 (2.1) 13.9 (2.1) 12.8 (2.1) <0.001 
Haematocrit (L/L)* 0.420 (0.063) 0.428 (0.062) 0.396 (0.063) <0.001 
Platelets (x109/L)* 291 (123) 286 (117) 306 (141) 0.127 
WCC (x109/L)* 13.6 (6.6) 13.2 (6.7) 14.9 (6.0) 0.016 
Neutrophil Count (x109/L)* 10.9 (5.3) 10.5 (5.2) 12.4 (5.4) 0.001 
Eosinophil Count (x109/L)* <0.01 (<0.01-0.1) <0.01 (<0.01-0.1) <0.01 <0.01-<0.01) <0.001 
     
Sodium (mmol/L)* 136.6 (5.2) 136.5 (5.2) 136.9 (5.3) 0.409 
Potassium (x109/L)* 4.6 (0.7) 4.6 (0.63) 4.7 (0.86) 0.141 
Urea (x109/L) † 7.2 (5.3-10.9) 6.7 (5.0-10.1) 9.35 (6.5-14.5) <0.001 
Creatinine (x109/L) † 89 (71-119) 88 (72-115) 90 (67-137) 0.658 
Albumin (g/L)* 37.8 (5.4) 38.5 (5.1) 35.5 (3.4) <0.001 
Glucose (mmol/L)* 8.6 (3.8) 8.6 (4.0) 8.5 (3.4) 0.856 
CRP (mg/L) † 52 (15-120) 48 (13-108) 69 (25-155) 0.005 
* Mean (SD) †Median (IQR) 
7.1.3.4ABGs (in the period prior to ventilation). 
Table 29 shows that lower pH, base excess, bicarbonate and time to acidaemia are all 
associated with in hospital mortality when analysed as continuous variables. BE and 
bicarbonate are likely to be highly correlated. The much wider interquartile range in time to 
acidaemia adds credence to the hypothesis that those that deteriorate later into admission 
are a select group in whom outcomes are worse. 
Table 29 Association with in-hospital mortality - blood gases. 
Variable Total Population Survived to discharge Died in hospital P value 
pH† 7.26 (7.2-7.3) 7.27 (7.21-7.31) 7.25 (7.17-7.29) 0.003 
PaCO2 9.9 (8.5-11.7) 10.0 (8.7-11.7) 9.5 (8.3-11.7) 0.139 
PaO2 8.3 (6.9-10.7) 8.4 (6.9-10.7) 8.3 (6.8-10.8) 0.737 
Base Excess 3.8 (6.4) 4.4 (6.1) 2.0 (7.2) 0.001 
Bicarbonate 33.4 (6.9) 33.9 (6.6) 31.7 (7.6) 0.005 
Time to acidaemia 
(minutes) 
146 (56-852) 133 (60-494) 585 (62-5224) <0.001 




7.1.4 Pruning of Candidate Indices. 
From the above univariate analyses, all indices p<0.1 are potential candidates for further 
analysis. Some of the reported associations are interesting and candidates for further study 
but the retrospective design did not allow robust enough collection to reliably include for 
further analysis. This is particularly true of subjective indices, not measured on a 
standardised scale. For example, the effectiveness of cough is strongly correlated with 
outcome but not reliably recorded, associated with reduced conscious level and highly 
subjective unless formally assessed in a standardised way. Therefore, it is not a candidate for 
inclusion in a clinical tool.  
Table 30 Variables associated with in-hospital mortality p<0.1 but not candidates for 
regression model. 
Variable Removed Reason  
Admitted from institutional 
care 
Ethically dubious method of stratification, availability of family 
support may well alter threshold. 
Congestive Cardiac Failure No universal definition. 
Current smoker Lacks face validity to reduce risk category, confounded. 
Ineffective Cough No standard definition, high risk recording bias. 
Mean Arterial Pressure No routinely available at bedside. 
Albumin 19% Missing data. 
BMI 13.9% missing data and not routinely available at admission. 
Chronic Atrial Fibrillation Replaced by composite variable. 
Paroxysmal Atrial 
Fibrillation 
Replaced by composite variable. 
Atrial Fibrillation at time of 
Acidaemia 
Replaced by composite variable. 
Diaphragm Height Exploratory only. Inter-user variability not characterised. 
 
To remove ambiguity for both tools the presence of AF at any point whether that be chronic, 
paroxysmal or de novo up to the point of decision will be used. (In the NIVO study historical 
paroxysmal AF specifically excluded a single previous episode in the context of acute illness). 
7.1.4.1 Correlation Assessment. 
With reference to methods section 5.4.2.5, several variables amongst those with significance 
<0.1 are conceptually measuring the same thing and so were evaluated immediately. These 
initial suppositions include WCC and neutrophil count, haemoglobin and haematocrit, and 




Table 31 Variables associated with in-hospital mortality p<0.1 removed following 
correlation analysis 
Variable Removed Reason  
Neutrophil Count Highly correlated with WCC: Pearson’s 0.848 
Haematocrit Highly correlated with haemoglobin: Pearson’s 0.95 
Bicarbonate Highly correlated with base excess: Pearson’s 0.93 
 
Aside from the three expected above there were no other significant correlates identified 
using a correlation matrix. Mean VIF was 1.324 with no individual value >2. 
7.1.4.2 Final List of Candidate Indices Point of Deterioration Tool. 
Table 32 and Table 33 show the indices to be taken forward for multivariate analysis.  
Table 32 Candidate predictors: point of deterioration tool. 
Variable for further evaluation  P Value 
Age  <0.001 
Any atrial Fibrillation up to deterioration 0.012 




Consolidation at Ventilation <0.001 
Pleural Effusion admission <0.001 
Confusion at ventilation <0.001 
GCS <0.001 
Systolic Blood pressure 0.026 
Heart Rate 0.057 
Respiratory Rate 0.041 
Haemoglobin  <0.001 
WCC  0.016 




Base Excess 0.001 




All eligible variables can be considered for the point of deterioration tool whereas ‘dynamic’ 
variables are unsuitable for the admission tool. The exception drawn here is the presence or 
absence of consolidation as this is ‘less dynamic’ and there is face validity that presence or 
absence of pneumonia will influence events further into admission in those not already 
acidaemic at the time of senior assessment. Compilation of observations into a clinical 
trigger score for example NEWS score is a potential way forward however there have been 
several iterations used in UK hospitals and future changes to national practice may render 
any tool redundant or difficult to calculate at the bedside, furthermore international 
adoption would be problematic. 
7.1.4.3 Final List of Candidate Indices for Admission tool. 
Table 33 Candidate predictors: Escalation tool. 
Variable for further evaluation  P Value 
Age  <0.001 
Any atrial fibrillation (up to senior review) 0.012 




Consolidation (up to senior review) <0.001 
Time to acidaemia <0.001 
 
7.2 Multivariate Modelling: Point of Deterioration Tool 
7.2.1 Full model 
Entering all variables as continuous variables and reporting all that do not ‘drop out’ using a 
significance level of p>0.05 during the backward elimination process gives an estimation of 
the best achievable model. Using this process and entering the list of variables in Table 32 





Table 34 Results of regression analysis - full model. 
Variable Included in final model B S.E Wald Sig Odds Ratio (95% CI) 
Age 0.062 0.17 13.0 <0.001 1.06 (1.03-1.10) 
Atrial fibrillation 0.773 0.316 6.0 0.014 2.17 (1.17-4.02) 
Base Excess -0.066 0.022 8.9 0.003 0.94 (0.90-0.98) 
Consolidation 0.629 0.285 4.9 0.027 1.88 (1.07-3.28) 
Eosinophil count -3.680 1.087 11.5 0.001 0.03 (0.003-0.21) 
eMRCD 0.710 0.171 17.3 <0.001 2.033 (1.46-2.84) 
GCS -0.215 0.047 20.9 <0.001 0.81 (0.74-0.88) 
Heart rate 0.013 0.007 3.9 0.048 1.01 (1.00-1.03) 
LTOT 0.864 0.321 7.3 0.007 2.37 (1.27-4.45) 
Respiratory rate 0.040 0.019 4.7 0.030 1.04 (1.004-1.08) 
Time to acidaemia <0.001 <0.001 18.9 <0.001 1.00 (1.00-1.00) 
Intercept: -9.607, R2 0.498, Percentage correct after final iteration, 84.7%. Hosmer and 
Lemeshow 0.177. AUROC 0.885. 
Studentised residuals: 3.3% of cases were >+/-1.96 including 0.8% +/-2.58. These 
proportions are within the predefined acceptable levels (5.4.3). Only one case had a Cooks 
distance of >1 this case (206) also had the studentised residual furthest from 0.  
Case 206 is exerting considerable influence, this is evidenced by a Cook’s distance of 1.857 
and a studentised residual of 3.134. This patient fully recovered from their episode of 
ventilation but deteriorated some time later from ischaemic bowel while awaiting discharge. 
The default position is to include all cases to avoid overfitting but, in this instance, due to 
excessive influence and after careful consideration case 206 was removed from future 
modelling of in-hospital mortality. 
Re-running the analysis with 206 removed does not affect the number of indices remaining 
in the full model but does obviously alter the results subtly. The full table is not reported as 
the indices are to be categorised but the key descriptives are:  
Intercept: -10.05, R2 0.517, Percentage correct after final iteration, 84.8%. Hosmer and 





Figure 22 ROC curve, full point of deterioration model, Case 206 removed. 
 
Figure 22 shows the ROC curve of predicted probabilities versus actual outcome using the 
full model (which maintains continuous variables as continuous). The AUROC for this curve is 
0.892 (slightly higher than with outlying case included) indicating excellent discrimination. 
Figure 23 Calibration plot of observed versus predicted probability of in-hospital death by 
decile of predicted risk. Case 206 removed. 
 Predicted probability of death

























This calibration plot takes the predicted probability for each case from the regression model 
and ranks them in ascending order remembering from section 5.4.3 that all will lie between 
0 (lowest predicted probability of outcome) to 1 (highest probability). Cases are then 
grouped by decile of predicted risk, n = 488 so there are 48 or 49 cases in each decile. The 
mean of the predicted risk in each decile is then plotted against the observed number of 
cases (expressed as n died/total in that decile). Given that most patients survive most points 
are clustered close to zero i.e. low predicted and low observed risk. Perfect calibration would 
see each point lying on a line of best fit with a gradient of 1. Good calibration is shown here, 
as the predicted risk from the model increases the number of actual (observed cases) within 
that decile also increases across the risk spectrum with no unexpected outlying deciles on 
visual inspection. 
7.2.2  Point of Deterioration Model Discussion. 
It is notable that pH drops out of this model whereas base excess remains. It was 
hypothesised in section 3.3.3 that the importance of pH as an absolute value may have been 
overstated and this finding is certainly worthy of exploration. There is some collinearity as 
may be expected between pH and base excess. The very fact that both do not 
simultaneously remain in a model together shows this. While pH is widely considered to be 
an important predictor of outcome it is pertinent to note that CO2 is not a significant 
predictor of outcome in this dataset. It may, however, be the case that in this dataset there 
is an unexpectedly high rate of concurrent metabolic acidaemia exerting an undue influence 
(I.E. overfitting to source data).  
Guidance suggests that variables should be selected using results of previous research and 
that clinical intuition is important to avoid such overfitting to source data. Therefore, a 
separate model was generated replacing base excess with pH.  
7.2.3  Conversion to Categorical Variables. 
Using the criteria described in 5.4.4.2 continuous variables are converted into categorical 
(ideally binary divisions) variables to facilitate development of a clinical tool that can be 
applied simply at the bedside. Table 35 shows the final categorical variable states. eMRCD is 
such a strong predictor of mortality in previous research that it has been stratified into 3 




Table 35 Categorical variable assignation. 
 Categorical value applied in regression equation. 
Variable  0 1 2 
Age <75 ≥75  
Atrial fibrillation No Yes  
Base Excess ≥0 <0  
Consolidation No Yes  
Eosinophil count <0.05 
x109/L 
≥0.05 <0.05  
eMRCD 1-4 5a 5b 
GCS 15 ≤14  
Heart rate <110 ≥110  
LTOT No Yes  
pH ≥7.25 <7.25  
Respiratory rate <30 ≥30  
Time to acidaemia <12 hours ≥12 hours  
 
7.2.4  Regression Using Categorical Variables. 
7.2.4.1 Base Excess Model. 
Following conversion to categorical variables the regression analysis is re-run. It is possible 
the when a continuous variable is reduced to a simple binary division it no longer imparts 
independent risk and drops out of the final model. 
Table 36 Regression results: Categorised variables using base excess.  
Variable  B S.E Wald Sig Odds Ratio (95% CI) 
Respiratory rate 0.747 0.272 7.5 0.006 2.11 (1.24-3.60) 
LTOT 0.895 0.310 8.3 0.004 2.45 (1.33-4.50) 
GCS 0.922 0.282 11.8 0.001 2.51 (1.45-4.37) 
Consolidation 0.980 0.280 12.3 0.001 2.66 (1.54-4.61) 
Base Excess 1.079 0.296 13.3 <0.001 2.94 (1.65-5.25) 
Atrial fibrillation 1.242 0.329 14.3 <0.001 3.46 (1.82-6.59) 
eMRCD 5a 1.247 0.337 13.7 <0.001 3.48 (1.80-6.74) 
Time to acidaemia 1.397 0.290 23.1 <0.001 4.04 (2.29-7.14) 
Eosinophil count <0.05 x109/L 1.606 0.319 25.3 <0.001 4.98 (2.66-9.32) 




Intercept -4.852, R2 0.486, Percentage correct after final iteration, 84.8%. Hosmer and 
Lemeshow 0.06.  
Table 36 shows that after categorisation that both age and heart rate drop out of the final 
model. They will therefore not form any part of the final score. This is an interesting example 
of the outcome from multi-variable modelling: Age is starkly associated with mortality on 
univariate analysis but when using multiple variables it imparts little additional independent 
information to the model. This is likely to be because the much of its association with 
mortality is absorbed into other variables. For example, the additional mortality effect of 
increasing age may be due to frailty as captured by eMRCD, higher likelihood of confusion as 
captured by GCS and more cardiac comorbidity as captured by AF.  
7.2.4.2 pH model.  
Table 37 shows that if pH <7.25 is substituted for a BE <0 then the same two variables age 
and heart rate drop out of the final model. It is also interesting (and unsurprising from a 
clinical perspective) that if BE is removed from the matrix then pH becomes and remains an 
independent predictor of in-hospital mortality albeit less significant. Furthermore, the final 
model performance is comparable. 
Table 37 Regression results: Categorised variables using pH.  
Variable  B S.E Wald Sig  (Odds Ratio 95% CI) 
pH 0.571 0.280 4.2 0.042 1.77 (1.02-3.07) 
Respiratory rate 0.675 0.270 6.3 0.012 1.97 (1.16-3.33) 
LTOT 0.764 0.302 6.4 0.012 2.15 (1.19-3.88) 
GCS 0.803 0.280 8.2 0.004 2.23 (1.29-3.87) 
Consolidation 1.019 0.276 13.6 <0.001 2.77 (1.61-4.76) 
eMRCD 5a 1.159 0.329 12.4 0.001 3.19 (1.67-6.07) 
Atrial fibrillation 1.298 0.328 15.7 <0.001 3.66 (1.93-6.96) 
Time to acidaemia 1.484 0.291 26.0 <0.001 4.41 (2.49-7.80) 
Eosinophil count <0.05 x109/L 1.538 0.315 23.8 <0.001 4.66 (2.51-8.64) 
eMRCD 5b 1.981 0.372 28.4 <0.001 7.25 (3.50-15.03) 





7.2.5 Variable Weighting. 
A maximum of 8 variables were desired therefore respiratory rate was dropped as a 
candidate for inclusion in the final tool as this is both the weakest predictor and conceptually 
the least reliable as it is highly dynamic and inherently linked to the frequency of 
observation. For the pH model, pH was included in lieu of base excess irrespective of its odds 
ratio as this is the desired exploration of the data. 
To ascribe weighting the Wald score and odds ratio for each independent variable following 
regression analysis in categorical states (Table 36) was divided by that of the lowest included 
variable (LTOT) the result of which is displayed in Table 38. Two methods of weighting are 
proposed, a simple one and a more complex one. Unless significantly better prediction or 
discrimination is offered by the complex weighting the simple weighting will be the final 
proposed model to maximise utility.  
The weighting of eosinophil count requires some consideration. This variable may be 
underweighted in the simple score however, clinically it is likely that severe steady state 
dyspnoea requiring assistance with ADLs (eMRCD 5b) is a stronger predictor of outcome 
than eosinopenia and hence ascribing the lower weighting of one is the preferred initial 
option. Another consideration in the weighting of the eosinophil count is the role of oral 
corticosteroids. Many patients receive steroids acutely in line with national and international 
guidance. In the DECAF studies all information was applied in the admission phase; whether 
eosinopenia was driven by failed primary (pre-admission) steroid therapy or sepsis it is 
plausible that this would be associated with worse outcome. In modelling the point of 
deterioration tool 25% of the population are deteriorating later into the admission and 
almost all will have been treated acutely with oral corticosteroids. The longer the duration of 
treatment the greater the chance corticosteroids will have induced eosinopenia but we can 
also see that later development of acidaemia is associated with increased mortality. Because 
this effect is only occurring in a minority of the patients it may not be identified by a 
correlation matrix but have a disproportionate effect on outcome due to the increased 
number of outcome events in the late deteriorating group. This is not easily testable with 
the available data but is a strong hypothesis and an additional reason not to overweight the 




It is reasonable and accepted practice to re-evaluate weightings (known as re-calibrating) in 
a validation cohort and adjust if a marked discrepancy is seen.(245)  
Table 38 Variable weighting. 





LTOT 1.0 1.0 1 1 
GCS 1.4 1.0 1 1 
Consolidation 1.5 1.1 1 1 
Base Excess 1.6 1.2 1 1 
eMRCD 5a 1.6 1.4 1 1 
Atrial fibrillation 1.7 1.4 1 1 
Time to acidaemia 2.8 1.6 1 2 
Eosinophil count <0.05 
x109/L 3.0 2.0 
1 2 
eMRCD 5b 3.5 3.1 2 3 
 
7.2.6  Predictive Score Development. 
Eight potential models are reported here; firstly using 8 variables and then using 6. A model 
is then created substituting pH for base excess. Each of these 4 potentials is then reported 
with the simple and complex weighting imposed. The following tables overeaf show in-





7.2.6.1 Eight Variable models. 
Table 39 Eight variable models with stepwise N and in-hospital mortality. 
 Simple scoring, (N, % Mortality) Complex Scoring, (N, % Mortality) 
Tool Score Model 1 (BE) Model 2 (pH) Model 3 (BE) Model 4 (pH) 
0 24 (0%) 22 (0%) 24 (0%) 22 (0%) 
1 50 (0%) 46 (0%) 29 (0%) 28 (0%) 
2 101 (5.0%) 91(4.4%) 62 (0%) 55 (0%) 
3 104 (13.5%) 106 (12.3%) 78 (7.7%) 74 (6.8%) 
4 89 (25.8%) 87 (25.3%) 79 (13.9%) 82 (12.2%) 
5 66 (59.1%) 76 (53.9%) 74 (25.7%) 72 (23.6%) 
6 33 (72.7%) 35 (62.9%) 47 (44.7%) 56 (42.9%) 
7 18 (83.3%) 21 (81.0%) 42 (57.1%) 40 (57.5%) 
8 3 (100%) 4 (100%) 25 (76.0%) 30 (70%) 
9 0  0 17 (88.2%) 17 (82.4%) 
10   8 (62.5%) 9 (66.7%) 
11   3 (100%) 3 (100%) 
12   0 0 
7.2.6.2 Six variable models. 
The two least influential predictors of in-hospital mortality from Table 36; LTOT and GCS are 
removed in the following models (therefore the maximum achievable score is reduced). 
Table 40 Six variable models with stepwise N and in-hospital mortality. 
 Simple scoring, (N, % Mortality) Complex Scoring, (N, % Mortality) 
Tool Score Model 5 (BE) Model 6 (pH) Model 7 (BE) Model 8 (pH) 
0 35 (0%) 30 (0%) 35 (0%) 30 (0%) 
1 88 (3.4%) 77 (3.9%) 47 (0%) 44 (0%) 
2 136 (8.8%) 126 ((5.6%) 76 (5.3%) 70 (4.3%) 
3 105 (26.7%) 121 (24.8) 103 (10.7%) 96 (8.3%) 
4 76 (53.9%) 79 (51.9%) 71 (28.2%) 84 (25.0%) 
5 33 (84.8%) 39 (79.5%) 23 (39.7%) 66 (39.4%) 
6 13 (69.2%) 14 (64.3%) 53 (52.8%) 43 (53.5%) 
7 2 (100%) 2 (100%) 21 (85.7%) 31 (77.4%) 
8   12 (91.7%) 13 (84.6%) 




7.2.6.3 AUROC, Models 1-8. 
Figure 24 and Table 41 show the areas under the receiver operated curves for the models 
described in Table 39 and Table 40. All show excellent discrimination. 
Figure 24 Area under the receiver operated curves for point of deterioration models 1-8. 
 
Table 41 Area under the receiver operated curves for point of deterioration models 1-8. 
Model Description AUROC (95% CI) 
Model 1  8, BE, Simple 0.86     (0.83-0.90) 
Model 2 8, pH, Simple 0.85     (0.82-0.89) 
Model 3 8, BE, Complex 0.87     (0.83-0.90) 
Model 4 8, pH, Complex 0.86     (0.83-0.90) 
Model 5 6, BE, simple 0.85    (0.81-0.89) 
Model 6 6, pH, Simple 0.85     (0.81-0.89) 
Model 7 6, BE, Complex 0.85     (0.82-0.90) 





7.2.7 Model Evaluation 
As can be seen from Figure 24 and Table 41 all of the models offer good prediction of in-
hospital mortality. From the 8 different models there here are 3 decisions to be made: 
1. To retain base excess or substitute in pH. 
2. To use an 8-variable or a 6-variable model. 
3. To use the simple or complex scoring system. 
In this population base excess is the better predictor and pH is being forced into the model. 
However, both models offer good predictions and the validation population will inevitably 
differ from the derivation population due to both inclusion of multiple centres and changes 
to national practice. The lower limit for CO2 has also risen in national guidance from 6.0 to 
6.5 kPa meaning potentially fewer patients with primarily metabolic acidaemia are selected. 
Furthermore Table 36 shows that the Hosmer and Lemeshow assessment of calibration is 
very nearly significant which would be indicative of a poorly calibrated model when using BE. 
This is not the case for the same model using pH although this observation is no longer 
present after categorisation. For these reasons the final proposed model will include both 
pH and BE as an either/or category. 
8 variables do produce slightly better prediction than 6 and particularly in those at higher 
risk of death which is important for score utility in clinical practice. If, however in the 
validation cohort good prediction is offered by 6 variables it would be reasonable to further 
prune GCS and LTOT to create the simplest model achievable. 
Finally, the simple scoring system is clearly superior for two reasons. Firstly, the greater 
stratification of the complex score leads to non-progressive mortality. Secondly, the simple 
score maintains in all its iterations a clear shoulder where risk jumps from the order of 25% 
to >50%. This jump has potential clinical utility. 
The position from these data is to use 8 variables and the simple scoring system with 
BE<0/pH<7.25 as described above. The main question to be answered by the validation 
cohort is to ensure the weightings remain accurate and see whether a six variable model can 




7.2.8 The Final Proposed Model. 
The final proposed model is the culmination of the steps taken above to create a simple 
bedside score to model in-hospital mortality in this cohort. The maximum achievable score is 
9 (remembering that one cannot score for both eMRCD 5a and 5b). 
Final Proposed Model  Points 
Atrial fibrillation  1 
Consolidation  1 





GCS ≤14 1 
LTOT 1 
Time to acidaemia >12 hours 1 
Base Excess <0 or pH<7.25 1 
 
This model clearly outperforms the more complex clinical scores in its derivation population. 
The full model is included as a ‘best achievable’ comparator however use of the full model is 
not easily achievable in current clinical practice as it requires complex computation of 
continuous variables. With greater digitalisation of healthcare records a model using 
continuous variables may have future utility. 
Table 42 Final proposed model: mortality by each point. 
Tool Score  Number Mortality 
0 20 0 (0%) 
1 41 0 (0%) 
2 93 4 (4.3%) 
3 101 11 (10.9%) 
4 93 21 (22.6%) 
5 73 38 (52.1%) 
6 39  25 (64.1%) 
7 24 20 (83.3%) 
8 4 4 (100%) 




Figure 25 ROC curves for point of deterioration tool: Full model, final proposed model and 
comparison scores from previous research. 
 
Table 43 Area under the receiver operated curve for full model, model 1 and comparison 
scores. 
Model AUROC (95%CI) 
Full Model 0.89     (0.86-0.93) 
Final proposed model 0.86     (0.82-0.89) 
APACHE 2 0.75     (0.70-0.80) 
CAPS  0.67     (0.62-0.73) 
Confalonieri Risk of Failure Chart 0.68     (0.63-0.73) 
 
The Confalonieri risk of failure chart 3.3.6.3 plots each patient into a risk group based upon 
three indices. This does not result in a variable easily interpretable for comparison so the 
odds ratios from the regression equation used to build the risk chart as reported in the 
original paper were taken and applied to relevant index. In this manner an individual score 
was built for each patient and used for comparison. Performance in this population is 




7.3 Multivariable Modelling: Admission Tool 
Two tools were always intended to be created: The variables identified in Table 33 were 
entered into a backward, stepwise regression model as continuous variables as per the point 
of deterioration tool. Case 206 removed. Methodology will follow the same stepwise 
method as earlier but reporting is somewhat reduced for simplicity. 
7.3.1  Full Regression results 
Table 44 shows the results following entry of all eligible admission tool variables. 
Table 44 Admission tool: Regression results: All variables entered as continuous variables. 
Variable Included in final model B S.E Wald Sig Odds Ratio 
Age 0.48 0.15 11.1 0.001 1.05 (1.02-1.08) 
Atrial fibrillation (Chronic +PAF) 0.626 0.316 3.9 0.480 1.87 (1.01-3.47) 
Consolidation at senior review 0.898 0.249 13.0 <0.001 2.45 (1.51-4.00) 
eMRCD 0.883 0.148 35.4 <0.001 2.42 (1.81-3.23) 
Time to acidaemia 1.249 0.257 23.6 <0.001 3.49 (2.11-5.77) 
Intercept -9.94, R2 0.348, Hosmer and Lemeshow 0.432 Percentage correct after final 
iteration 79.5%, AUROC 0.822 
7.3.2  Categorisation and Weighting. 
eMRCD was handled as previously 7.2.3. There is no obvious split from ROC curve analysis of 
age. 75 was chosen as a round number close to the median split. However, following 
categorisation, age drops out of the final model. In order to maximise the chance of 
identifying a high-risk patient cohort in whom ventilation may be futile a time threshold of 
48 hours was selected. 
Table 45 Admission tool: Regression results: Independent predictors entered as categorical 
variables. 
Variable Included in final model B S.E Wald Sig Odds Ratio 
Atrial fibrillation (Up to Senior) 0.792 0.293 7.3 0.007 2.21 (1.24-3.92) 
Consolidation at senior review 1.108 0.251 19.4 <0.001 3.03 (1.85-4.95) 
eMRCD 5a 1.383 0.303 20.9 <0.001 3.99 (2.20-7.22) 
Time to Acidaemia >48hours 1.973 0.344 32.9 <0.001 7.19 (3.66-14.12) 




Table 45: Intercept -2.017, R2 0.346, Hosmer and Lemeshow 0.222 Percentage correct after 
final iteration 79.5%, AUROC 0.820 
Using the methods described independent categorical predictors were assigned weights to 
develop a prognostic tool. 
Table 46 Admission Tool: Variable weighting assignation. 







Atrial fibrillation (Up to Senior) 1.0 1.0 1 1 
Consolidation at senior review 2.7 1.4 1 1 
eMRCD 5a 2.9 1.8 1 2 
Time to Acidaemia >48hours 4.5 3.3 3 3 
eMRCD 5b 6.3 4.1 3 4 
7.3.3 Score development and evaluation. 
Unlike with the point of deterioration tool the score is comparatively simple to develop as 
the only decision to make is which weighting system to adopt. Clearly, with only four 
independent variables remaining all four will be included in the model and as no blood gas 
data is included there is no BE vs pH differential. 
Table 47 In-hospital mortality by both simple and complex admission tool score. 
 Simple Score Complex Score 
Tool Score Number Mortality Number Mortality 
0 102 2 (2.0%) 102 2 (2.0%) 
1 162 18 (11.1%) 94 9 (9.6%) 
2 77 22 (28.6%) 77 10 (13.0%) 
3 50 24 (48.0%) 78 27 (34.6%) 
4 52 26 (50.0%) 48 21 (43.8%) 
5 21 13 (61.9%) 45 24 (53.3%) 
6 10 5 (50.0%) 20 12 (60%) 
7 N/A N/A 10 5 (50%) 
8 N/A N/A 11 10 (90.9%) 




Figure 26 ROC curves for admission tool: Full model, simple score, complex score and 
comparisons from previous research. 
 
Table 48 Area under the receiver operated curves for various models of Admission Tool. 
Model AUROC (95%CI) 
Full Model 0.82     (0.78-0.86) 
Simple score 0.82     (0.77-0.86) 
Complex Score 0.82     (0.78-0.86) 
 
Curves for other tools is included on Figure 26 for visual comparison. AUROC data for these 
comparison tools is the same as in Table 43.  
7.3.4 Admission Tool Comments. 
There is an important conceptual difference for the admission tool. The potential indication 
is for use in the admission window to give stratified risk. The median time for consultant 
review is 10 hours by which time in about three quarters of patients the indication for 
ventilation has already arisen and the tool is therefore used in real time. The other use is to 




patient not currently needing assisted ventilation in a discussion regarding what to do if they 
were to subsequently deteriorate to the point where they might need it. These two 
subpopulations are distinct; those acidaemic at admission are more numerous with lower 
mortality risk. The performance of this tool should be examined in both of these 
subpopulations to ensure consistent performance. 
When only those patients that deteriorate after 12 hours are selected the simple tool has an 
AUROC of 0.768 (0.687-0.848) and the complex weighting tool has an AUROC of 0.775 
(0.696-0.854). This means that the scoring in this group is somewhat poorer with wider 
confidence intervals.  
7.4 Multivariable modelling: Rule of Thumb. 
7.4.1 Aim and Approach to Creating a Rule of Thumb? 
Sometimes a tool no matter how simple and refined, is more complex than clinicians require, 
and therefore not used. In some instances, a very simple piece of information to guide a 
decision is useful. The rule of thumb does not need to be differentially weighted by odds 
ratios and the aim is not to identify stratified risk merely to give a very simple guide to be 
incorporated into a larger decision framework. Detailed and more bespoke risk can be 
obtained by using a more elegant and specific model as already described. 
The rule of thumb attempts to identify a group of patients with a high short-term mortality 
risk that could influence clinical decisions (death in-hospital or within 90 days of discharge). 
7.4.2 Rule of thumb Development 
The strongest three predictors were used to develop the rule of thumb; eMRCD count, the 
eosinophil count and the time to development of acidaemia. Eosinophil count was excluded 
immediately because does not identify progressively higher mortality risk in the same way 
and is unlikely to work as well in the desired rule of thumb so was dropped. 
The following tables display in-hospital and 90-day mortality (including hospital deaths) 
using the three identified time cut offs and the eMRCD score, first using just 5b and secondly 
combining 5a and 5b (i.e. the traditional MRCD grade 5). Each table is presented in four 




adverse (e)MRCD score without late deterioration, only late deterioration but without 
adverse (e)MRCD risk and both adverse indicators present.  
Table 49 Rule of thumb chart using eMRCD 5b and acidaemia after 12 hours 
Adverse feature(s) Total I/P mortality 90 Day Mortality 
Neither 296 37 (12.5%) 62 (20.9%) 
eMRCD  5b only 64 27 (42.2%) 41 (64.1%) 
Acidaemia >12 hours only  92 33 (35.9%) 37 (40.2%) 
Both eMRCD 5b AND acidaemia >12 hours 36 26 (72%) 28 (77.8%) 
Table 50 Rule of thumb chart using eMRCD 5b and acidaemia after 48 hours.  
Adverse feature(s) Total I/P mortality 90 Day Mortality 
Neither 352 51 (14.5%) 80 (22.7%) 
eMRCD 5b only  77 35 (45.5%) 49 (63.6%) 
Acidaemia >48 hours only 36 19 (52.8%) 19 (52.8%) 
Both eMRCD 5b AND acidaemia >48 hours 23 18 (78.3%) 20 (87.0%) 
Table 51 Rule of thumb chart using MRCD 5 and acidaemia after 12 hours.  
Adverse feature(s) Total I/P mortality 90 Day Mortality 
Neither 173 9 (5.2%) 17 (9.8%) 
MRCD 5 only 187 55 (29.4%) 86 (46%) 
Acidaemia >12 hours only 51 13 (25.5%) 14 (27.5%) 
Both MRCD 5 AND acidaemia >12 hours 77 46 (59.7%) 51 (66.2%) 
Table 52 Rule of thumb chart using MRCD 5 and acidaemia after 48 hours. 
Adverse feature(s) Total I/P mortality 90 Day Mortality 
Neither 205 12 (5.9%) 22 (10.7%) 
MRCD 5 only  224 74 (33%) 107 (47.8%) 
Acidaemia >48 hours only  19 10 (52.6%) 10 (52.6%) 
Both MRCD 5 AND acidaemia >48 hours 40 27 (67.5%) 30 75%) 
7.4.3 Rule of Thumb Discussion. 
The addition of dyspnoea severity scoring to late acidaemia development identifies a much 
higher mortality risk than either factor individually. Exploring the data in late deteriorators 
only shows 128 patients deteriorate after 12 hours of whom 59 (46%) die in hospital (Table 




(or eMRCD 5a and 5b combined). Of these 77 patients 46 die in hospital. Therefore, using 
this single index 12 hours after admission over three quarters (78%) of the future inpatient 
deaths in those receiving assisted ventilation are captured. This is a potentially powerful way 
of selecting those to instigate active escalation planning. By extension the 51 patients 
deteriorating after 12 hours with an MRCD score of 4 or less have an in-hospital mortality of 
25.5% more or less identical to the overall population mortality.  
There is potential to identify those with high mortality using both the traditional and 
extended MRCD. This information may be informative to a clinician faced with a patient 
deteriorating after the admission period. The highest mortality is seen in those deteriorating 





Chapter 8. Derivation Results Part 3: Mortality, Readmissions, 
Predictors of Key Post Discharge Events and Sub-group 
Analysis. 
8.1 Mortality 
124 patients died in hospital. Figure 27 is a Kaplan Meier plot is of the entire population up 
to 2 years after admission date, including those that die in hospital. 
Figure 27 Kaplan Meier survival curve, whole study population from admission to Two 
years. 
 
Table 53 is limited to survivors to discharge. In this population over half of patients 
ventilated for their ECOPD who survive to discharge will be alive after two years. As can be 
seen from Figure 27 and Table 53 there is a steady attrition of survivors to discharge without 
any particular shoulder or threshold where mortality rate changes markedly. Nearly half of 
those surviving to discharge are still alive after 2 years.  
Time

















Table 53 Post discharge mortality amongst survivors to discharge up to 2 years. 
Amongst Survivors to Discharge (n=365) 
Time point (from admission) 
Deceased (Percentage of survivors) 
30 day mortality  16 (4.4%) 
90 day mortality  47 (12.9%) 
180 day mortality  70 (19.2%) 
1 year mortality  106 (29.0%) 
2 year mortality  174 (47.7%) 
 
8.2 Prediction of Six-month mortality. 
This section aims to identify predictors of death in the 70 patients who survive to discharge 
but then die within 6 months. Methodology is the same as that used for creation of previous 
tool(s) 5.4. Only those indices that conceptually have association with readmission are 
included. Due to the low numbers here are lower this data analysis should be considered 
with caution and has not been subject to separate power calculations. 
8.2.1 Univariate Associations with Six-month Mortality. 
Table 54 reports the univariate associations with six-month mortality amongst the 365 
patients who survived to hospital discharge. There is no missing data amongst these 
variables. Ischaemic heart disease (IHD) is patients with a history of one or both of angina or 
myocardial infarction (MI). Cardiovascular disease is consistently associated with mortality in 
COPD. Due to small numbers in this cohort a composite cardiovascular risk score was also 
created including: LVSD, cor-pulmonale, IHD or cerebrovascular disease (CVD). This was 
modelled as conceptually it is a potentially useful way of including medium term risk of 
death from co-morbidity into a single simple entity. There were variable rates of missing 
data amongst the ‘pre-discharge’ blood tests. The only blood tests recorded reliably in the 
pre-discharge window are the constituents of a full blood count (FBC) and urea and 
electrolytes (U+E).  Missing data rates here were typically 10-13%. Albumin was rarely 
collected pre-discharge but admission albumin has some face validity to predict medium 
term prognosis so is used in lieu. Only admission albumin imparted independent risk upon 
multivariable modelling but was subsequently dropped. Pre-discharge blood gas data is also 
frequently missing; the majority did not have sampling after cessation of ventilation (Table 




Table 54 Associations with 6-month mortality amongst survivors to discharge. 
Variable 
Total Population  
N=365 
Alive after 6 
months N=295 
Died within 6 
months N=70 
P value 
Age* 71.0 (10.0) 70.2 (9.8) 74.5 (10.4) 0.001 
Gender (% female) 226 (61.9%) 178 (60.3%) 48 (68.6%) 0.220 
FEV1%* 37.6 (16.1) 37.9 (16.0) 6.6 (16.8) 0.553 
eMRCD† 4 (4-5a) 4 (4-5a) 5 (5a-5b) <0.001 
LTOT 96 (26.3%) 70 (23.7%) 26 (37.1%) 0.034 
Previous NIV 82 (22.5%) 64 (21.7%) 18 (25.7%) 0.524 
Consolidation 148 (40.5%) 118 (40.0%) 30 (42.9%) 0.686 
Late Deterioration 69 (18.9%) 58 (19.7%) 11 (15.7%) 0.501 
Late Failure 23 (6.3%) 19 (6.4%) 4 (5.7%) 1.000 
     
Asthma 33 (9.0%) 26 (8.8%) 7 (10.0%) 0.816 
Bronchiectasis 27 (7.4%) 19 (6.4%) 8 (11.4%) 0.200 
IHD 98 (26.8%) 68 (23.1%) 30 (42.9%) 0.001 
MI 50 (13.7%) 34 (11.5%) 16 (22.9%) 0.019 
LVSD 44 (12.1%) 32 (10.8%) 12 (17.1%) 0.155 
Cor-Pulmonale 67 (18.4%) 49 (16.7%) 18 (25.7%) 0.087 
AF (Acute, Chronic or PAF) 42 (11.5%) 32 (10.8%) 10 (14.3%) 0.409 
Anxiety 80 (21.9%) 62 (21.0%) 18 (25.7%) 0.422 
Depression 114 (31.2%) 92 (31.2%) 22 (31.4%) 1.000 
Cognitive impairment 28 (7.7%) 18 (6.1%) 10 (14.3%) 0.041 
CVD 37 (10.1%) 27 (9.2%) 10 (14.3%) 0.194 
Composite Cardiovascular 
(R/LVF, IHD, CVD) 
170 (46.6%) 128 (43.4%) 42 (60.0%) 0.016 
     
Benzodiazepine 53 (14.9%) 41 (14.2%) 12 (17.9%) 0.449 
Regular strong Opiate  24 (6.8%) 15 (5.2%) 9 (13.4%) 0.027 
Diuretic 167 (47.0%) 138 (47.9%) 29 (43.3%) 0.501 
Beta Blocker 42 (11.8%) 31 (10.8%) 11 (16.4%) 0.209 
ACE inhibitor 85 (23.9%) 72 (25.0%) 13 (19.4%) 0.427 
Statin 143 (40.3%) 120 (41.7%) 23 (34.3%) 0.333 
LABA 338 (95.2%) 276 (95.8%) 62 (92.5%) 0.335 
LAMA 320 (90.1%) 264 (91.7%) 56 (83.6%) 0.066 
ICS 341 (96.1%) 277 (96.2%) 64 (95.5%) 0.733 
Carbocisteine 87 (24.5%) 72 (25.0%) 15 (22.5%) 0.753 
Theophylline(s) 22 (6.2%) 18 (6.3%) 4 (6.0%) 1.000 
Azithromycin 28 (7.9%) 22 (7.6%) 6 (9.0%) 0.801 




Table 55: Reporting of relationship between 6-month mortality amongst survivors to 








Alive after 6 
months 
N=295 





BMI* 8.5% 25.3 (7.3) 26.1 (7.2) 22.2 (6.6) <0.001 
Haemoglobin* 11.0% 13.0 (2.0) 13.2 (2.0) 12.3 (1.7) 0.001 
WCC* 11.0% 10.4 (5.2) 10.2 (3.7) 11.6 (9.0) 0.039 
Platelet count* 10.7% 307 (121) 310 (125) 296.0 (101) 0.374 
Eosinophil count† 9.6% 0.1 (<0.05-0.2) 0.1 (<0.05-0.2) 0.1 (<0.05-0.2) 0.043 
Sodium* 10.1% 139.0 (3.9) 139.1 (2.4) 138.4 (3.2) 0.110 
Potassium* 11.0% 4.2 (0.5) 4.2 (0.5) 4.2 (0.5) 0.910 
Urea† 10.1% 5.6 (4.5-8.1) 5.6 (4.5-7.7) 5.8 (4.5-9.1) 0.460 
Creatinine† 10.4% 79 (65-96) 79 (66-97) 77 (61-100) 0.425 
CRP† 19.5% 14 (5-34) 13 (5-32) 19 (5-44) 0.146 
Albumin* 13.2% 38.9 (4.7) 39.4 (4.5) 37.1 (4.9) <0.001 
Admission 
Bicarbonate* 
4.1% 33.9 (6.7) 33.8 (5.9) 33.7 (5.9) 0.936 
* Mean (SD) †Median (IQR). (n.b. Eosinophil count, lower value confers increased mortality) 
There are several noteworthy observations from the univariate analysis:  
• Having received NIV prior to the index event is not associated with medium term 
mortality in either direction.  
• In this cohort few medications impact upon 6-month mortality. Strong opiates (in 
small numbers) does.  
• In keeping with previous observations as described in 3.3.2.7 cardiovascular disease 
appears to exert a stronger influence upon medium term outcomes with IHD strongly 
significant.  
• Albumin and BMI both of which were also associated with in-hospital mortality but 
not carried forward for multivariable analysis (missing data in case of albumin and 
unsuitability for a point of emergency care tool in case of BMI) are of significant 
prognostic value. While 13% missing data in the case of albumin is not extremely high 
it is greater than our stated 10% cut-off. Additionally, this requires using the 
admission albumin rather than discharge. These combined uncertainties render 





8.2.2 Multivariate Modelling of Six-Month Mortality. 
15 variables: Age, eMRCD, long term oxygen prescription, history of ischaemic heart disease, 
MI, cor-pulmonale, cognitive impairment, composite cardiovascular, prescription of strong 
opiate on discharge, long acting muscarinic agonist, BMI, haemoglobin, white cell count, 
eosinophil count and serum albumin were associated with 6-month mortality after 
univariate analysis with a p value of <0.1. Variables were categorised using the previously 
described hierarchy. Opiate use and cognitive impairment capture less than 10% of the 
population so were not carried forward. MI is captured within the IHD variable but captures 
a smaller percentage of the population and is less significant so was also not entered into 
regression analysis. 
Following categorisation the variables in Table 56 remain independent predictors of 
outcome. The same variables remain in the equation whether run categorised or as 
continuous variables. Assessed as categorical variables no case had a Cook’s distance of >1 
and 10 (3.7%) had a studentised residual of +/- 1.96 indicating good model fit. (Continuous 
variables no case had a Cooks distance of >1 and 15/365 (4.1%) had a studentised residual of 
+/- 1.96).  
Table 56 Independent predictors of six-month mortality. 
Variable  B S.E Wald Sig Odds Ratio 
Cor Pulmonale 0.638 0.372 2.947 0.086 1.89 (0.91-3.92) 
Albumin <38 g/dL 0.695 0.305 5.184 0.023 2.00 (3.16-16.80) 
IHD 1.170 0.331 12.48 <0.001 3.22 (1.68-6.16) 
eMRCD 5a 1.379 0.351 15.47 <0.001 3.97 (1.98-7.89) 
BMI <20 1.556 0.333 21.758 <0.001 4.74 (2.64-9.11) 
eMRCD 5b 1.986 0.426 21.70 <0.001 7.29 (3.16-16.80) 
R2 0.315, Percentage correct after final iteration, 83.3%. Hosmer and Lemeshow 0.374. 
AUROC 0.821. 
If only the three strongest predictors are used: eMRCD categorised, IHD and BMI <20 there 
results an AUROC of 0.801, R2 of 0.285 and Hosmer and Lemeshow of 0.779. 
As may be expected when using so few variables and modelling from a smaller number of 




of the variation is explained by the model than for example when using the NIVO score. 
Nevertheless, an AUROC of >0.8 is encouraging. 
8.2.3 Simple Score to Predict Six-month Mortality. 
A very simple score can be generated using 1 point for IHD, BMI and eMRCD 5a and 2 points 
for eMRCD 5b. The resultant maximum 4 point score outcomes are shown in Table 57.  
Table 57  Six and twelve-month mortality by simple score. 
Mortality Score  Number 6 Month-Mortality 12 Month-Mortality 
0 125 5 (4.0%) 14 (13.2%) 
1 121 16 (13.2%) 28 (26.4%) 
2 86 29 (33.7%) 38 (35.8%) 
3 29 16 (55.2%) 22 (75.9%) 
4 4 4 (100%) 4 (100%) 
 
The comparator 5 variable model and 3 variable model AUROC values shown in Table 58 are 
generated from probabilities using full regression equation for the categorised variables and 
handles beta coefficients in absolute terms. 
Table 58 Area under the receiver operated curves for models of six month mortality 
amongst survivors to discharge. 
Model AUROC (95%CI) 
5 Variable model (categorised) 0.82     (0.77-0.88) 
3 variable model (categorised) 0.80     (0.74-0.86) 
Simple score 0.79     (0.73-0.84) 
8.2.4 Six-month Mortality Model Discussion 
Importantly these variables are conceptually sound and discrimination is maintained beyond 
six months adding credence to this model of risk of medium term death. Having a score of 0 
or 1 identifies two thirds of the population (67.4%) who are at relatively lower risk of post 




Albumin was omitted from this model due to high rate of missing data, the fact that we were 
forced to use admission data rather than pre-discharge values and the attraction of using 
less dynamic values to model the medium to long term. 
8.3 Readmissions 
Of the 365 patients who survived to discharge there were 381 readmissions in the year 
following. 142 (38.9%) had no readmission although this figure will include those that die at 
home without being readmitted (n=35). 23% of patients were re-admitted within 30 days 
and 35.3% by 90 days. The median number of readmissions was one (IQR 0-2) and 14.5% of 
the population had 3 or more admissions in the subsequent year following discharge. 
8.4 Sub-Groups 
5 sub-groups were identified ‘a priori’ to examine mortality and readmission rates in greater 
detail. 
• Late failure of NIV  
• Long-term oxygen therapy. 
• Home mechanical ventilation on discharge. 
• Eosinopenia at discharge. 
• Persistent hypercapnia at discharge. 
Due to the uncontrolled study design we were unsure whether data would have been 
collected by the managing clinical team to accurately characterise these sub-populations. 
Persistent hypercapnia at discharge and eosinopenia are both reliant on blood sampling in 
the period prior to discharge once a patient is stable.  I.e. There was no way of knowing 
whether data would be complete enough to accurately define the subgroup until the 
analysis phase. 
The in-hospital outcomes for late failure and those in receipt of LTOT are interesting and 
data is pertinent to the population receiving the primary intervention so the comparisons 
are for the entire population not just the survivors unless specified. Post discharge outcomes 




8.4.1 Subgroup 1: Late Failure 
8.4.1.1 Definition 
As has been discussed in detail in 3.3.7.2 there is no universally agreed definition of late 
failure (LF) but it refers to a cohort who deteriorate after initial improvement with an 
associated high mortality. We used the following definition: “Late failure is recurrence of 
respiratory acidaemia prior to discontinuation of ventilation. pH should drop to 
below 7.35 with a rise in CO2 of at least 1kPa and to >6.5kPa from the lowest 
recorded post pH correction at least 24 hours after pH correction.” Of note a lower 
CO2 threshold of 6.0kPa was used in the derivation study in keeping with the guidelines of 
the time. 
8.4.1.2 Late Failure Population 
35 (7.2%) patients met the precise definition above. There were many others that met part 
of the definition but not all facets. The imposition of a time between correcting pH and 
subsequent fall of at least 24 hours excluded many that may have been captured using other 
group’s definition. This was to ensure that those that transiently correct pH to ≥7.35 are not 
included. 
Of these 35 patients experiencing late failure none were intubated, 3 were immediately 
palliated and a further 5 had NIV withdrawn within 24 hours. Excluding 3 immediately 
palliated, NIV was provided for mean 12.4/24h pre LF and 17.1/24h post. Median pressures 
were modestly increased from median 18/4 to 20/5. Patients experiencing late failure had 
higher eMRCD score and a trend toward increased LTOT prescription. Compared to those 
not experiencing late failure in hospital mortality is significantly higher if late failure occurs 
(12/35, 34.3%) however, is far lower than the 92% quoted in a paper by Moretti et. al. (see 
section 3.3.7.2) when they continued NIV in the setting of late failure.(237) There is no 
significant difference in post discharge mortality to 1 year or readmissions to 90 days in 






Table 59 Description and outcome of patients with and without late failure of NIV. 




Age* 74.5 (8.1) 72.6 (10.2) 
FEV1 % * 36.0 (16.0) 38.2% (16.4) 
LTOT 15 (42.9%) 128 (28.2%) 
Consolidation at Ventilation* 11 (31.4%) 220 (48.5%) 
Acidaemia development >12 hours 
after admission 
13 (37.1%) 115 (25.3%) 
eMRCD # 5a (5a-5b) 5a (4-5a) 
Proportion eMRCD 5b  10 (28.6%) 90 (19.8%) 
APACHE 2 score at ventilation outset† 19 (15-22) 20 (16-24) 
Deceased in hospital # 12 (34.3%) 112 (24.7%) 
Deceased by 90 Days  16 (45.7)% 153 (33.7%) 
Deceased by 365 Days  20 (57.1)% 208 (45.8%) 
1+ Readmission 90 Days (survivors) 5/23 (21.7%) 124/342 (36.3%) 
* Mean (SD) †Median (IQR) # p<0.05 
8.4.2 Subgroup 2: Patients receiving LTOT at admission. 
In a population of patients with advanced COPD requiring assisted ventilation a large 
proportion (29.2%) were prescribed LTOT. 
Table 60 Description and outcome data in patients prescribed LTOT or not on admission. 
Variable  LTOT n=143 No LTOT n=346 
Age* 74.1 (9.1) 72.2 (10.3) 
%FEV1 * 
# 34.4 (15.0) 39.6 (16.6) 
Consolidation at Ventilation 63 (44.1%) 168 (48.6%) 
Acidaemia development >12 hours after 
admission 
33 (23.1%) 95 (27.5%) 
eMRCD #  5a (4-5b) 4 (4-5) 
Proportion eMRCD 5b† #  51 (35.7%) 49 (14.2%) 
APACHE 2 score at ventilation outset 20 (17-24) 20 (15-23) 
 
Deceased by 90 Days (survivors)# 21/96 (21.9%) 26/269 (9.7%) 
Deceased by 365 Days (survivors)# 42/96 (43.8%) 64/269 (23.8%) 
1+ Readmission 90 Days (survivors)# 42/96 (43.8%) 87/269 (32.3%) 
1+ Readmission 365 Days (survivors)# 72/96 (75.0%) 139/269 (51.7%) 




Those in receipt of LTOT have more severe COPD; specifically, percent predicted FEV1 is 
lower and eMRCD score is higher. In hospital mortality is higher in those requiring LTOT at 
admission (7.1.2.2) and furthermore among those surviving the index admission, there is a 
significant increase in both short and medium term death and readmission. 
8.4.3 Subgroup 3: Home Mechanical Ventilation (HMV) on Discharge  
The time period under review in the derivation project predates several of the major trials in 
HMV and home ventilation for COPD was used infrequently, but accurate national data is not 
available. Only 10 patients were admitted who were in receipt of HMV and 6 of these died 
during their admission. A further 7 were commenced on HMV during their index admission 
giving a total of 11/365 (3.0%) discharged patients receiving HMV. 
Table 61 Description and outcome data in patient receiving home mechanical ventilation 
at discharge. 
Variable HMV at Discharge No HMV 
Age* 69.7 (9.5) 71.1 (10.1) 
%FEV1* 30.6 (7.9) 37.9 (16.3) 
LTOT 5/13 (38.5%) 91/352 (25.9%) 
eMRCD† 4 (4-5b) 4 (4-5a) 
Deceased by 90 Days 1/13 (7.7%) 46/352 (13.1%) 
Deceased by 365 Days 4/13 (30.8%) 102/352 (29%) 
1+ Readmission 90 Days 
(survivors) 
7/13 (53.8%) 122/352 (34.7%) 
1+ Readmission 365 Days 
(survivors) 
10/13 (76.9%) 201/352 (57.1%) 
* Mean (SD) †Median (IQR) 
Statistical comparison to the total population has not been included for those with HMV at 
discharge due to small numbers. Given that this intervention was quite restricted there is 
likely to be a significant level of patient selection on clinical grounds in addition to the 
enhanced level of support these patients receive rendering statistical analysis obsolete.  
8.4.4 Subgroup 4: Eosinopenia at discharge. 
Eosinopenia was defined as <0.05 x109/L and the last blood test prior to discharge was used 
with none more than 7 days prior to discharge included. Dates were not recorded but 
anecdotally a large proportion had blood tests within 48 hours of discharge. 35/365 patients 




Table 62 Description and outcome data in patient with and without eosinopenia 
(eosinophil count <0.05 x109/L) in survivors to discharge. 






Age* 72.2 (11.0) 70.5 (9.5) 0.131 
%FEV1* 38.0 (16.1) 37.4 (16.1) 0.731 
LTOT 28/118 (23.7%) 68/247 (27.5%) 0.525 
eMRCD† 4 (4-5a) 4 (4-5a) 0.764 
Deceased by 90 Days  21/118 (17.8%) 26 /247 (10.5%) 0.066 
Deceased by 365 Days 34/118 (28.8%) 72/247 (29.1%) 0.947 
1+ Readmission 90 Days  43/118 (36.4%) 86/247 (34.8%) 0.815 
1+ Readmission 365 Days  66/118 (55.9%) 145/247 (58.7%) 0.651 
* Mean (SD) †Median (IQR) # p<0.05 
This data suggests that eosinopenia on the last pre-discharge sample is not a useful predictor 
of post discharge outcome with no significant differences between groups identified 
although short term post discharge mortality may warrant further study. It may be the case 
that re-sampling of the eosinophil count in the weeks post discharge so the influence of the 
acute period is mitigated on such a dynamic value may afford greater insights. 
8.4.5 Subgroup 5: Persistent Hypercapnia at Discharge 
Of the 365 patients who survived to discharge, only 127 had a steady state ABG defined as 
the last available pre-discharge after complete weaning from ventilation. Therefore, this 
sub-group cannot be accurately defined and will not be explored in any greater detail.  
8.5 Derivation Results Summary 
This historical cohort of 489 patients admitted to hospital with ECOPD complicated by RA 
and requiring assisted ventilation has yielded many insights. The patients were collected 
consecutively and with a high degree of confidence that all eligible are captured.  
Our desire was to maximise generalisability leading to inclusive selection criteria; our typical 
patient was or is a heavy tobacco smoker, is housebound, has an FEV1 of 38% predicted, and 
is soon to turn 73. Polypharmacy and comorbidity are the norm. They receive good quality 




will be re-admitted by 90 days and a fifth will not survive to 6 months. In short this is 
convincingly a real-world population. 
We have shown that accurate prediction of in-hospital mortality is feasible, and the final 
proposed model is workable if successfully validated. The key predictors of outcome have 
face validity and all have previously been shown to be associated with mortality risk though 
not in the same tool. A rule of thumb to help guide escalation planning and post discharge 
outcome scores offer further potential utility to the attending clinical teams. 
Prioritising generalisability and by extension not controlling usual care means that the data 
at the time of discharge is less complete than in the acute phase (when blood tests and 
other clinical data are more complete) and thus drawing out common threads is perhaps less 
reliable.  
Amongst subgroups late failure was found to be associated with higher in-hospital mortality 
but continued optimised NIV in this cohort yielded much better outcomes than previous 
studies suggest with very close to two thirds surviving to discharge. Those in receipt of LTOT 
have poorer long term outcomes whereas pre-discharge eosinophil count did not influence 





Chapter 9. Validation Results. 
9.1 Introduction. 
The results from the validation study are not reported in the same detail as the derivation 
study. The report is limited to population descriptors to give insights into generalisability, 
some methodical steps and the validation of the predictive model. Repetition of univariate 
associations with mortality has not been done unless pertinent to the population 
description, or to emphasise similarities or differences between the derivation and 
validation cohorts. Further exploration of the data and post discharge outcomes are the 
subject of another thesis as previously indicated. Fewer indices were collected per patient in 
the non-consenting aspect of the validation study so not all reported outcomes from 
derivation, for example number of exacerbations in the year preceding index admission, are 
unavailable from the validation dataset. 
9.2 Data Handling. 
9.2.1 Data Verification. 
Throughout the project, real time data verification took place and potentially anomalous 
results and missing data were queried with local sites via email. All physiological parameters 
had upper and lower limits imposed by the database to prevent anomalous values being 
entered. As an additional screen once data entry complete, data were sorted by value and 
outliers examined and any potentially anomalous results were verified with source data. 
When examining dates and times all calculated values for example the time from X to Y were 
similarly ranked by value post calculation to ensure potentially anomalous results were 
identified. This identified several suspicious instances which were verified with source data. 
This process was not to exclude any data but to maximise data quality. 
9.2.2 Data Verification Visits. 
Upon recruitment closure each external site had an on-site data verification visit at which 
key indices were verified with source documentation. The PI at each site made the final 




9.2.3 Data Import. 
In keeping with the derivation results the final dataset was exported into excel and then into 
IBM SPSS v22.  
9.2.4 Missing Data. 
Missing data rate was low amongst the variables with a univariate association with mortality 
from the derivation project. Most missing data relevant to the validation of the predictive 
models was found in patients who deteriorated late and did not have a repeat set of bloods 
in the 24 hours prior to commencing NIV. Amongst univariate associates with mortality 
missing data was: 
AF 0%, consolidation 0%, eMRCD 0%, LTOT 0%, LVSD 0%, pH 0%, Time to NIV 0%, base 
excess 1.1%, haemoglobin 1.4%, WCC 1.4%, confusion 1.5%, systolic blood pressure 2.2%, 
respiratory rate 2.2%, Glasgow coma scale 2.3%, eosinophil count 2.9%. Missing data 
amongst components of the NIVO tool was low. In the validated model, the only missing 
data was in the recording of GCS. 
Missing data is greatest in the point of deterioration blood tests. In this table the rate of 
missing data is included for information. 
Missing data was imputed using the expectation-maximisation algorithm. Unless specified, 
EM data is presented. 
9.3 Population Description. 
9.3.1 Headline Summary. 
733 unique cases were captured across 1 internal and 9 external NHS trusts. Recruitment 
opened on 14/10/16 and closed on 28/2/18. Overall inpatient mortality was 20.1%. Internal 
recruitment closed when the 200 patient limit was met. External sites closed when a pre-
agreed target was met or on 28/02/2018. Recruitment targets have been withheld to 




9.3.2 Demographics – All Sites. 
The typical patient in NIVO is most likely to be white and female, in their seventh decade, a 
current and historically heavy smoker with a two thirds chance of a hospital admission in the 
last year.  
Table 63 Selected population descriptors. 
Variable Value Derivation data (for 
comparison) 
Female 58.3% 62.6% 
Age*  70.5 (9.3) 72.8 (10.0) 
Cigarette Pack Years* 44.8 (23.7) 49.5 (26) 
Current smoker  63.1% 48.7% 
1(+) admission in last 12 months 68.9% 48.0% 
Caucasian 98.0% 100% 
* Mean (SD) †Median (IQR) 
The fact that the population is so strongly Caucasian is at first appearance a concern for 
generalisability. 86% of the population of England and Wales is Caucasian, however, 95.5% 
of over 65s are Caucasian.(257) Therefore, while there is some discrepancy perhaps due to 
regional demographics the population is close to representative. Current smoking rates are 
higher than in the derivation study, the reasons for this are unclear. Admissions in the 
preceding year are also higher, variance in local practice may be contributing. Our own trust 
has well established and longstanding community and hospital outreach services in COPD 
which may have contributed to an artificially low number of admissions in the derivation 
study. It should also be noted that mortality is lower, this means a larger cohort of survivors 
in whom hospital admission is common. 
9.3.3 Site Recruitment and Mortality. 
733 patients were included, 147 (20.1%) died in hospital. Table 64 shows hospital mortality 
varies by site with highest mortality seen in site E (28.4%) and the lowest at site I (12.2%). 
Site mortality data is provided for interest, variation in mortality is expected as individual 
sites are underpowered. Median length of stay amongst survivors was 8 (6-14) days, post 




Table 64 Recruitment by site and associated in hospital mortality. 
Site N In-hospital mortality (%) 
A  200 18.0 
B 116 19.8 
C 77 19.5 
D 69 26.1 
E 67 28.4 
F 60 18.3 
G 49 12.2 
H 44 25.0 
I 37 13.5 
J 14 21.4 
Total 733 20.1 
 
Figure 28 shows the distribution of recruiting centres all of which are in England or Wales. 
Sites were deliberately dispersed around the country encompassing metropolitan and more 
rural areas. 






9.3.4 Effect of Unique Patients on Mortality. 
Both derivation and validation collect unique patients. This is likely to increase the reported 
mortality as previous successful treatment with NIV is a protective factor. Therefore, 
patients with frequent admissions but favourable outcome are equally represented initially, 
but subsequently excluded. This was seen in the DECAF validation study (employing unique 
patient methodology) where mortality was higher than in national audit data (7.7 vs 
4.3%).(29,82)  
A similar effect was seen in the NIVO study: In the derivation study mortality in the first 100 
patients is 17.5% vs 27.1% in the remainder. In the validation study the same analysis would 
be unhelpful as not all sites started recruitment at the same time. Therefore; the first 20% at 
each site were compared to the remainder and mortality rises from 14.4% to 21.6%. This 
observation is important to be aware when considering the results in a wider context.  
9.3.5 Home Circumstances. 
Three quarters of the patients were admitted from their own home without any formal care 
package (Table 65). It is highly likely that a large number receive informal care from family or 
friends, given the median eMRCD score was 5a (i.e. housebound but not requiring assistance 
with washing and dressing), but this is not captured in the data. The rate of formal care has 
risen from the derivation study (derivation 12.1%) which may reflect regional variation 
Table 65 Pre-admission home care circumstances. 
Admitted From Percentage of Total 
Home 74.8 
Home + formal carers 17.5 
Sheltered accommodation 1.4 
Sheltered accommodation + formal carers 1.0 
Residential care 3.1 
Nursing care 1.6 







9.3.6 COPD Details. 
Spirometry values and proportion of LTOT prescription are consistent with the derivation 
study adding credence to their validity. In keeping with previous studies (section 3.3.2.5) 
neither FEV1 as an absolute value (p=0.185) or as percent predicted (0.953) was significantly 
associated with in-hospital mortality using a two tailed T test. 
Table 66 Key Descriptors of COPD. 
Variable Value Derivation data for 
comparison 
FEV1 (L)* 0.84 (0.36) 0.81 (0.36) 
FEV1 (%)* 37.2 (15.4%) 38.0 (16.4) 
FEV1/FVC* 0.44 (0.12) 0.44 (0.12) 
1+ value missing but airflow 
confirmed 
35 (4.8%) N/A 
eMRCD† 5a (4-5a) 5a (4-5a) 
BMI* 25.5 (7.96) 24.6 (7.3) 
LTOT on admission 28.6% 29.2% 
Previous NIV 35.9% 21.9% 
Home ventilation on admission 8.7% 2.0% 
* Mean (SD) †Median (IQR) 
In cases where either the FEV1, the FVC or both were missing but there is objective evidence 
that airflow obstruction has been confirmed by another specialist clinician, patients could be 
included. If no objective evidence of airflow obstruction then, irrespective of duration of 
COPD diagnosis or clinical likelihood, patients would be eligible for the clinical diagnosis 
dataset only (section 5.2). 
The objective criteria for LTOT prescription have been established for many years and hence 
the only minor observed variation between derivation and validation is to be expected. 
However, as described in the introduction there is an ongoing evolution in both acute and 
long-term ventilation practice with greater availability so it is unsurprising that rates of 
previous NIV and HMV increased in the modern cohort.  
9.3.7 Comorbidity. 
Limited data on comorbidity was collected in the validation dataset, only components of the 
APACHE II score and univariate associations with mortality from the derivation study were 




Table 67 Selected comorbidity. 
Comorbidity Percentage present 
Cor Pulmonale 22.5 
LVSD 14.1 
Depression 23.6 
AF admission 18.7 
IHD 22.5 
Cerebrovascular disease 9.7 
Cognitive impairment 7.8 
 
9.3.8 eMRCD. 
The strongest predictor of mortality from the derivation study remains significantly 
associated with mortality (Mann-Whitney U, p<0.0001). Table 68 shows a strong positive 
association between eMRCD score and mortality. 118/147 (80.2%) deaths occurred in 
patients with eMRCD score of 5a or 5b which between them make up 56.0% of the total 
number of patients. 
Table 68 eMRCD: Frequency and in hospital mortality. 
eMRCD Total % of Total In Hospital Mortality 
1 9 1.2 0% 
2 18 2.5 0% 
3 53 7.2 3.8% 
4 242 33.0 11.2% 
5a 251 34.2 24.7% 
5b 160 21.8 35.0% 
9.3.9 Admission Medications. 
Amongst the recorded medications, patients were prescribed a median of 4 (3-6) with 97.4% 
taking 2 or more. No data was collected for any additional medications not specifically 
reported in the table here; there is no missing data. 
In comparison to the derivation data there are several noteworthy observations, accepting 
the problem of comparing a single centre to multiple centres. Table 69 shows the proportion 




considered first line treatment for hypertension.(258) Prescription of beta blockers has risen; 
there is more widespread acceptance that cardio-selective beta blockers are not harmful in 
COPD.(259) Prescription rates for Carbocisteine and Azithromycin are higher which may 
represent their acceptance as mainstream treatments in selected patients with COPD. 
Certainly since 2011 the evidence to support the use of Azithromycin in some circumstances 
has expanded.(260) The dramatic expansion in Carbocisteine prescription is less explainable 
but probably relates to variations in local prescribing habits. Those not recorded as taking 
LABA/LAMA may have regular nebulised bronchodilators not captured. 
Table 69 Admission medications. 
Medication Percentage taking on 
admission (Validation) 
Percentage taking on 
admission (Derivation) 
Long term steroid 10.2 11.0 
Diuretic 36.7 44.4 
ACE inhibitor/ARB 26.9 29.7 
Beta Blocker 23.2 10.8 
Statin 44.2 41.3 
Long Acting Beta Agonist (LABA) 89.5 82.0 
Long Acting Muscarinic Agonist 
(LAMA) 
78.9 76.6 
Inhaled Corticosteroid (ICS) 79.0 83.4 
Carbocisteine 47.3 22.5 
Theophylline 10.0 7.0 
Azithromycin 12.3 6.5 
 
Finally, the unsuitability of medications as predictors of mortality was also discussed in 
section 6.2.6 and that taking Carbocisteine was significantly associated with increased in-
hospital mortality, albeit weakly (Chi squared p=0.046). This was thought to be a quirk of 
data collection and a statistical anomaly and, as expected, this finding is not replicated in the 
validation cohort (Chi squared p=0.415). 
9.3.10 Observations. 
These observations represent the worst recorded post admission in the 24 hours prior to the 
ABG that prompted the decision to ventilate. Time frames for data collection are explained 




Table 70 Clinical observations post admission and up to 24 hours pre-decision to ventilate. 
Observations 24 hours prior to ventilation Value  
Systolic Blood pressure* 133.3 (34.2) 
Diastolic Blood Pressure* 75.4 (20.7) 
Mean Arterial Pressure* 94.7 (23.3) 
Heart Rate* 109.9 (21.4) 
Respiratory Rate* 28.4 (7.4) 
Temperature* 36.7 (0.98) 
Lowest oxygen Saturations* 84.2 (9.8) 
GCS† 15 (14-15) 
* Mean (SD) †Median (IQR) 
9.3.11 Blood Tests and Chest X-ray. 
Blood tests are included for accurate characterisation of the study population. There are no 
results that stand out as anomalous in Table 71.  
Table 71 Blood test results post admission and up to 24 hours pre-decision to ventilate. 
Blood Test % Missing Value  
Haemoglobin (g/dL)* 1.4 13.7 (2.1) 
Haematocrit (L/L)* 1.6 0.433 (0.064) 
Platelets (x109/L)* 1.5 272 (107) 
WCC (x109/L)* 1.4 13.1 (6.8) 
Eosinophil Count (x109/L)* 2.9 <0.05 (<0.05-0.1) 
Eosinophil count <0.05 2.9 53.5% 
Sodium (mmol/L)* 1.5 136.9 (5.5) 
Potassium (x109/L)* 6.5 4.62 (0.64) 
Urea (x109/L) * 3.1 8.49 (5.26) 
Creatinine (x109/L) * 1.8 87.2 (49.1) 
Albumin (g/L)* 19.6 37.7 (5.2) 
Glucose (mmol/L)* 14.1 8.18 (3.36) 
CRP (mg/L) † 4.6 40 (13-110) 
* Mean (SD) †Median (IQR) 
Many patients will have their liver function tests and serum glucose checked on admission to 
hospital but not routinely thereafter unless indicated. Therefore, it is unsurprising that in the 
24 hours prior to the point of deterioration, which in 17.9% of patients is >24 hours into 




less clinical value in the assessment of a deteriorating patient and it is possible glucose was 
more frequently measured but less well recorded as it may be a bedside test. Potassium is 
more likely to be missing than other results from the same panel due to haemolysis 
occurring during venesection or analysis. 
9.3.12 Arterial Blood Gases. 
Table 72 shows acidaemia at outset of ventilation is very similar to the derivation study 
where it was median pH 7.27, IQR 7.21-7.31. Mean CO2 is slightly higher (derivation pCO2 
9.34 (2.94); this is likely explained (at least in part) by the lower limit for inclusion rising from 
6.0 KPa to 6.5 KPa to reflect national guidelines changing.  
The blood gases in Table 72 do not include EM data as there is a complete dataset for the 
main point of interest (NIV decision) and the other data is for description only. 
Table 72 Arterial blood gas results at various time points. 
Time Missing pH† pCO2* pO2* BE* Bicarbonate* 
Admission 2.7% 7.30 (7.24-7.34) 9.35 (2.86) 8.78 (5.4) 4.9 (6.5) 30.3 (6.7) 
At NIV 0% 7.27 (7.22-7.30) 10.22 (2.71) 9.02 (5.04) 4.6 (6.6) 30.5 (6.8) 
24 hours 14.5% 7.37 (7.33-7.41) 7.50 (1.93) 8.42 (2.45) 5.7 (6.2) 30.3 (6.3) 
Steady 43.7% 7.41 (7.38-7.45) 7.14 (1.65) 8.08 (2.14) 8.3 (5.7) 32.8 (5.7) 
* Mean (SD) †Median (IQR) 
9.3.13 Non-invasive Ventilation Description. 
One of the greatest challenges in NIVO is that the intervention being assessed is not 
controlled; to do so would have rendered the data poorly generalisable. Limited data was 
collected about the intervention provided (Table 73). The sites were selected for their well-
developed and streamlined services to mitigate this. All sites deliver high quality NIV, adhere 
to national guidance and provide NIV liberally.  
Door to mask time (DTMT) measures the time from patient’s presentation to initiation of 
ventilation. Of those with a blood gas indication for NIV within 12 hours of admission, who 
did not correct with medical therapy there was a median of 123 minutes (IQR 61-236 
minutes) from door to mask. In the entire population i.e. including those in whom 
deterioration occurs later into admission, the median time and is prolonged with a 




minutes). DTMT has limitations as a metric in an individual case, but it remains a useful 
broad measure of the NIV service provided and is included in the recent quality standards. 
The target is less than 120 minutes for those who meet “evidence based criteria for acute 
NIV” on presentation to hospital. (162) In the NIVO study, 74.1% of those with an initial pH of 
<7.35 achieved the 2-hour door to mask target. 
In all patients, time from the ABG prompting ventilation to ventilation initiation was 42 
minutes (19-76 minutes) within the 60 minute target from the quality standards.(162) These 
metrics paint a picture of well-functioning services.  
Table 73 NIV Settings. 
Variable 1 hour Maximum 
IPAP† 18 (14-21) 20 (18-24) 
EPAP† 5 (4-5) 5 (4-6) 
Back up rate† 14 (12-16) 14 (12-16) 
* Mean (SD) †Median (IQR) 
Ventilation was delivered for a median of 62 hours (25-109 hours). It should be remembered 
the period of ventilation includes those that may deteriorate and die quickly and those 
ventilated for a very long time so is perhaps of limited use beyond giving a flavour of the 
intervention delivered.  
9.3.14 Ventilation location, Modality and Escalation Decision. 
9.3.14.1 Location of NIV Delivery. 
There are a number of physical places within a hospital where NIV can be provided (2.4.4). 
Invasive ventilation is delivered in an intensive care unit. Figure 29 shows the largest 
proportion of NIV is delivered in a respiratory support unit, however, if Site A (the largest 
recruiter where all patients are managed on an RSU) is excluded, the distribution is slightly 
altered as follows: ward 38.1%, RSU 35.8%, HDU 16.5%, ICU 9.6%. If a patient is ventilated in 





Figure 29 Location where NIV delivered. 
 
9.3.14.2 Modality of Ventilation.  
In keeping with the derivation study, the majority of patients received non-invasive 
ventilation alone. 21 patients (2.86%) received invasive ventilation of whom 15 had received 
prior NIV. In hospital mortality amongst those receiving NIV alone was 19.9% and was 23.8% 
in those invasively ventilated.   
9.3.14.3 Do Not Attempt Resuscitation and ‘Level of Care’ Decisions. 
All patients at the outset of ventilation should have an active decision made about 
resuscitation and ‘level of care’ i.e. whether this patient would be suitable for intensive care 
treatment.(133) 294 (40.1%) were considered eligible for escalation to invasive ventilation and 
328 (44.7%) remained for resuscitation in the event of cardiac arrest.  
The NIVO manual states: “unless actively stated to the contrary, patients should be 
assumed to be considered for full escalation. If a senior clinician changes this 
status at the first senior review (provided within 24 hours of initiation of 
ventilation) then record this as the status. Changes made after 24 hours 
irrespective of clinician grade do not affect this status.” 
Amongst those that died in hospital, at outset of ventilation, 21.1% were for consideration of 




9.3.15 Timing of Acidaemia. 
The median time from admission to the blood gas informing the decision for ventilation was 
137 (41-767) minutes. The wide IQR is because this encompasses those that deteriorate late 
into their admission. Arterial pH corrected to ≥7.35 post ventilation initiation in 643 patients; 
median time to correction was 522 (176-1490) minutes. In 190 (29.5%) patients’ first pH 
correction was within 4 hours of ventilation commencement. 
The time from admission to development of acidaemia was a strong univariate predictor of 
outcome; Mann Whitney U p<0.0001 median 137 (41-767) minutes and is similar to that 
observed in the derivation study 146 (56-852) minutes. When split by the previously 
explored time thresholds incrementally increased mortality is seen. 
Table 74 Mortality and time to acidaemia development. 
Time to acidaemia 
development 
% of total Mortality if deteriorate 
earlier than threshold 
Mortality if deteriorate 
later than threshold 
>12 hours 25.2 81/548 (14.8%) 66/185 (35.7%) 
>24 hours 17.9 93/602 (15.4%) 54/131(41.2%) 
>48 hours 10.1 110/659 (16.7%) 37/74 (50.0%) 
9.3.16 Comparison Scores. 
A number of comparison scores were recorded and calculated. The scores presented here 
were calculated using data from the 24-hour period prior to ventilation being initiated.  
Score Potential Range Median (IQR) 
DECAF  0-6 3 (2-3) 
CURB 65 0-5 2 (1-3) 
CAPS 0-100 22 (16-28) 
APACHE II 0-71 19 (16-22) 
Confalonieri* 0-12.33 5.37 (4.08-6.63) 




9.4 Selected Descriptors by Recruiting Site. 
The breakdown of the components of the final predictive model is shown in Table 84. Further population descriptors are shown in Table 76.  
Table 75 Selected descriptors of population by recruiting site 1. 
Site Female 
(%)Ω 





1+ Admission last 
12 months (%) 








A  56.5 71.9 
(9.2) 
39.0 75.0 61.5 25.9 (8.3) 5 (4-5) 40.5 (16.6) 25.0 40.0 5.5 
B 62.9 68.9 
(8.5) 
89.4 80.2 73.3 23.2 (6.7) 5 (4-5) 34.5 (14.6) 30.2 37.1 10.3 
C 62.3 70.2 
(10.1) 
87.0 74.0 64.9 26.9 (8.4) 5 (4-5) 38.6 (13.3) 26.0 28.6 9.1 
D 63.8 72.8 
(10.1) 
52.2 71.0 76.8 24.8 (3.5) 4 (4-5) 38.1 (16.2) 33.3 29.0 4.3 
E 53.7 70.5 
(9.6) 
65.7 73.1 86.6 28.1 (9.6) 5 (4-6) 38.1 (15.5) 35.8 34.4 4.5 
F 50.0 67.7 
(9.1) 
66.1 55.0 73.3 25.5 (7.8) 4 (4-5) 30.6 (13.8) 38.3 58.3 30.0 
G 46.9 71.8 
(8.6) 
59.2 81.6 69.4 25.7 (7.1) 4 (4-5) 35.8 (13.4) 24.5 28.6 6.1 
H 63.6 70.1 
(9.6) 
77.3 84.1 56.8 26.7 (7.7) 4 (4-5) 36.5 (13.4) 15.9 20.5 2.3 
I 56.8 68.9 
(8.3) 
70.3 73.0 62.2 24.5 (7.3) 5 (4-6) 36.9 (16.7) 35.1 37.8 13.5 
J 78.6 68.3 
(10.5) 
42.9 92.9 71.4 21.1 (6.2) 3 (2-4) 34.0 (13.8) 21.4 21.4 7.1 
Total 58.3 70.5 
(9.3) 
63.1 74.8 68.9 25.5 (8.0) 5 (4-5) 37.2 (15.4) 28.6 35.9 8.7 
P 
Value 





Table 76 Selected descriptors of population by recruiting site 2. 




















10.1 (2.7) 95 (59-135) 7.27 (7.22-
7.30) 






68.1 (37.7) 39 (15-
128) 
9.9 (2.6) 61 (35-81) 7.26 (7.21-
7.29) 






84.1 (46.0) 49 (24-
120) 
10.3 (2.2) 39 (17-89) 7.26 (7.19-
7.29) 






95.5 (75.9) 40 (13-
103) 
10.1 (3.5) 31 (18-67) 7.27 (7.21-
7.29) 






77.9 (33.1) 60 (17-
144) 
10.1 (2.6) 91 (51-123) 7.30 (7.23-
7.32) 






81.8 (45.8) 24 (9-91) 10.0 (2.4) 33 (12-72) 7.26 (7.22-
7.29) 






89.4 (50.1) 67 (12-
116) 
10.6 (2.2) 36 (15-99) 7.23 (7.17-
7.27) 






90.4 (43.1) 25 (9-67) 10.1 (2.5) 52 (24-132) 7.27 (7.20-
7.30) 






79.2 (31.0) 63 (17-
136) 
11.7 (3.3) 24 (12-123) 7.25 (7.17-
7.27) 






66.1 (30.1) 51 (17-
154) 
11.5 (3.2) 32 (9-94) 7.21 (7.16-
7.29) 






87.2 (49.1) 40 (13-
110) 
10.2 (2.7) 65 (25-111) 7.26 (7.21-
7.30) 




0.006 0.002 <0.0001 0.091 0.042 <0.0001 <0.0001 0.001 0.215 <0.0001 <0.0001 




9.4.1 Location of Ventilation by Site. 
There was marked variation in the location within a hospital where ventilation was provided 
between sites. Most sites have a clear ‘default’ location where ventilation is provided 
representing the majority of cases in that particular site. 
Figure 30 Highest level of care by site. 
 
In all the description sections above further, more in-depth, analysis is interesting, 
warranted and will follow in a forthcoming thesis. 
9.5 Examination of the Proposed Derivation Model. 
9.5.1 Validation Multivariate Analysis Introduction. 
The derivation study has selected the important, independent predictors of in hospital 
mortality and the appropriate categorisation thresholds. The validation study’s principle role 
is to ensure this model was not overfitted to the population in which it was derived and is 
hence generalisable to a wider population.  
The validation process included two important steps:  whether to use pH or base excess in 
the final model; and whether the final model can be simplified or recalibrated in improve 






















predictor than pH, but the change in ventilation guidelines that occurred after the derivation 
study completed recruitment may alter this (7.2.7).  
Only variables included in the final NIVO model using the thresholds selected for that model 
were eligible for evaluation. It is important that the results are not a rederivation of a model 
in a second population. 
9.5.2 Validation Step 1: pH vs BE. 
As has been stated (7.2.7) there was suspicion that the inclusion of base excess was a result 
of overfitting (predominately temporally rather than geographically). The first simple step is 
to assess pH vs BE, naturally the 9 variables are categorised as determined by the derivation 
results.  
Table 77 Components of predictive model from derivation results. 
1 Base Excess <0 
2 Atrial Fibrillation up to NIV 
3 Consolidation on CXR up to NIV 
4 Eosinophil count <0.05 x109/L in 24 hours prior to NIV 
5 eMRCD (categorised 1-4,5a,5b) 
6 GCS ≤14 24 hours prior to NIV 
7 LTOT 
8 pH <7.25 24 hours prior to NIV 
9 Time to acidaemia >12 hours from admission 
 
If all variables are forced into the model together, the relative strength of BE vs pH can be 
determined. In this instance: BE is a non-significant predictor p=0.620 in contrast to pH 
p=<0.001. Therefore, base excess will be replaced by pH in all subsequent models. 
9.5.3 Validation step 2: Model Simplicity. 
Predictive models are a balance of accuracy versus utility. In a non-automated setting, utility 
becomes akin to simplicity. If the number of variables in the model can be reduced while 
maintaining accuracy, then this is attractive to the end user. Again, it is important to stress 
that only those variables and categorisation thresholds determined by the derivation study 




Therefore the 8 variables were re-examined using backward regression Table 78. Variables 
not imparting independent prediction to the model are removed using a significance level of 
0.1. 
Table 78 Results of backward, logistic regression using predictors from derivation less base 
excess. 
Variable  B S.E Wald Sig Odds Ratio (95% CI) 
Consolidation 0.358 0.210 2.9 0.089 1.43 (0.95-2.16) 
GCS <15 0.658 0.217 9.2 0.002 1.93 (1.26-2.95) 
AF 0.842 0.239 12.4 <0.001 2.32 (1.45-3.71) 
pH <7.25 0.961 0.222 18.7 <0.001 2.61 (1.69-4.04) 
Time to Acidaemia >12 hours 1.289 0.225 32.8 <0.001 3.63 (2.33-5.64) 
eMRCD 5a 1.425 0.267 28.5 <0.001 4.16 (2.46-7.02) 
eMRCD 5b 1.960 0.287 46.7 <0.001 7.10 (4.05-12.46) 
Intercept -2.832,  R2 0.285, Percentage correct after final iteration, 81.9%. Hosmer and 
Lemeshow 0.130. 
As can be seen two variables drop out of the model namely the eosinophil count and LTOT 
prescription. This model comprises 6 variables with the eMRCD categorised into 1-4, 5a and 
5b. CXR consolidation is the weakest predictor with a significance level of 0.089. However, in 
order to make as few changes to the derived model as possible it is retained.  
LTOT was one of the weakest predictors from the derivation. There are question marks 
about the suitability of the eosinophil count in this setting (7.2.5). The role of acute 
prescription of oral corticosteroid treatment influencing the eosinophil count renders this 
variable conceptually unreliable at the very least. Those deteriorating late into admission are 
likely to have greater exposure to steroid and also have worse outcome raising the prospect 
of a confounding element. There is no value in carrying forward non-significant variables, 
that they were originally significant is probably representative of overfitting to the derivation 





9.5.4 Validation Step 3: Weightings 
It is accepted practice to re-examine weightings in a final model. Having decided to reduce 
the number of variables one must re-examine weightings as the relative weights necessarily 
alter.(261,262)  
The same process as in the derivation model is followed whereby the beta co-efficient is 
divided by the lowest value to give easier to follow proportionality. In this case it is chest X-
ray consolidation. The relative strength of the variables gives rise to a simple weighting 
system. 
Table 79 Relative weightings. 
Variable  B/1.43 (CXR B) Wald Weighting 
Consolidation 1.0 2.9 1 
GCS <15 1.4 9.2 1 
AF 1.6 12.4 1 
pH <7.25 1.8 18.7 1 
Time to Acidaemia >12 hours 2.5 32.8 2 
eMRCD 5a 2.9 28.5 2 
eMRCD 5b 5.0 46.7 3 
 
9.5.5 The NIVO Score. 
The final model is shown here, it has been named the NIVO score for simplicity. 
Table 80 The NIVO score 
NIVO score Points 
Consolidation 1 
GCS <15 1 
AF 1 
pH <7.25 1 
Time to Acidaemia >12 hours 2 








Following validation steps 1-3 the validated model (NIVO score) is shown in Table 80. Six 
variables and a simple weighting system yield a maximum score of 9 (one can only score 5a 
or 5b not both).  
9.6 Assessment of NIVO Score. 
9.6.1 Mortality by NIVO Score. 
The following table shows the mortality for each point of the NIVO score. There is a 
progressive increase in mortality as the score increases, except between 1 and 2 when the 
small absolute number of deaths results in a minor fall in mortality percentage. When 
converted to risk categories this is inconsequential. 
Table 81 Mortality at each point of NIVO tool. 
Tool Score Survived Died Total Mortality 
0 67 0 67 0% 
1 72 7 79 8.9% 
2 126 7 133 5.3% 
3 129 23 152 15.1% 
4 94 22 116 19.0% 
5 63 34 97 35.1% 
6 25 29 54 53.7% 
7 9 17 26 65.4% 
8 1 7 8 87.5% 
9 0 1 1 100% 
Total 586 147 733 20.1% 
 
Using data in Table 81 three risk categories (Table 82) have been assigned and identify 
clinically distinct groups, with nearly 40% falling into the low risk group. Mortality here is low 
(5.0%) and has potential clinical applications to including guiding level of care. As one may 
expect only very few patients fall into the very high-risk group and further verification of 





Table 82 NIVO score risk categories. 
Risk category  
(score) 
Survived Died Total Mortality 
Low  
(0-2) 
264 14 279 5.0% 
Medium 
(3-4) 
223 45 268 16.8% 
High 
(5-6) 
88 63 151 41.2% 
Very High  
(7-9) 
10 25 35 71.4% 
 
 Table 81 and Table 82 are important and encouraging assessments of the NIVO score. They 
show that the model provides robust risk stratification; a simple 6 variable tool identifies 4 
groups of patients with clearly distinct mortality risks. If the results showed non-progressive 
mortality the validity would be called into question, however, across different sites, models 
of care and demographics the findings are encouraging.  
The predicted mortality is the averaged mortality for all patients at a site calculated from 
their NIVO scores and associated mortality. The total predicted, and actual mortality shown 
in Table 83 must be identical as the mortality for each increment generated from the same 
data and therefore the totals must necessarily equate. 
Table 83 Mortality by recruiting site: Predicted vs actual. 
Site n Score Predicted mortality (%) Actual Mortality (%) 
A  200 3 (2-5) 21.4 18.0 
B 116 3 (2-5) 19.1 19.8 
C 77 3 (2-4) 20.4 19.5 
D 69 3 (2-5) 21.9 26.1 
E 67 3 (2-5) 21.9 28.4 
F 60 3 (1-3) 15.6 18.3 
G 49 3 (2-5) 20.0 12.2 
H 44 3 (2-4) 19.1 25.0 
I 37 3 (2.5-4.5) 19.5 13.5 
J 14 2 (1-4) 13.6 21.4 





The breakdown across the sites is interesting: One would not expect to see a perfect spread 
as numbers in each site are not large enough for this but there is clearly a correlation 
between actual and predicted mortality, the correlation is better in the centres with greater 
numbers. The ‘unique patient effect’ described earlier (9.3.4) may also be having differential 
contribution due to varying n at each site. 
Table 84 Components of NIVO score by recruiting site. 
 Percentage in which adverse indicator present. 
Site CXR GCS AF pH Time 5a 5b 
A  41.5 38.0 21.0 34.0 25.0 38.0 22.0 
B 31.9 32.8 13.8 43.1 24.1 40.5 19.0 
C 24.7 39.0 22.1 40.3 26.0 37.7 24.7 
D 39.1 27.3 18.8 37.7 39.1 26.1 21.7 
E 41.8 28.4 22.4 28.4 26.9 35.8 29.9 
F 31.7 28.3 11.7 38.3 18.3 30.0 18.3 
G 40.8 46.9 30.6 59.2 24.5 24.5 18.4 
H 56.8 27.3 20.9 38.6 27.3 27.3 18.2 
I 45.9 32.4 18.9 45.9 13.5 32.4 32.4 
J 28.6 50.0 14.3 71.4 14.3 21.4 0.0 
Total 38.1 36.2 19.5 38.6 25.2 24.5 18.8 
For each of the components of the NIVO score there is variation within sites. This will partly 
be due to numbers at each site however variation is good and will enhance generalisability. 
The fact that patients are accruing their total score via varying components and the score 
performs well is in itself encouraging. 
9.6.2 Model fit. 
The results for the final model are shown under Table 78. The model is well calibrated 
(Hosmer and Lemeshow test = 0.130) and Nagelkerke R squared shows the model accounts 
for 28.5% of outcome variable variance. 
9.6.3 Area under the receiver operated curve. 
Figure 31 shows the plots of the receiver operated curves for the NIVO score and its 




Figure 31 Areas under the receiver operated curve for various models of in-hospital 
mortality prediction. 
 
Table 85 AUROC and confidence intervals for predictive models. 
Model AUROC (95%CI) 
NIVO score 0.79  (0.75-0.83) 
DECAF score (in 24 hours pre vent) 0.73  (0.68-0.77) 
APACHE II score 0.66  (0.61-0.70) 
CAPS score 0.65  (0.60-0.70) 
Confalonieri score 0.64  (0.59-0.68) 
CURB 65 (in 24 hours pre vent) 0.64  (0.59-0.69) 
 
Using only 6 variables, 5 of which are binary, and one has 3 categories the NIVO score 
outperforms comparators in this independent population. Three of the scores (APACHE II, 
CAPS and Confalonieri) are complicated to administer. The closest performing score is the 
DECAF which score was designed for use on admission in patients with an exacerbation of 




comparator to include an assessment of steady state dyspnoea which is likely to account for 
its superior performance. The other ‘simple’ score here is CURB 65 which was never 
designed for use in this population but is included as a useful comparison and is inferior to 
the NIVO score.  
Of note if, instead of using the simple categories the 6 variables are entered as continuous 
variables the AUROC is minimally increased to 0.80 (7.6-8.4). The NIVO score also works well 
in the derivation population using the ascribed weighting, AUROC 0.83 (0.79-87).  
9.7 Rule of Thumb. 
The combination of deterioration after a 12-48 hour threshold and a high eMRCD score 
conferred a high in-hospital and 90 day mortality in the derivation study. Using these very 
simple indices shows promise again. In-hospital mortality data only is available for the 
validation study. Table 23 shows mortality for differing combinations of (e)MRCD and time 
from admission to acidaemia.  
MRCD 5 is the combination of eMRCD 5a and 5b. The added mortality risk conferred by 
eMRCD 5b is less dramatic than in the derivation data (1337.4.2). While there is a rise in the 
mortality at each threshold by selecting only those with eMRCD 5b as opposed to the 
combined 5a and 5b it leads to fewer deaths being captured. This table again illustrates that 
selecting those with high mortality is possible using only limited and simple indices. Half, 
rising to two thirds, of patients will not survive to discharge depending on how steady state 
dyspnoea and time to deterioration are combined. 
Table 86 Rules of thumb: Mortality by steady state dyspnoea and timing of acidaemia. 




MRCD 5 + 12 hours 50/101 (54.6%) 46/77 (59.7%) 
eMRCD 5b + 12 hours 21/38 (55.3%) 26/36 (72%) 
MRCD 5 + 48 hours 30/45 (60.8%) 27/40 (67.5%) 






9.8 Validation Results Summary. 
The research team collected a large volume of data in 733 patients across 10 hospital trusts. 
These trusts are disparately spread and draining differing populations and using differing 
models of care. However, distribution by ethnicity was low with the population being 
overwhelmingly Caucasian. Predictors of outcome identified by the derivation project have 
been proven to be robust predictors of outcome in a separate population of prospectively 
collected patients. The hypothesis that base excess may have been overfitted to the 
derivation population at the expense of pH was proven correct and there is sound logic and 
clinical intuition to support this. Thereafter, we were able to remove two variables from the 
score that were probably overfitted to the derivation population. Models can be ‘re-
calibrated’ by addition of new variables but this would probably warrant re-validation. 
Removal of variables is uncontentious but there are no clear guidelines as to what to do 
following this and whether further validation is needed is context specific. In this instance it 
is reasonable to assume re-validation is unnecessary.(261,262) 
The final model is simple, effective and produces clinically meaningful risk categories. Rules 
of thumb employing time of deterioration and steady state dyspnoea alone again select 




Chapter 10. Discussion 
10.1 Summary of main findings 
10.1.1 Derivation study summary. 
489 retrospective patient records were included following robust identification of 
consecutive patients. All patients came from the same centre in the North East of England. 
Modelling using structured and established methodology (5.4) and guided by reported 
evidence and clinical intuition allowed identification of a number of variables independently 
associated with mortality. The final variables selected for further study were atrial 
fibrillation, chest X-ray consolidation, Eosinophil count, eMRCD score, Glasgow coma scale, 
long term oxygen prescription, timing of acidaemia relative to admission time, base excess 
and pH. A simple model using these variables outperformed any previously reported model 
(in this dataset) substantially. Using data from the time of deterioration clearly 
outperformed using only information available at admission. Several ‘rules of thumb’ also 
help to identify risk of in-hospital death using only two variables.  
10.1.2 Validation study summary. 
Patients were recruited prospectively in ten UK centres. Inclusion criteria were subtly altered 
to reflect change in national guidance. Data collected was more focussed than during the 
derivation study. Further analysis of this data will form a further thesis, so analysis has been 
limited to validation of a model and key descriptors to allow assessment of generalisability.  
Of the candidate variables not all remained significant indicating overfitting to source data in 
the derivation cohort so two were dropped from the model. The presence of eosinopenia 
and prescription of long-term oxygen were the removed variables. A simplified model 
outperformed all pre-specified comparison models in both derivation and validation cohorts 
and is shown below. Stratification using this score allows creation of 4 clinically meaningful 
risk categories showing progressive mortality from low (5.0% in hospital mortality) up to 





Table 87 The NIVO score. 
NIVO score Points 
Consolidation 1 
GCS <15 1 
AF 1 
pH <7.25 1 
Time to Acidaemia >12 hours 2 





10.2 Potential uses of NIVO tool. 
Most of the ideas here have been previously mooted but in this section they have been 
expanded and linked directly to the results of the study.  
1) Shared decision making. During a period of critical illness close communication 
between clinical team and a patient and their family is essential. Being able to offer 
factual expectations rather than unverified estimation is desirable and in keeping 
with the empirical basis on which modern medicine is built. For example, if a patient 
falls into the high risk group (49% in hospital mortality) they may be more motivated 
to persevere with NIV knowing the threat to life or a family member may feel better 
able to judge whether to travel to visit. 
2) Enhanced decision making, particularly reducing inappropriate pessimism. For 
example, it could be argued if a patient is admitted and falls into a medium risk 
(mortality 18.2%) category there is almost no reason not to offer ventilation unless a 
highly individual counter reason exists. This objectification could prevent delay and 
denial of treatment. Given clinicians inherent cognitive biases and fallacies (3.1.3), 
objectification of decision making can lead to a a more equitable distribution of finite 
healthcare. In the small number of very high-risk patients (in-hospital mortality 
88.9%), knowledge of the chances of a favourable outcome may open discussions 
about alternative palliative care. 
3) Guiding level of care. As has been shown (2.4.4) limited access to higher level of care 




in busy periods. Targeting enhanced staffing and monitoring to those in high or very 
high-risk groups (41.2% or 71.4% in hospital mortality) may help to bring overall 
mortality down. This also has benefit which is very hard to measure such as relieving 
pressure on out of hours staff by placing high acuity patients appropriately. Whilst it 
can be argued that all patients requiring NIV should be cared for in areas with 
enhanced staffing (RSU, for example), this may not be practicable in many hospitals. 
The NIVO tool could be used to identify low risk patients who can be more safely 
cared for in a ward based setting.  Furthermore, considerable emphasis is quite 
correctly placed upon proactive escalation planning ideally in consultation with 
patient and family. Empirical data can only enhance this process. 
4) Identification of outlying trusts. It is likely that with increasing digitisation of patient 
records occurs scrutiny of outcomes will become easier and more frequent. 
Objectification of expected vs actual outcome allows for targeted improvements. 
10.3 Further Questions the NIVO Study Will Address. 
This thesis is not the complete evaluation of a vast amount of data. The further analysis of 
the validation study results is ongoing and will form a separate thesis. Remaining questions 
we hope to address include but are not limited to: 
• More in-depth assessment of in hospital data beyond validation of the predictive 
model. 
• Validation of post discharge survival findings with reference to identification of high-
risk patients to consider enhanced palliative care. 
• Multi-centre evaluation of patients experiencing late failure of NIV. 
• Evaluation of longitudinal quality of life and patient attitudes to assisted ventilation. 
• One-year outcomes in specified subgroups including HMV. 
10.4 Strengths and weaknesses of the study. 
10.4.1 Strengths 
We were able to learn from previous similar studies. We deliberately narrowed our focus of 
attention to COPD rather than all situations where NIV may be used. This is because the 




and most crucially while some factors associated with mortality may be shared others are 
likely to be disease specific. Making this methodological decision and determining a dataset 
prior to data collection based upon previous literature and expert opinion maximised the 
chance of successfully answering a well-defined research question. 
This study is the largest that we know of to attempt to derive and prospectively validate a 
predictive model in this population. Other large studies have used existing datasets or 
coding data to derive predictive models, but this approach severely limits the potential 
indices available for analysis and there are concerns regarding the diagnostic accuracy of 
coding records.(263) The derivation study was a single site and included 489 patients; the 
validation project included 10 sites and recruited 733 patients. Overall 1222 patients were 
included across both arms. The wide geographical spread of a large number of recruiting 
centres representing urban and rural areas and both large and small hospitals is a strength.  
This study’s methodology is also relatively rare within the reported literature addressing 
similar questions. We observed good research practice: Public and patient opinion was 
sought in trial design, our protocols including defined outcomes and analysis plan were 
publicly available ahead of recruitment opening, research governance best practice as 
mandated by regulatory bodies was observed. Regular trial steering committee meetings 
took place with an independent chair and data verification has been extensive. 
As illustrated in the introduction many studies have been published identifying univariate 
associations with mortality or derived models that have no or weak validation. 
Recommendations are clear that there is no substitute for validation of findings in a second 
dataset. This study achieves the gold standard of validation; our validation dataset is both 
temporally and geographically separate to the derivation dataset. The findings are upheld in 
the validation study which adds plausibility that the predictors of mortality are true and not 
the product of chance. The fact that we are presenting a fully derived and validated model 
based on a pre-determined analysis plan is clearly a strength of this work. 
The data we have collected is generalisable to real world practice. This population was 
ventilated predominately on a ward or in an RSU within a ward. This is a strength as ICU 
populations are inherently not the same as the population seen outside of the ICU. As 
discussed previously (3.3.1), much of the previous data has stemmed from ICU populations. 




criticism oft levelled at randomised controlled trials is that the population studied is not the 
same as the one seen in day to day clinical practice. For the results of our study to have any 
utility it was essential that the population was generalisable. The methodology was designed 
in such a way to maximise this and few selection criteria were imposed. Similarly, both 
cohorts represent consecutive patients. Patients are not missed at random, those that are 
admitted to particular parts of a hospital, at particular times of day or those who die very 
soon after admission may be more likely to be missed. Unless all patients are captured 
generalisability will be compromised.  
We acknowledge that certain methodological decisions are open to debate, for example the 
decision to use a conventional 70% cut off in FEV1/(F)VC rather than the perhaps more 
nuanced lower limit of normal model. Given the accepted heterogeneity in COPD we did not 
want to over define our population and hence limit modelling to a limited cohort of those 
that receive ventilation under the umbrella of COPD.  
In late failure of NIV we have defined a clear cohort of patients who have been recognised in 
the past as having very high mortality. Our pilot data challenged this which has been 
substantiated by the derivation study, the validation study will further explore this subgroup. 
With further verification one would hope guidance may shift more definitively in this group 
toward continuing NIV. 
Prior to outset the two variables we were most interested in were the steady state dyspnoea 
as measured by the eMRCD and the timing of acidaemia. While both have an intuitive basis, 
the supporting evidence is of variable quality. If nothing else, from this work, the evidence 
that these two variables are strongly linked to in-hospital mortality has been furthered.  
The predictive model we have generated is a robust predictor of outcome. It would be 
expected to outperform comparison scores in its derivation population. However, in the 
validation population the only comparison score approaching similar performance is the 
DECAF score which shares a number of components and was created by the same research 
group. Not only is the score a good predictor of outcome but the score stratifies patients 
into clinically meaningful risk groups which have implications for clinical practice. It is also far 
simpler to administer than particularly the Confalonieri, APACHE II or the CAPS score which 





One of the main reasons why we thought this study necessary is the underuse of ventilation 
nationally amongst patients experiencing an exacerbation of COPD who meet ventilation 
criteria. This in itself presents a challenge for study design. To accurately identify the 
predictors of outcome it is essential that systematic biases are not included. For example, 
older patients may be disproportionately less likely to receive ventilation. Those over a given 
age threshold that are ventilated inherently then become a selected group which may 
impact upon whether or not that variable is significant or not. We were confident in our own 
ventilation practices for the derivation study with a well-resourced and established service. 
We could however only mitigate this potential bias rather than eliminate it. We selected 
sites with well set up, streamlined ventilation services and assessed their audit data for signs 
of selection bias. As previously described no absolute criteria were imposed. Overall, the risk 
that the validation study collected a biased cohort is real but cannot be quantified and 
efforts were made to mitigate this risk. 
The second and linked weakness is another direct consequence of study design, albeit a 
conscious decision. As described, we view the attempt to capture a readily generalisable 
population as a strength of the study. In order to achieve this, it was essential that the 
validation data did not require individual patient consent which would have meant that the 
most unwell patients or those unable to consent would not be included. The absence of 
consent does mean that the intervention under study is not controlled (although all sites 
follow the same national guidelines). To consider this absence of a controlled intervention 
three influences are important: 1) that the condition (RA in ECOPD) confers a high mortality, 
2) that the intervention is highly effective at reducing mortality but delivery of the 
intervention requires coordination of complex human and system factors and 3) that the 
results really pertain to outcome event i.e. deaths. The ideal scenario is one where all sites 
delivered an identical intervention and no consent is required however this is not 
achievable. Therefore, it must be borne in mind that the outcome events may in part be 
related to variation in practice both within and between sites.  
Having decided to study COPD alone the next question was how to define it. It is, as 
described in the introduction, a heterogeneous condition. There are varying opinions as to 
how best to impose spirometry criteria to diagnosis of COPD. In using a FEV1/(F)VC ratio of 




excluded. This may be particularly pertinent to the group with emphysema but without 
significant airflow obstruction. All these patients whom the primary investigator thought to 
have IECOPD as their primary reason for RA are captured as ‘clinical diagnoses’ and will be 
analysed in the next thesis from the group. These patients were also allowed in if they had 
confirmation of airflow obstruction prior to any subsequent admissions meeting other 
selection criteria.  
This population, while readily generalisable to the UK is the product of UK systems of care 
and ventilation practices. Individual overseas hospitals or countries may compare favourably 
but others particularly a US model of care may be very different and hence results may be 
less generalisable. One variable that may hinder international comparison is probably the 
frequency of IMV both as an index and rescue treatment which in this study was low in 
keeping with UK practice.  
The recommendations for data-handing from an influential group in prognostic modelling 
are explicit and contrary to our approach, they favour retaining continuous variables rather 
than dichotomisation or categorisation.(251) It is intuitive that the greater the number of 
divisions in a particular continuous variable the closer it remains to the original variable. 
Deciles have been proposed as acceptable. The purest form is to use the formula for the line 
of best fit. However, whilst this will offer better prognostication when the change in risk is 
linear across the range encountered, this is often not the case. If the distribution of risk is 
highly skewed (e.g. eosinopenia in DECAF), dichotomisation may offer similar performance. 
Furthermore, methods that require computation will dramatically reduce potential utility 
outside of automated systems. We decided to adopt an approach of dichotomising 
continuous variables to achieve maximum simplicity. One can contend that the 
recommendations are fit for only certain types of prognostic model. The final NIVO model 
only includes one variable that could be considered continuous, the GCS however both it and 
the eMRCD could also be argued to be categorical. Truly continuous variables such as serum 
creatinine or age are not included. Nevertheless, the handling of continuous variables in our 
study is at odds to some recommendations although, is in line with previous prognostic 
research, is an acceptable method of creating simple tools and again, this was a conscious 
decision. We assessed the impact of this approach; it was minimal (NIVO AUROC = 0.79, 





The fact that the originally derived model was not the best final model in the validation 
dataset could be a weakness. There are no rules as to how this situation should be handled. 
We could have carried an unmodified model to final validation however this seemed 
counter-intuitive as it meant carrying additional variables and hence complexity for no 
additional prognostic value. We do not feel that this significantly detracts from the final 
validation as only those variables in their final format were considered for inclusion and 
hence this is clearly not a re-derivation. 
Some analyses in the derivation section of the results have not yet been repeated in the 
validation section and are allocated to the next wave of analysis. Drawing firm conclusions 
from the derivation dataset alone is premature with a larger, more up to date, multicentre 
sample available to verify or refute findings. Therefore, final judgement should be reserved 
for the time being an example is the post discharge model to predict 6 month mortality. 
Similarly, with the exception of late failure, our prespecified subgroups yielded 
disappointingly incomplete data. The uncontrolled nature of the study means that while we 
specified these groups a priori we could not mandate the data would be present to analyse. 
It transpired that rates of HMV were very low and pre discharge blood tests and arterial 
blood gases are rather sporadically collected rendering study difficult. These problems may 
be replicated in the validation study. 
10.5 Response to NCEPOD and national quality standard recommendations 
The previous results in this field have been extensively reviewed previously and found to be 
somewhat lacking. The results clearly outline the performance of the NIVO tool in 
comparison to other tools; it markedly outperforms them. The NIVO study was grounded 
upon observations of poor care that have been soundly echoed by influential bodies recently 
and hence this section is included as a response to these calls rather than the published 
work. 
During the time this study has been conceived and executed a major report into NIV 
provision in the UK has been published. This study has been referenced numerous times 
from the introduction onwards. Many of the concerns that led to this study were raised by 




importance of NCEPOD reports in driving change in NHS practice is considerable with the 
scope widening from their initial inception in the 1980s as reviews of surgical deaths. 21 
specific recommendations were made including that national quality standards (now 
published) be developed.  
Broadly the NCEPOD report and the quality standards recognise that NIV care has been poor 
and provide a road map to national improvement. The recommendations and quality 
standards attempt to ensure that respiratory acidaemia is seen as the medical emergency it 
is and that hospitals and trusts are adequately placed to respond. Attention is specifically 
paid to not missing those who could benefit, and that care is delivered and overseen by 
appropriately trained staff.  
We feel that the aims and results of this study are aligned with national priorities in the field 
of ventilation and have a role in addressing the recommendations. Of the 21 NCEPOD 
recommendations all are relevant to this study in some way, several have been specifically 
selected. 
Recommendation 7: “All hospitals where acute NIV is provided must have an 
operational policy that includes, but us not limited to: a) appropriate clinical 
areas where acute NIV can be provided, and in those areas the minimum safe level 
of staff competencies; b) staff to acute NIV patient ratios, c) escalation of treatment 
and step down care procedures; d) standardised documentation; e) minimum 
frequency of clinical review and seniority of reviewing clinician.”  
Recommendation 9: “All patients treated with acute NIV must have a treatment 
escalation plan in place prior to starting treatment. This should be considered 
part of the prescription for acute NIV and include plans in relation to: a) 
escalation to critical care; appropriateness of invasive ventilation; c) ceilings of 
treatment. This should take into account d) the underlying diagnosis; the risk of 
acute NIV failure and the overall management plan” 
Recommendation 19: “All acute NIV services should be audited annually. These 
results should be reported to the hospital board.” 
Recommendation 20: “All hospitals should monitor their acute NIV mortality rate 




The final concluding paragraph reads: NCEPOD strongly encourages the establishment 
of quality improvement work both locally and nationally to target the issues 
identified by this study… Effective quality improvement initiative and their 
results should be shared locally and nationally wherever possible. NCEPOD 
would support dissemination of this work at future report launches and NCEPOD 
newsletters.  
In response to these recommendations this body of work and the NIVO tool may directly 
have a role to play. The NIVO tool could specifically be used to aid compliance with 
recommendations 7,9,19 and 20.  
10.6 Suggestions for future research. 
While we hope this work provides a solid evidence base to support the use of the NIVO 
model to guide clinical decision making in this precise population several questions arise 
from the project. Further validation in other countries which may have differing structures of 
care or populations would be desirable if the NIVO score were being considered outside of 
the NHS.  
The UK COPD audit provides an excellent basis by which a larger population could be 
assessed to further verify this model. The caveat being that within a research project we 
have the additional capacity to gather data robustly on consecutive admissions as described 
and were able to mitigate the effect of selection bias.  
Several questions raised in the derivation study will be answered at least in part by the 
validation study as the large volume of data is analysed. Subgroups were explored and 
indeed the next thesis from the research group will address some of these questions. Of 
particular interest are the validated findings within the late failure of ventilation. The 
derivation data suggests as we hypothesised supported by pilot data that mortality with 
continued, optimised NIV is far lower as prior evidence had suggested. 
With the increasing role of HMV in the population of patients with COPD there is cause to 
believe that there may be ‘a shifting of the goalposts.’ Hypothetically this could occur by 
altering those surviving to discharge by preventing aggressive weaning amongst those with 




‘brittle’ who historically required ventilation following minor triggers less frequently require 
a discrete episode of ventilation as they are adequately treated at home. Conceptually it 
may be the case that markers of severity of acute insult become more important at the 
expense of markers of disease severity in this case. Re-validation of the findings in a 
population adequately powered to investigate HMV may be necessary if national rates of 
HMV do alter significantly.  
 
Chapter 11. Conclusions. 
There is an underuse of assisted ventilation in exacerbations of COPD. The reasons for this 
are varied but are likely to include both systematic/infrastructure factors and human factors 
related to decision making. No previous work in this field has produced any prognostic 
model that has to our knowledge passed into routine clinical use in the UK. 
This study has derived and validated a predictive model to determine the risk of in-hospital 
death in exacerbations of COPD complicated by respiratory acidaemia requiring assisted 
ventilation. The model outperforms other tools which may be used in this setting.  
The study design was robust and the extensive validation in a highly generalisable 





Chapter 12. Appendices 
12.1  A, Glossary of Abbreviations. 
6MWT 6 Minute Walk Test 
ACE (inhibitor) Angiotensin Converting Enzyme (inhibitor) 
AF Atrial Fibrillation 
AHRF Acute Hypercapnic Respiratory Failure 
ALS Amyotrophic Lateral Sclerosis 
APACHE Acute Physiology and Chronic Health Evaluation  
ASMR Age Standardised Mortality Rate 
AUROC Area Under the Receiver Operated Curve 
BMI Body Mass Index 
BP Blood Pressure 
BPH Benign Prostatic Hypertrophy 
BTS British Thoracic Society 
BUR Back Up Rate 
CAD Coronary Artery Disease 
CAOS COPD and Asthma Outcomes Study 
CAP Community Acquired Pneumonia 
CAPS COPD and Asthma Physiology Score 
CHF Congestive Heart Failure 
Cm Centimetre 
CO2 Carbon Dioxide 
COPD  Chronic Obstructive Pulmonary Disease 
CPAP Continuous Positive Airways Pressure 
CRF Chronic Renal Failure 
CRP C-Reactive Protein 
CT Computerised Tomography 
CVA Cerebrovascular Accident 
CWD Chest Wall Deformity 
CXR Chest X-Ray 
DECAF Dyspnoea, Eosinopenia, Consolidation, Acidaemia, 
Fibrillation (score) 
DJD Degenerative Joint Disease 
DPT Dual Process Theory 
ECOPD Exacerbation of Chronic Obstructive Pulmonary 
Disease 
eMRCD Extended Medical Research Council Dyspnoea 
(scale) 
EPAP Expiratory Positive Airway Pressure 
FBC Full Blood Count 




FVC Forced Vital Capacity 
GERD Gastroeosphageal Reflux Disease 
GCS Glasgow Coma Scale 
GOLD Global Initiative for Chronic Obstructive Lung 
Disease 
HDU High dependency Unit 
HMV Home Mechanical Ventilation 
HR Heart Rate 
ICU Intensive Care Unit 
ICS Inhaled Corticosteroid  
IHD Ischaemic Heart Disease 
IMV Invasive Mechanical Ventilation 
IPAP Inspiratory Positive Airway Pressure 
LABA Long Acting Beta Agonist 
LAMA Long Acting Muscarinic Agonist 
LF Late Failure  
LOS Length Of Stay 
LTOT Long Term Oxygen Therapy 
MI Myocardial Infarction 
MRCD Medical Research Council Dyspnoea (scale) 
NCEPOD National Confidential Enquiry into Patient Outcome 
and Death 
NCSLC Non-small Cell Lung Cancer 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIV Non-invasive Ventilation 
NIVO Non-invasive Ventilation Outcomes (study) 
NMD Neuromuscular Disease 
NNT Number Needed to Treat 
OHS Obesity Hypoventilation Syndrome 
OSA Obstructive Sleep Apnoea 
PAD Peripheral Artery Disease 
PAF Paroxysmal Atrial Fibrillation  
PCS Palliative Care Support 
pECOPD Pneumonic Exacerbation of Chronic Obstructive 
Pulmonary Disease 
PEEP Positive End Expiratory Pressure 
pO2 Partial Pressure of Oxygen 
RA Respiratory Acidaemia 
RCP Royal College of Physicians 
RCT Randomised Controlled Trial 
RR Respiratory Rate 
RSU Respiratory Support Unit 




TNFα Tissue Necrosis Factor alpha 
U+E Urea and Electrolytes(s) 
UK United Kingdom 
USA United States of America 
VC Vital Capacity 
VIF Variance Inflation Factor 
V/Q Ventilation/Perfusion 

















12.3 C, Validation Trial Manual. 
In order to embed this guidance here the formatting from originally distributed document 
has been changed but content identical. Original document available upon request. It should 
also be noted that a number of aspects within this manual are not relevant to this thesis but 
are included so as faithfully replicate the information presented to external sites. Of note this 
was presented with a PowerPoint presentation and discussion during a face to face site 
initiation visit. 
Introduction: 
Welcome to the NIVO Study. We are excited to work with a group of progressive hospitals 
and research departments to deliver what we hope will be practice changing results. 
This manual will explain the principle aims of the study, itemise documents, guide 
information flow, give data collection guidance and provide useful information. Any 
oversights you identify or additional information you think would be useful for inclusion 
please let us know.  
Study Overview 
We have developed a clinical tool to predict in-hospital mortality in patients with an 
exacerbation of COPD who experience respiratory academia requiring ventilation. Following 
on from this, the current study has two distinct but closely related components, the 
understanding of which is essential (see flow diagram overleaf). 
The first component of the study will ‘validate’ this prognostic tool in a separate, 
geographically and demographically diverse group of patients to check whether the 
prediction model remains sound. This component of the study is termed the validation study 
and is NON-CONSENTING. It is akin to a national audit where routinely available data is 
collected from the patients’ records and notes by the usual care team (this includes a wide 
range of personnel). Within this data are all the indices we require to validate our tool, and 
to compare performance to alternative tools. This is principally a study of patients receiving 
NIV and a much smaller number of patients who receive invasive mechanical ventilation 




diagnosis of COPD but without spirometric confirmation we will capture a minimum dataset, 
provided all other selection criteria are met. This is because our prognostic tool is likely to be 
used in this population, if shown to be a robust predictor of outcome. 
The second component of the study involves the longitudinal follow up of patients from the 
validation study who survive to discharge over one year and will assess their quality of life, 
functional status, levels of anxiety and depression, their attitude to future ventilation and 
some basic physical measurements. This component of the study is termed the Longitudinal 
study and will require INDIVIDUAL PATIENT CONSENT. Patients without spirometric 
confirmation of COPD (see above) will not be eligible. 
Lastly, it is important to note that there are two 2 site types within the longitudinal study (a 
and b) and the distinction will outline the scope of data collection required in the 
longitudinal study. Your site will be fixed from the start and the majority will be type b sites. 
Ethical and HRA Approval 
The Study has been reviewed by: North East - Tyne & Wear South Research Ethics 
Committee with a favourable opinion granted, Ref: 16/NE/0213, IRAS ID 206694. HRA 











Document Version Notes 
NIV Outcomes study  2.4 Full study protocol. 
Validation CRF 1.4 CRF for use in all patients meeting inclusion 
criteria. 
NIVO study manual 1.4 This document 
Clinical Diagnosis CRF 1.1 Limited data capture CRF for use in patients with a 
clinical diagnosis of COPD, but without previous 
confirmation of obstructive spirometry. NOTE 
DEFINITIONS. 
Late Failure/Relapse CRF 1.1 A subgroup of validation patients will experience 
‘late failure’ or ‘relapse’ this group require this 
record to be completed in addition to the Validation 
CRF. NOTE DEFINITIONS. 
Longitudinal CRF Type A 1.1 CRF for use in type A sites only, this is the single 
CRF for type A sites. For use in consenting patients. 
Longitudinal Baseline Type 
B CRF 
1.1 For use in patients who have consented to inclusion 
in the longitudinal study at type B sites. This should 
be completed pre discharge. 
HMV CRF 1.0 For use in anyone commencing home ventilation 
during the index admission or over the 12 month 
longitudinal study at type B sites. 
Longitudinal CRF Type B 1.2 Large document to be given to the patient to take 
home. Includes all information and assessments for 
each month of the longitudinal study. 
 
Consent form 1.2 Universal consent form for use in the longitudinal 
study 
GP letter type A site 1.0 Information letter for a Patient’s GP informing them 
of involvement in the longitudinal study 
GP letter type B site 1.0 Information letter for a Patient’s GP informing them 
of involvement in the longitudinal study 
Patient Information sheet, 
type A site 
1.3 Information sheet about the longitudinal study at 
type a sites for patient reference prior and post 
consent. 
Patient information sheet, 
type B site 
1.3 Information sheet about the longitudinal study at 







NAME Role Email Phone 
Stephen Bourke Chief Investigator Stephen.bourke@nhct.nhs.uk Secretary: 0191 
2934026 
Tom Hartley Research fellow tomhartley@doctors.org.uk 
tom.hartley@nhct.nhs.uk 
07793107550 
Vicky Ferguson Trial Administrator Victoria.ferguson@nhct.nhs.uk 0191 293 4160 
    
    
Glossary/Definitions 
ABG    Arterial blood gas 
ACE inhibitor   Angiotensin converting enzyme inhibitor, eg Lisinopril 
ARB    Angiotensin II receptor blocker, eg Irbesartan 
AECOPD   Acute exacerbation of chronic obstructive pulmonary disease 
BUR    Back up rate  
CXR    Chest X-Ray 
EPAP    Expiratory positive airways pressure (typically 2-10 cmH20) 
FEV1    Forced expiratory volume in one second 
FVC    Forced vital capacity 
HDU    High dependency unit 
HMV    Home Mechanical ventilation (Home NIV) 
ICU    Intensive care unit 
IPAP    Inspiratory positive airways pressure (typically 10-30cmH20) 
LTOT    Long term oxygen therapy 




NIV    Non-invasive ventilation 
RSU    Respiratory support unit 
VC    Vital Capacity  
Site Administration/Communication/Data Flow 
Each site will receive at least one initiation visit with a member of the team from the lead 
trust.  Further queries should be directed to either site PI, Victoria Ferguson for 
administration queries or Tom Hartley. Data entry is via an online database hosted by 
Northumbria Healthcare, this is within the NHS N3 secure communications network. 
www.nivo.org.uk 
Paper documents should be stored in a locked filing cabinet in a locked office. Once patient 
information has been collected on paper a new patient should be created on the online 
database. This will generate a unique study number (note these numbers may not be 
consecutive within your institution) which should be immediately added to the paper CRF. At 
each site you should create a password protected database “Site Demographic Database” of 
unique study numbers and corresponding patient demographics. This database should only 
be accessible by an individual site and should be automatically backed up. Date of birth, 
ethnicity and gender may be uploaded to the online database. A scanned copy of the CRFs 
minus patient identifying information should be sent to the lead site for data verification 
purposes. 
 
Validation Component Notes 
We recommend daily screening of all areas where ventilation is provided to identify 
participants. It is vital that all consecutive, eligible patients are included. The vast majority of 
participants will receive Non-Invasive ventilation (NIV) however those that receive Invasive 
Mechanical Ventilation (IMV) may also be eligible. Patients who die shortly after admission 
are more likely to be missed during screening of relevant units, but it is particularly 
important that we capture them. We therefore recommend additional screening of coding 




included in the validation component and the ‘validation CRF’ completed, but will not be 
eligible for the longitudinal component.  
In potentially eligible patients, all possible sources of previous spirometry should be 
checked, including lung function department, clinical letters, notes, and primary care 
records. Patients who are being treated as an exacerbation of COPD based on a clinical, but 
not spirometrically confirmed, diagnosis of COPD will be identified (predominantly new 
diagnosis).* In this instance a reduced dataset should be collected and entered onto the 
database. The clinical diagnosis should be confirmed by the site PI in the first instance, if the 
PI is not available then another respiratory consultant should be approached (typically the 
patient’s consultant). Such patients will not count towards recruitment targets (they will not 
be included in the primary outcome analysis) and are not eligible for the longitudinal study. 
This CRF is termed ‘Clinical Diagnosis CRF’. It is important to note that spirometry performed 
during their inpatient stay or post discharge is not sufficient and obstructive spirometry must 
have been performed pre-admission for an individual to be eligible for full data collection 
and the longitudinal study. Please record the number of patients you exclude based on 
unlikely to survive a year grounds and remember this is intended to be inclusive and that 
expected death from COPD does not count. 
We are interested in a subgroup of patients who experience late failure or relapse after 
treatment with ventilation. Please familiarise yourself with the definitions of both. If late 
failure or relapse occurs an additional CRF: ‘Late Failure/Relapse CRF’ should be completed. 
* Note this is different to confirmed airflow obstruction with missing values, see later. 
Validation Component Data Collection Guidance 
General:  
Complete ‘validation CRF’ in entirety in all eligible patients. All indices should be recorded 
and no indices should be identified as unavailable until all potential sources of information 
have been exhausted. Any unavailable information will need to be positively identified on 
the database so please actively record unavailable information.  A tick or cross should be 
used in marked boxes to identify a positive or negative result. For certain key indices yes or 




been explained as some are self-explanatory. They are grouped as they appear on the CRF 
and database. 
Demographics 
Largely self-explanatory. Hospital number refers to your institution’s specific identifier and is 
for your own ease of identification.  
Ethnicity is either Caucasian, Afro-Caribbean, Asian. 
Patient ID is a unique identifier for the NIVO study and is generated by the online database 
(instructions above). This must be added to the CRF (and all other CRFs) at the earliest 
opportunity (you require only date of birth, ethnicity and gender to create a new patient 
record). Please also record the NIVO Patient ID with full identifying information in the locally 
held “Site Demographic Database”. 
Selection Criteria (Inclusion Criteria) 
Primary diagnosis of AECOPD (Acute exacerbation of COPD) 
In likelihood, this will be the diagnosis given by the consultant on the post take ward round. 
If it is apparent from the notes that the initial working diagnosis was incorrect and the 
patient does have an AECOPD then they should be considered for inclusion in the study; 
similarly patients who were incorrectly diagnosed with AECOPD should be excluded. Please 
note initial consultant ward round diagnoses may be incomplete. 
Please note the following diagnoses refer to an acute exacerbation of COPD (AECOPD), this 
list is not exclusive. If you are unsure please check with the Principle Investigator. 
- Infective exacerbations of COPD 
- Non-infective exacerbations of COPD 
- Lower respiratory tract infections in patients with COPD 
- Chest infections in patients with COPD (both viral and bacterial) 




The term “primary” refers to the main reason they have been admitted. For example, if the 
main reason a patient is admitted is appendicitis and they happen to incidentally have an 
AECOPD then this does not fulfil the “primary diagnosis of AECOPD” criterion. Please be 
aware, though, that if a patient is admitted with confusion because they have an AECOPD 
then it would be acceptable to include this patient. 
If a patient has severe bronchiectasis and mild COPD, and they have a diagnosis of a lower 
respiratory tract infection this should be regarded as an exacerbation of bronchiectasis. It is 
not uncommon for patients with severe COPD to have secondary bronchiectasis. These 
patients may have an AECOPD (rather than exacerbation of bronchiectasis) and can be 
included in the trial. Clinical judgement may be required and these patients can be discussed 
with the Primary Investigator. 
 
Respiratory Acidaemia (pH <7.35, CO2 ≥6.5) treated NIV or IV 
An arterial blood gas corresponding to the initiation of ventilation must show respiratory 
acidaemia. The pH must be less than 7.35 and the CO2 must be greater than or equal to 6.5. 
Smoking ≥10 pack years 
20 cigarettes/day for one year = one pack year. 60 cigarettes/day for 1 year = 3 pack years. 
Note that 50 grams of tobacco a week for 20 years is approximately 14 pack years. 5 cigars a 
day for 20 years is 20 pack years. (Two ounces of tobacco is approximately 50 grammes). 
http://smokingpackyears.com/calculate 
Spirometry FEV1/FVC <0.7 
Any obstructive spirometry prior to ventilation is valid, if more than one result is available 
record the most recent obstructive result. FEV1/FVC ratio is the forced expiratory volume in 
one second divided by the forced vital capacity. Ideally, the patient will also have performed 
a slow/ relaxed VC. If the FEV1/VC (slow/ relaxed vital capacity) has also been recorded the 
lowest ratio (i.e. the most obstructive) should be recorded. Some patients terminate forced 
spirometry before expiration is complete (“early finish”), and the presence of airflow 




NOTE: if obstructive spirometry is confirmed but precise values are unavailable they may still 
be eligible for full inclusion, see guidance on page 10 under ‘Obstructive spirometry 
confirmed but values unavailable’ 
Age >35 (self-explanatory) 
Selection Criteria (Exclusion Criteria) 
Previous inclusion in the study 
Note that as this component of the study does not require individual patient consent the 
patient will not know if they have previously been included. It will not be uncommon for a 
patient to have more than one admission requiring ventilation during the recruitment 
period, so please check your site demographic database if you are unsure whether a patient 
has previously been included. 
Other Illness limiting life to less than one year 
This does not refer to expected mortality related to their COPD; co-morbidity is common in 
this group of patients and we are keen not to inappropriately exclude anyone. This criterion 
principally refers to metastatic cancer with an expected poor outcome, and a small number 
of other serious diagnoses. If in doubt ask your principle investigator. 
Date/Time of key events 
A&E: This is the time of arrival in A&E or equivalent acute receiving environment. It most 
circumstances this is the time recorded on PAS (not the time seen in triage etc). Occasionally 
(usually in the case of emergency treatment) entry onto PAS occurs after other key times as 
ABG or initiation of ventilation. If there is a discrepancy where the PAS time is obviously 
delayed, record the earliest time you can objectively identify. 
Senior review: This is the Consultant physician or intensivist (but excludes the A/E 
consultant). 
Ward: This is the time the patient passes from A+E to their next destination including: 





Home Circumstance: select the one, most appropriate option. 
Smoking status: Either current (incudes up to 6 weeks prior to admission) or Ex. 
Pack Years: Record total number rounded to whole number following guidance above. 
Number of Admissions in last year: Admissions for any reason. 
eMRCD: This is probably the most important piece of information recorded. It is vital this is 
accurately scored. It is different from the traditional MRCD score, notably 1) the term 
“housebound” is replaced by “unable to leave the house unassisted”; 2) transition between 
levels is clearly defined; and 3) level 5 is separated into 5a and 5b. Please take time to 
familiarise yourself with this score as it is prominent throughout the study. 
Extended MRC Dyspnoea (eMRCD) Score  
“In the past 3 months, when you were feeling at your best, which of the following statements best 
describes your level of breathlessness?” (please circle) 
Only Breathless on strenuous exertion 1 
Breathless hurrying on the level or walking up a slight hill 2 
Walks slower than contemporaries, or stops when walking on the level for 15 min 3 
Stops for breath after walking 100m, or for a few minutes, on the level 4 
Too breathless to leave the house unassisted but independent in washing and/ or dressing 5a 
Too breathless to leave the house unassisted and requires help with both washing and dressing 5b 
 
Guidance notes: 
Remember that you are asking the patient about their level of breathlessness on a good day 
over the preceding 3 months, not breathlessness during an exacerbation / on admission. 
A patient only achieves a higher grade if they are as breathless as defined in that higher 
grade. 
- for example, if worse than defined in eMRCD 3, but not as bad as eMRCD 4, they remain 
eMRCD 3. 
A key distinction is between eMRCD 4 and eMRCD 5a/5b: 




- if a patient can only walk 30 to 40 metres, but can leave the house unassisted, they are 
eMRCD 4. 
- if a patient can walk 5 or 10 metres, perhaps from their front door to a car, but need a 
wheelchair otherwise, they require assistance: eMRCD 5a or 5b. Simple walking aids do not 
constitute assistance. 
If a patient requires assistance in personal washing and dressing they are eMRCD 5b. If they 
only require assistance in washing or dressing they are eMRCD 5a. Remember to ask about 
putting on socks and shoes. 
If patients are limited for a reason other than breathlessness, score based on their functional 
limitation. 
Most recent obstructive spirometry: See guidance above in inclusion criteria. 
Obstructive spirometry confirmed but values unavailable: This is NOT THE SAME as a clinical 
diagnosis. In this instance you can objectively identify that spirometry has taken place prior 
to admission and it was obstructive but the values are incomplete or unavailable. For 
example an outpatient letter may say ‘there is evidence of airflow obstruction’ or 
‘obstructive spirometry’ but then precise values are unavailable. Only tick this if all sources 
of actual values have been exhausted, these sources include, Lung function department, 
inpatient notes, outpatient letters, GP (this is often recorded in a COPD annual review.) If in 
doubt ask your PI. 
Comorbidities 
LVSD (left ventricular systolic dysfunction): May be referred to as left heart failure. This 
diagnosis should be confirmed on an echocardiogram or cardiac MRI or on clinical grounds 
(such as   a previous documented episode of pulmonary oedema with cardiomegaly or 
BNP>2,000, or confirmed by a cardiologist). Have a higher index of suspicion if patient takes 






IHD: Ischaemic heart disease, any diagnosis of angina or previous MI. 
CVD: Cerebrovascular disease, any diagnosis of stroke (ischaemic or haemorrhagic) or TIA. 
Cognitive impairment: any diagnosis of chronic confusion, cognitive impairment or 
dementia. 
Cor Pulmonale: Right heart failure due to respiratory disease may be a clinical or echo 
diagnosis. Old letters must be reviewed as well treated right heart failure may not be readily 
apparent on admission. Have a higher index of suspicion if patient takes diuretics. 
APACHE II Liver Failure: The score will be compared to existing scores one of which is the 
APACHE II score so accurate scoring is necessary. A positive result is defined as: “Biopsy 
proven cirrhosis and documented portal hypertension; episodes of past upper GI bleeding 
attributed to portal hypertension; or prior hepatic failure/encephalopathy/coma.” 
APACHE II Renal Failure: Receiving chronic dialysis (haemodialysis or peritoneal) 
APACHE II Immunocompromise: The patient has received therapy that has suppressed 
resistance to infection within 4 weeks of admission, eg immunosuppression, chemotherapy, 
radiotherapy, high dose steroids (>1.5mg/kg). Has immunosuppressive disease such as 
leukaemia, AIDS, lymphoma. Please ensure should not be excluded on basis of estimated 1 
year survival. 
AF: This is recorded at 2 time points, up to 4 hours (the admission period) and up to 




period prior to ventilation (these time points will more often than not be the same). AF is 
recorded as being present if chronic AF, paroxysmal AF or acute AF are noted.   
Medications 
Record whether patient was prescribed at admission and discharge. Long term steroid is for 
at least 1 month continuously prior to admission. Admission medication listed on records but 
with verified non-adherence should not be included. 
LABA=long acting beta agonist, LAMA= long acting muscarinic antagonist, ICS=inhaled 
corticosteroid. Please note you should tick all that apply. There are a number of combination 
inhalers on the market containing either LABA/ICS or LABA/LAMA. Please check in the BNF 
or with a pharmacist. Of note, many doctors are unfamiliar with these newer medications so 
they may be inaccurately recorded initially. 
 
Clinical Information 
Effective cough: This is the ability or inability to effectively clear secretions. It is often 
recorded by respiratory physiotherapists. Only record ineffective cough if patient clinically 
appears to have excess secretions in their airways that they cannot clear independently. If a 
patient has a reduced GCS they are more likely to have an ineffective cough. 
Height: Record in meters. Historical spirometry records are often a good source of this 
information. (A reading taken in the future may be retrospectively added for this variable). 
Weight: This should be most recent available. Previous values are acceptable if the patient 
does not report weight change in the intervening period. 
BMI: Please only record BMI if height and weight separately are unavailable and always 
record height if at all feasible. 
CXR consolidation on admission: Presence or absence of consolidation on the first technically 
adequate chest X-ray taken. Interpretation should be that of the most senior clinician 
available (often a consultant will comment on an X-Ray on a post take ward round taken the 




be misinterpreted as pulmonary oedema, if you have suspicion of this, or are uncertain for 
any other reason please ask the principle investigator or supervising clinician. 
CXR consolidation at ventilation: Particularly relevant if ventilation occurs later in the 
admission. 
Diaphragm height: This is the height in centimetres from a line drawn between the lateral 
and medial insertion points on a CXR and the maximum height of the dome. Use the right 
hemidiaphragm preferentially. 
LTOT on admission: Long term oxygen, (not short burst or palliative). 
NIV 
Previous Episode: Record number of distinct (max one per admission) previous episodes of 
NIV (not invasive mechanical ventilation or CPAP) for any reason.  
Domiciliary NIV admission/discharge. Be aware this is NIV at home and NOT CPAP. Patients 
themselves and frequently non-specialist doctors and nurses are imprecise about home 
ventilation. Of note if a patient has home NIV the initiation time will correspond to the 
deviation from their normal ventilation routine (including change onto a different 
ventilator). Discontinuation will correspond to the re-establishment of their normal 
ventilation pattern or the establishment of a new chronic ventilation pattern. 
Ventilation initiated date/time: This is the time that NIV or IMV was initiated (time mask 
applied, time of intubation). If the precise time of initiation of ventilation is unavailable, 
please use the best estimate available from the notes (e.g. time of ABG prior to initiation, 
time of decision to initiate ventilation if recorded). 
Ventilation discontinuation date/time: This is when a continuous period of ventilation has 
ended. If a patient goes from NIV to IMV and back to NIV this is one period of ventilation. If 
there is more than 24 hours gap between 2 periods of ventilation, the first episode of 
ventilation would be considered complete and second episode a relapse. Gaps of less than 
24 hours are considered part of one continuous period of ventilation. Note for the purposes 
of this study we consider ventilation to have ended when the mask is removed from a 
patient NOT when the machine is removed from the bedspace (which may be some 




documented for morning removal following a final night on NIV then use 08.00 as a default 
in this specific situation. 
pH correction: The first time that pH is greater than or equal to 7.35 after ventilation has 
been initiated irrespective of whether it subsequently drops again. If pH never corrects then 
record in comments. 
IPAP/EPAP/BUR 1-2hr and max: IPAP is the inspiratory pressure and EPAP is the expiratory 
pressure. Often recorded as, for example, 24/5 (where 24 is the IPAP and 5 is the EPAP). BUR 
is the back up rate provided by the ventilator.  Record these pressures for NIV only. Patients 
will typically have a review after 1hr on NIV with a review of the setting in conjunction with 
an ABG. It is the pressures achieved after this review we are seeking to capture and clinicians 
other duties can contribute to delays; please be flexible in interpretation of the 1 hour guide 
and allow up to 2 hours. Max is the maximum achieved at any point during their NIV. Note 
that especially those experiencing late failure may achieve their maximum values late into 
their admission. 
Reason for cessation: The reason ventilation was discontinued.  
At the time of ventilation was the patient for intubation/resuscitation: unless actively stated 
to the contrary, patients should be assumed to be considered for full escalation. If a senior 
clinician changes this status at the first senior review (provided within 24 hours of initiation 
of ventilation) then record this as the status. Changes made after 24 hours irrespective of 
clinician grade do not affect this status. 
Highest level of care received. This is the actual level received NOT the hypothetical ceiling 
of care. 
Was patient invasively ventilated? If yes: NIV pre and/or  NIV post: Note: this refers to 
whether the patient received NIV before and/or after IMV. See guidance on recording 
ventilation initiation and discontinuation time. 
Duration invasively ventilated: Note this is the time invasively ventilated, not total 
ventilation time which may include NIV also. If a patient receives a tracheostomy this is 






4Hr/Ventilation: Record the worst available observations either up to the point NIV is 
initiated or up to 4 hours whichever comes first.  
24hr pre Vent: If ventilation is initiated within the first four hours of admission these 
readings are not relevant (i.e. will be by definition the same) so tick box and leave blank as 
directed on the CRF. If ventilation occurs after 4 hours record the worst available readings 
(even if they are the same as the 4 hours) up to a maximum of 24 hours prior to ventilation 
BP record the lowest.  
HR record the greatest deviation from 70. 
Temp record the greatest deviation from 37.0 
GCS record the lowest, (if not accurately documented record the best guess from available 
information, table below) 
O2 sats/FiO2 record the lowest O2 sats, document Fi02 as follows: RA (room air), V (Venturi) 
+ the % or Un (uncontrolled) and the flow rate in litres. 







Admission is the first ABG recorded.  
1st acidaemia is the first blood gas showing respiratory acidaemia and may be the same as 
admission.  
NIV decision is the ABG that prompted ventilation. This must, by definition, show respiratory 
acidaemia. 
24 hours post is 24 hours (+/- 12 hours) after ventilation initiated.  
Steady is steady state, it must be after acute ventilation has ceased, use the closest to 
discharge available. (note guidance about discontinuation in domiciliary ventilation). 
Date and Time is vital to allow interpretation of key indices. A best guess is better than 
nothing if not objectively available.  
pH/PaCO2/PaO2 self-explanatory. BE may be positive or negative please ensure accurate 
recording of such. Bicarb (bicarbonate) is sometimes routinely reported in U+Es. Use venous 
bicarbonate if no ABG is available for the specified time. 
Art/venous. By default, assume ABGs are arterial. If an ABG is objectively recorded as being 
venous (as opposed to an attempted ABG being recorded as ?venous) then specify as 
venous. tcCO2 is transcutaneous CO2 (TOSCA) some centres may use this in to supplement 
venous gas. More commonly, PtcCO2 will be unavailable / not recorded. 
 
Bloods 
Admission: use the first recorded bloods within 24 hours of admission (ie. by default, the 
first recorded bloods.) Creat base is the pre admission creatinine: document the lowest 
value recorded in the last 3 months preceding admission. If no results within this timeframe, 
record stable state creatinine during the last 12 months. 
NIV decision: In approximately 75% of cases this will be the same as admission. If so, tick box 




If ventilation occurs later than 4 hours, a new set of bloods may be needed (particularly in 
those with acidaemia developing more than 24 hours after admission). Record bloods taken 
within 24 hours prior to ventilation initiation.  For example if NIV is instigated on day 7 of 
admission at 14.30 then additional bloods should be recorded in the NIV decision column 
using bloods taken between Day 6, 14.30 and day 7, 14.30. 
Discharge is the last available bloods (they do not need to come from the same time). 
n.b Na=Sodium, K=potassium, Hb=haemoglobin, Hct=Haematocrit, WCC=white cell count. 
Do not neglect eosinophils - this is another of our key indices. 
 
Outcomes 
Did the patient survive to discharge: Largely self-explanatory.  
If the patient is dying and requests transfer out of a hospital setting to die for example in a 
hospice or home on a  care of the dying pathway and dies within 7 days of leaving the acute 
hospital we consider this an INPATIENT death. In this setting select NO (did not survive to 
discharge) and record details in comments. This situation is NOT the same as going home 
with an Emergency Healthcare Plan (EHCP) stating they should not be readmitted . 
Date of discharge: Leave blank if does not survive to discharge. 
Home NIV (HMV) commenced within 1 year post discharge? Yes/No include HMV 
commenced upon discharge from index admission and record date commenced. 
Reason commenced: Answer yes to all that apply. 
Date of death: Includes deaths up to 12 months post discharge. 
Cause of death: Details from death certificate. 
 
Readmissions 




Adm date= Admission date, Dsc date= discharge date, R/O = respiratory/other, NIV? = 
whether patient received NIV during this readmission, diagnosis if available. 
Late failure/Relapse 
Late Failure (LF) is recurrence of respiratory acidaemia prior to discontinuation of 
ventilation. pH should drop to below 7.35 with a rise in CO2 of at least 1kPa and to >6.5kPa 
from the lowest recorded post pH correction at least 24 hours after pH correction.  
(It is not simply delayed correction of initial respiratory acidaemia).   
This definition may seem complex, however, if you consider the group under study it 
becomes easier to understand: We wish to capture those who deteriorate on treatment (still 
receiving ventilation) after initial improvement (ie after pH correction). We don’t want those 
that have an early ‘wobble’ (hence >24 hours after pH correction”). We want to capture 
respiratory deterioration rather than a new metabolic acidaemia (so a rise in paCO2 of 
>1KPa to greater than PaCO2 6.5) but we require a reference point to measure this rise (so 
lowest recorded after correction). 
Relapse is recurrence of respiratory acidaemia 24 hours after NIV cessation. (if less than 24 
hours after discontinuation consider as late failure.) 
Only capture LF occurring during primary episode of ventilation not during any subsequent 
episodes (ie relapses) 
 
The CRF is otherwise self-explanatory. 
Clinical Diagnosis 
 
In potentially eligible patients, all possible sources of previous spirometry should be 
checked, including lung function department, clinical letters, notes, and primary care 
records. Patients who are being treated as an exacerbation of COPD based on a clinical, but 




diagnosis). In this instance a reduced dataset should be collected and entered onto the 
database. The clinical diagnosis should be confirmed by the site PI in the first instance, if the 
PI is not available then another respiratory consultant should be approached (typically the 
patient’s consultant). Such patients will not count towards recruitment targets (they will not 
be included in the primary outcome analysis) and are not eligible for the longitudinal study. 
This CRF is termed ‘Clinical Diagnosis CRF’. It is important to note that spirometry performed 
during their inpatient stay or post discharge is not sufficient and obstructive spirometry must 
have been performed pre-admission for an individual to be eligible for full data collection 
and the longitudinal study.  
 
Longitudinal Component Notes  
This component of the study will require individual patient consent. All patients surviving to 
discharge should be considered for inclusion with inability to provide informed consent 
being the only exclusion criteria. Participants should be approached when they have 
achieved clinical stability in the 2-3 days prior to their expected discharge date. They should 
be given the site specific patient information sheet (PIS) and have time to consider it and ask 
any questions regarding it. If a patient wishes to partake, consent should be taken using the 
provided consent form. A letter to send to the patient’s GP is also provided informing them 
of the study. 
Type A site: There is only one CRF for type A sites termed: ‘Longitudinal CRF Type A’. The pre 
discharge component of the CRF should be completed. Patients should be given a copy of 
their consent form and the ‘Patient Information sheet, type A site’. No additional CRF needs 
to be given to the patient for type A sites. The remainder of CRF should be completed at 3 
months. 
Type B site: This is most (or all) sites and represents a much more thorough follow up 
schedule. Before discharge from hospital complete ‘Longitudinal baseline type b CRF’. 
Patients should be given a copy of the longitudinal CRF, a copy of ‘Patient Information sheet, 
type B site’ (if not already) and a copy of ‘Longitudinal CRF Type B’ in a single file. A large, 
addressed, postage paid envelope should also be provided. Patients must be educated how 




discharge date is definitively known it can be entered onto the database and an interview 
schedule generated to include in the patient pack. Please only use this function if you KNOW 
the patient is going home on the specified day. Otherwise this can be printed at a later date 
and posted to the patient. Each month’s post discharge assessment should be taken from 
the discharge date NOT the consent date. Following discharge the patient should complete 
assessments themselves 1 and 2 months after discharge (they will also do this at month 4/5 
and 7-11). Some sites have opted to phone participants each month to complete the 
assessments with them over the phone to enhance data completion. This method is 
encouraged but not mandated from the sponsor. The 3rd, 6th and 12th month assessment is 
face to face with a researcher either in the patient’s own home or in hospital, which we will 
leave to the discretion of individual sites. At each face to face visit please clarify with the 
patients that any readmissions you have identified did occur and any others to other trusts 
or missed admissions. The number of COPD exacerbations either treated or requiring 
admission since last assessment should be recorded. Note this is not cumulative and is from 
0-3 months then 3-6 months and finally 6-12 months. Please ensure you take a copy of all 
study documents with you. At these visits completed assessments should be collected. 
Please also verify the patient has the required documents to complete any outstanding 
assessments, including the schedule filed at the front (bring a copy of the schedule to the 
first visit) and that they understand the schedule between your current face to face contact 
and the next.  Readmissions you have identified electronically should be verified with the 
patient, when possible.  
This group of patients have a high one year mortality and so there is a significant chance the 
participant may not survive to the end of the follow up period. Please ensure there is a local 
system for checking survival prior to any patient contact. Ensuring that the patient pack 
always has a prepaid envelope and collecting assessments regularly should maximise data 
capture. In the event of a patient’s death between visits, please sensitively arrange for the 
study file to either be posted back in the provided envelope, or collected. 
The assessments to be completed each month are CAT, EQ 5D 5L, eMRCD, HADS, NEADL. 




Please assume your site is a type B site unless expressly told otherwise. Type A sites have a 
single CRF. Type B sites have a baseline CRF (to be completed pre discharge) and a 
longitudinal CRF. 
 
Longitudinal Component Data Completion Guidance. 
 
Patient ID must be added to all sheets. 
Height need only be entered once, weight should be entered at each face to face 
assessment. 
Record FiO2 as per Validation guidance. 
Spirometry should be measured for the baseline (pre-discharge) assessment and at each 
face to face visit, do not input old values. 
Future ventilation questions are sensitive and should be handled so. Please remind the 
patient of the dates of their index admission as they may have subsequent admissions and 
become confused. 
Each tool has completion guidance attached, please read each tool prior to use with a 
patient, if there is any uncertainty around completion please ask. 
Of Note in the HADS score the top right question reads ‘I feel as if I am slowed down’ this 




Anyone who commences HMV during the index admission or subsequently during the 
longitudinal follow and has consented to involvement in the longitudinal study should 




completed. If they commence after 5 months complete the 6 and 12 month boxes and mark 
the 3 month box as not applicable.  
If in doubt about the indication for initiation (particularly the HOT-HMV criteria please ask 
your PI) 
Please note that to activate the additional information to be recorded in the database HMV 
must be selected in the OUTCOMES section which will reveal additional tabs in the 
longitudinal study. 
Database  
A database hosted by the Northumbria NHS foundation trust has been commissioned. It is 
accessible at: http://n3.nivo.org.uk All data entry should be via here and unique study 
numbers will be generated by the database. A work list will be generated for you and details 
of missing data flagged for completion. All study documents are also available for download. 
Missing data must be actively identified. All fields have a small check box which if ticked 
positively identifies the field as missing. Please check all available sources of information and 
if information is still missing check the missing data box. Training will be provided at site 
initiation visit. If you are struggling with the database please contact Tom (mobile above). 
Data Monitoring 
When Validation CRF is completed (one year post index admission) after readmission data 
has been collected. This form should be scanned and emailed (minus identifying 
information) to Vicky Ferguson (email address at the beginning of this document). There is 
no requirement to send on Longitudinal study CRFs. There is no planned formal monitoring 
visit. 
Adverse Event Monitoring 





12.4 D, Missing data analysis (Derivation Study) 
Variable %missing Mean 
original 
SD original Mean EM SD EM 
Phosphate 87.9 N/A, immediately discarded. 
Troponin 87.0 N/A, immediately discarded. 
Glucose 25.8 8.41 3.58 8.57 3.84 
Bilirubin 23.1 9.93 6.81 9.77 6.44 
Total protein 20.2 69.5 6.82 69.1 6.82 
Albumin 19.0 37.9 5.40 3.78 5.38 
Potassium 6.7 4.65 0.70 4.63 0.70 
Oxygen 
saturations 
4.5 83.8 10.7 83.9 10.7 
Haemoglobin 4.5 13.64 2.15 13.62 2.14 
Eosinophil count 4.1 0.094 0.18 0.095 0.18 
White cell count 3.9 13.73 6.61 13.63 6.58 
Platelet count 3.9 291.1 123.5 294.6 126.0 
Haematocrit 3.9 0.420 0.063 0.420 0.063 
Neutrophil count 3.9 10.95 5.34 10.87 5.33 
Sodium 3.3 136.6 5.26 136.6 5.23 
Urea 3.3 9.15 5.65 8.96 5.69 
Base excess 3.1 3.78 6.35 3.78 6.46 
Diastolic blood 
pressure 
1.6 70.1 18.8 69.7 19.2 
Systolic blood 
pressure 
1.4 123.9 31.5 123.0 32.4 






Univariate Associations with mortality  Original Dataset P Value EM 
Age*  <0.001 <0.001 
Any atrial Fibrillation up to 
deterioration 
<0.001 <0.001 
Left Ventricular Systolic Dysfunction* 0.025 0.025 
Depression* 0.097 0.097 
eMRCD <0.001 <0.001 
LTOT* 0.014 0.014 
Consolidation at Ventilation* <0.001 <0.001 
Pleural Effusion admission <0.001 <0.001 
Diaphragm Height 0.063 0.063 
Confusion at ventilation <0.001 <0.001 
GCS* <0.001 <0.001 
Systolic Blood pressure 0.008 0.026 
Heart Rate 0.085 0.057 
Respiratory Rate 0.041 0.041 
Haemoglobin  <0.001 <0.001 
WCC  0.025 0.016 
Eosinophil Count  <0.001 <0.001 
Urea <0.001 <0.001 
CRP 0.002 0.005 
pH* 0.003 0.003 
Base Excess <0.001 0.001 







12.5 E, Presented Abstracts. 
Only abstracts directly pertaining to the NIVO study are listed: 
 
1. Predicting Outcome from Exacerbations of COPD requiring Assisted Ventilation: Results 
from the NIV Outcome (NIVO) study. Oral presentation, British thoracic Society (BTS) 
winter meeting, 2019. 
2. Late Failure of NIV in Exacerbations of COPD: All is not lost. Poster presentation and 
discussion, BTS winter meeting, 2018. 
3. NIV in exacerbations of COPD: Prognostication is not all baseless. Oral presentation at 
BTS winter meeting, 2018. 
4. The NIVO Study: attitudes to ventilation following acute NIV. Poster presentation and 
discussion, ERS International Congress, Paris 2018 (Presented by Dr Nick Lane) 
5. Timing of Acidaemia onset in exacerbations of COPD requiring assisted ventilation and in-
hospital mortality. Oral presentation, BTS winter meeting 2017. 
6. The Role of Ventilation in Pneumonic Exacerbations of COPD (pECOPD). Poster 
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